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This thesis describes research performed on several generalized autoimmune diseases with 
the main focus on primary Sjögren’s syndrome. Interferon type I has been implicated in the 
pathogenesis of these diseases and will be introduced in this chapter together with other 
important immune factors in these diseases such as BAFF and Th17 cells. In this chapter first 
a general introduction about the immune system will be given, followed by introduction 
about Interferon type I, BAFF, Th17, Sjögren’s syndrome and finally the other two studied 
autoimmune diseases. 
1.1 THE IMMUNE SYSTEM
1.1.1 Innate immune system  
Humans live in a microbial world composed of various danger signals. The community of 
microbes includes both pathogenic and nonpathogenic commensal organisms, which the 
host must tolerate in order to support normal tissue and organ function. Next to microbes, 
our environment contains a spectrum of possibly harmful toxic or allergenic substances. The 
appearance of the first multicellular organisms, has probably led to the need for a robust 
innate immune system. Innate immunity is present in all multicellular organisms. The innate 
immune system reacts immediately, however in a stereotype non-specific kind of way. The 
innate immunity includes the barriers of the body consisting of the epithelial surfaces of 
the skin, gut and respiratory tract. These barriers can produce antimicrobial peptides, small 
chains of amino acids that are very potent at inhibiting many bacteria and fungi. Next to 
these barriers, the innate immune system is composed of different cell types which are 
activated upon identification of the microbes by pattern recognition receptors (PRRs) such 
as the Toll like receptor (TLR). Components of the complement system can also tag microbes 
for destruction by the cells  of the innate system. Cell types involved in the innate immune 
system are granulocytes, natural killer (NK) cells, monocytes, macrophages and dendritic 
cells (DC). Peripheral blood monocytes are thought to be the precursors for macrophages 
and DCs in the peripheral tissues. However studies from our group indicate a contribution 
of local tissue precursors to the pancreatic DCs and macrophage populations as well [1, 2].   
1.1.2 Adaptive immune system 
The adaptive immune system, that is only present in mammals, changes with repeated 
exposure to the antigen and results in long-lasting antigen specific immunological memory. 
Key-players of the adaptive immune system are T cells and B cells. During adaptive immunity a 
virtually unlimited spectrum of antigen specific receptors is randomly formed on the surface 
of  T cells (TCR) and B cells (BCR). Two major types of T cells are the CD4+ T helper (Th) cells 
and the cytotoxic CD8+ cells. Th cells recognize antigens bound to major histocompatibility 
complex class II (MHC class II) molecules and can be subdivided in Th1, Th2 and the recently 
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discovered Th17 subtypes. CD8+ T cells recognize antigens bound to MHC class I molecules 
and are important in killing infected or damaged cells. Since TCRs and BCRs are randomly 
formed, a significant part of these receptors recognizes harmless antigens from its own body, 
inducing an autoimmune response. Another T cell type, is the regulatory T cell (Treg). This 
CD4+FoxP3+ cell maintains tolerance to self-antigens, preventing autoimmune reactions. 
A primary function of B cells is to produce antibodies (immunoglobulins). After activation 
of naive B cells by specific antigens, the B cells develop into long living memory B cells 
and antibody secreting plasma cells. B cells can also use complement to tag pathogens for 
destruction and they can serve as antigen presenting cells (APC).   
1.2 INTERFERON TYPE I
The family of interferons (IFN) comprises type I interferons, the type II interferon IFNγ and 
the recently described type III interferons, called IFNλ [3, 4]. The type I interferons were 
originally defined in 1957 by their capacity to interfere with viral replication [5]. This viral 
interference was the reason that the name ‘interferon’ was chosen [6]. IFN type I includes in 
humans more than 13 different members of IFNα as well as IFNβ, IFNε, IFNκ and IFNω [7]. 
Since this large group of structurally similar cytokines signal through the same receptor, the 
IFN type I receptor (IFNAR), these cytokines are characterized by the term IFN type I. IFNAR 
is a heterodimeric receptor consisting of 2 membrane spanning polypeptide chains, IFNAR1 
and IFNAR2 [8]. 
In response to viral infection, all nucleated cells have the ability to produce relatively small 
amounts of IFN type I, but the “professional” IFN type I producing cell is the plasmacytoid DC 
(pDC). Althoug pDCs constitute only 0.2%-0.8% of peripheral blood cells, these cells secrete 
up to 1.000-fold more IFN type I compared to other cell types [9]. pDCs are round cells 
with a prominent rough endoplasmatic reticulum (ER) resembling that of immunoglobulin 
secreting plasma cells and are therefore called plasmacytoid [10]. pDCs are characterized 
by the presence of 2 dendritic markers termed blood dendritic cell antigens (BDCA 2 and 4) 
and the receptor FcγRII, which contributes to the internalization of immune complexes [11]. 
IFN type I production is induced by viruses, bacteria, or microbial nucleic acids when 
sensed by the PRRs, such as TLRs, RIG-I like receptors (RLRs) and NOD-like receptors (NLRs) 
[12]. Both TLR7 and TLR9 are expressed at the endosomal membranes of pDCs and can 
therefore become activated by pathogens invading the pDC through receptor-mediated 
endocytosis [6]. DNA/RNA containing immunecomplexes (ICs) can also get endocytosed via 
FcγRIIa, leading to activation of the endosomal TLR7 and 9. The first step in the production 
of IFN type I involves the association of MyD88 with TRAF6 and IRAK 1 and 4 (Figure 1, 
middle panel). Upon this complex formation, IFN regulatory factor (IRF)-3, 5 and 7 are 
activated, form homodimers or heterodimers and translocate to the nucleus where they 
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bind to regulatory elements in the promoter region of IFN type I genes and subsequently 
trigger transcription of these genes [13]. The third endosomal TLR is TLR3. TLR3 is expressed 
by DC, but not by pDC or monocytes [14]. TLR3 is the only TLR that does not signal via the 
MyD88. The signal from TLR3 is transduced by TIR containing adaptor molecule (TRIF) which 
activates the transcription factors IRF3 and IRF7 triggering IFN type I production [15].
In contrast to the pDC, the majority of cell types expresses the cytoplasmic RNA helicases 
belonging to the RLR family − RIG-1, MDA5 and LGP2. When a virus enters directly into 
the cytosol of the cell, RIG-1 and MDA-5 recognize the RNA which further interacts with 
the MAVS adaptor protein (Figure 1 left panel). MAVS assembles with a signaling complex 
including TRAF3, TBK1 and IKKE. Finally NF-KB is activated together with IRF3/IRF7 resulting 
in IFN type I production [15]. 
TLR4 can also initiate IFN type I production after binding of LPS. This happens in a TRIF 
dependent way involving IRF3 [16]. Interestingly, the constitutive expression of IRF7 and 
IRF5 in the pDCs makes a rapid onset of IFN type I production possible [15]. The expression 
of IRF7 and 5 is further enhanced by stimulation with IFN type I, the so called priming 
effect. In other cells without constitutive IRF5 or IRF7 expression, a signal through IRF3 
phosphorylation is required to activate IFN type I expression and thereby upregulates the 
level of IRF7 and primes the cell to IFN type I production [9]. 
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Figure 1. Adapted from Rönnblom L. et al. (2011)[15]. Signaling pathways of the IFN type I system. On the left the 
induction of IFN type I in response to viral RNA/DNA through PRRs (MDA5, RIG-1, DAI, AIM2) is depicted. In the 
middle IFN type I production by interferogenic ICs is depicted and by LPS binding on TLR4. On the right the IFN 
signaling via the IFNAR is depicted.
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Binding of IFN type I to the IFNAR results in activation of Tyk2 and Jak1. These activated 
kinases recruit and phosphorylate the transcription factors STAT1 and STAT2, which 
translocate to the nucleus where STAT1:STAT1 homodimers bind to gene promoters and 
activate transcription [17] (Figure 1 right panel). In contrast, STAT1:STAT2 heterodimers 
associate with IRF9 forming a complex that binds to IFN-stimulated response elements 
(ISRE) and activates the transcription of hundreds of IFN type I induced genes (IFIGs). The 
exact function of many of these IFN type I inducible genes is far from clear. However, it is 
known that IFN type I induces and activates enzymes such as MxA (Myxovirus-resistance 
protein 1), which is a key mediator of the IFN-induced antiviral response [18-20].  
Because of the anti-viral capacities, IFN type I has been widely used for the treatment 
of hepatitis B and C virus infection [21]. Next to these anti-viral functions, IFN type I inhibits 
tumor growth by suppressing proliferation and inducing cell apoptosis, IFN type I inhibits 
angiogenesis and activates cytotoxicity against tumor cells [21]. For these reasons, IFN type 
I has been used in the treatment of malignancies such as melanoma, leukemia and Kaposi’s 
sarcoma [21, 22]. However, early on it was noted that upon IFN type I treatment, higher 
autoantibody prevalence occurred as well as the development of autoimmune diseases [23, 
24]. 
In recent years, an increasing number of immunomodulatory effects of IFN type I has been 
reported including: activation of immature dendritic cells through upregulation of MHC class 
I, chemokines and costimulatory molecules; B cell activation and immunoglobulin (Ig) class 
switching through induction of BAFF and APRIL or enhancement of B cell receptor-mediated 
responses; stimulation of Fas ligand expression on NK cells and target cell apoptosis; 
enhancement of T cell proliferation and survival, skewing of the immune response to the Th1 
type and triggering CD8+ memory T cell activation. Finally, IFN type I induces a wide array of 
chemokines including CXCL9, CXCL10, CXCL11, that are potent chemoattractants for CXCR3 
expressing pDC and lymphocytes [10]. IFN type I can also induce increased expression of 
autoantigens, such as Ro52 [25, 26] and promote the release of autoantigens by induction 
of apoptosis [27]. 
1.3 BAFF
B cell activities are orchestrated by members of the tumor-necrosis factor (TNF) family 
[28]. This large group consists of three members: the TNF-like weak inducer of apoptosis 
(TWEAK), a proliferation-inducing ligand (APRIL) and the B cell activating factor of the 
TNF family (BAFF) [29]. BAFF and APRIL share the transmembrane activator and calcium 
modulator ligand interactor (TACI) and the B cell maturation antigen receptor (BCMA). Only 
BAFF binds to the BAFF receptor (BAFF-R) [30] (Figure 2). 
BAFF is a type II transmembrane protein, which is mainly expressed on the cell surface 
of monocytes, macrophages, neutrophils and activated T cells [31-34]. Alternatively, BAFF 
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is proteolytically processed by proteases and found in the soluble form. Other cell types 
also express BAFF: stromal cells from the bone marrow [35], follicular dendritic cells [36], 
synoviocytes [37], astrocytes [38] and epithelial cells of the salivary glands in Sjögren’s 
syndrome [39]. Next to membrane or soluble forms, BAFF offers a cluster of variants: 
glycosylated or non-glycosylated forms, monomer or trimers, homotrimers or heterotrimers, 
heterotrimers with APRIL or heterotrimers with BAFF variants, or even virus-like aggregates 
of 60 monomers [29, 40, 41]. 
BAFF has a major role in B cell differentiation/maturation and survival of peripheral B 
cells and emerges as a very important factor that allows B cells to mature and remain as 
peripheral B cells (Figure 2). Pathological excess of BAFF rescues autoreactive B cells from 
peripheral deletion and allows them to home into microenvironments where chances of 
inappropriate activation are greater [42, 43]. Excessive BAFF production leads to the survival 
of low affinity and self reactive B cells resulting in a decrease in B cell tolerance [40].  
In 2003 an alternative splice isoform of BAFF was identified, ΔBAFF [44]. ΔBAFF 
suppresses BAFF function by competitive co-association. Studies in the ΔBAFF transgenic 
mouse showed that ΔBAFF and BAFF have opposing effects on B cell survival [45]. In humans, 
although the ΔBAFF transcript was found is some tissues, the corresponding protein has not 
been detected yet [38]. 
B cell survival
Plasma cell survival
Isotype switching
T cell–independent responses
Isotype switching
Plasma cell survival
BAFF
BR3
TACI
BCMA
B cell
APRIL
Figure 2. Adapted from Martin and Dixit (2005)[46]. Receptors for BAFF and APRIL. BAFF and APRIL share the 
transmembrane activator and calcium modulator ligand interactor (TACI) and the B cell maturation antigen receptor 
(BCMA). Only BAFF binds to the BAFF receptor (BR3 or BAFF-R). BAFF has a major role in B cell differentiation/
maturation and survival of B cells.
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1.4 TH17 CELLS
Th1 cells are promoted by IL-12 which induces expression of transcription factor T-bet 
and secretion of the hallmark cytokine IFN-γ [47-49]. Th2 cells are induced by IL-4 that 
upregulates the transcription factor GATA3, producing the cytokines IL-4, IL-5 and IL-13. 
[50, 51] (Figure 3). The discovery of Th17 cells formed an addition to the previous Th1/Th2 
paradigm.  
Figure 3. Adapted from Deenick and Tangye (2007)[52]. Molecular requirement for Th17 cell differentiation. Naive 
CD4+ T cells differentiate to Th17 cells under the influence of IL-6 and TGFβ. The expansion and stability of the Th17 
population is  regulated by IL-21 and IL-23, respectively. Th17 cells secrete IL-17A, IL-17F, IL17A/F heterodimers, as 
well as IL-21, IL-22, granulocyte macrophage-colony-stimulating factor (GM-CSF), and many other factors.
Naive CD4+ T cells differentiate to Th17 cells under the influence of IL-6 and TGFβ [53] 
(Figure 3). The expansion and stability of the Th17 population is  regulated by IL-21 and IL-
23, respectively [54, 55]. Th17 cells secrete IL-17A, IL-17F, IL17A/F heterodimers, as well as 
IL-21, IL-22, granulocyte macrophage-colony-stimulating factor (GM-CSF), and many other 
factors [56]. In this thesis we studied both chemokine receptor defined Th17 cells (defined 
as CD4+CD45RO+CCR6+CCR4+CXCR3-CCR10- cells) and IL-17A and IL-17F producing CCR6+ T 
memory cells. The latter enriches for Th17 cells, but contains also other cell types (Figure 4). 
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Figure 4. Composition of CCR6+ T memory cell subset with chemokine receptor expression. Chemokine defined 
Th17 cells are represented by the red cell (CD4+CD45RO+CCR6+CCR4+CXCR3-CCR10- cell). IL-17 producing CCR6+ 
cells are represented by both the red and the orange cell.
 
Next to Th17 cells, IL-17A is produced by several other immune cell types, including 
CD8+ T cells, CD4-CD8-CD3+ (double negative, DN) T cells, NK cells, γδ-T cells and mast 
cells. The proinflammatory effects of IL-17 are mediated through the IL-17 receptor (IL-17R), 
composed of IL-17RA and IL-17RD subunits [57]. IL-17R is widely expressed by immune 
cells like T cells, B cells and neutrophils, but also by other tissues such as epithelium, 
endothelium, fibroblasts, mesenchymal stromal cells and keratinocytes [57]. Il-17A 
promotes granulopoesis by triggering the secretion of granulocyte-colony-stimulating factor 
(G-CSF) in bone marrow stroma [58]. Moreover, IL-17 induces cytokines (GM-CSF, TNFα, 
IL-1β, IL-6), chemokines and chemokine receptors that act as powerful chemoattractants 
for granulocytes. Tissue damage by Th17 cells might be caused by direct recognition of the 
antigen-specific target, or it can result from the recruitment of neutrophils and macrophages 
into the microenvironment [59]. IL-17 also mediates the formation of inducible secondary 
lymphoid tissues following local infection [60] and plays an important role in immunity 
against a variety of micro-organisms [61]. 
Finally, Th17 cells have been implicated in the pathogenesis of autoimmune diseases in 
studies of experimental autoimmune encephalomyelitis (EAE) which is an animal model of 
multiple sclerosis (MS) [56, 62]. Since then, Th17 cells have been the subject of increasing 
attention in the context of systemic autoimmune diseases such as SLE, but also pSS, 
rheumatoid arthritis (RA) and psoriasis [63].  
1.5 SJÖGREN’S SYNDROME
1.5.1 Nomenclature
Jan Mikulicz-Radecki, a Polish-Austrian surgeon, was the first to report in 1888 on a male 
patient with bilateral enlargement of the parotid and lacrimal glands and diminished 
production of tears and saliva. The term Mikulicz’s syndrome could encompass all kinds of 
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diseases with swelling of the lacrimal and salivary glands such as tuberculosis, sarcoidosis 
and lymphoma. Consequently, this name gradually became a repository for a variety 
of diseases and fell into disuse. Also in 1888, Dr. W.B. Hadden described a woman with 
symptoms of dry eyes, mouth and skin which was successfully treated with pilocarpine. 
But it was not until 1933 that the Swedish ophthalmologist Henrik Sjögren described 19 
patients with symptoms of dry mouth, dry eyes and inflamed joints. He introduced the 
term ‘keratoconjuctivitis sicca’ (dry eyes) to distinguish it from dry eyes caused by lack of 
vitamin A (xerophthalmia). Given the high number of patients Henrik Sjögren described, the 
syndrome has been characterized by the term ‘Sjögren’s syndrome’ (SS). 
1.5.2 Clinical manifestations ― overview
SS is a generalized autoimmune disease, characterized by lymphocytic infiltrates of the 
salivary and lacrimal glands (also named sialoadenitis and dacryoadenitis, respectively). 
Patients suffer from dryness of the eyes (xerophthalmia) and dryness of the mouth 
(xerostomia) [64]. Characteristic eye symptoms are burning and/or itchy eyes as though 
there is sand or a foreign body in the eyes. The most characteristic symptom of the mouth is 
that patients need to drink when eating dry food in order to be able to swallow it (so called 
cracker-sign). Due to the lack of lubrication, the incidence of opportunistic infections in both 
the eyes and the mouth is increased and the poor quality of the saliva may be the cause of 
severe dental caries and periodontal disease [65]. 
Besides the ocular and oral complaints, symptoms can be observed in many other organs 
as well as systemically. Many patients are affected by general symptoms like fatigue, joint 
pain, muscle pain and Raynaud’s phenomenon (abnormal vasoconstriction in digits). SS can 
be divided in primary and secondary SS, the latter being associated with another systemic 
autoimmune disease, such as rheumatoid arthritis, systemic lupus erythematosus (SLE) or 
systemic sclerosis (Ssc). In this thesis the focus will be mainly on primary Sjögren’s syndrome 
(pSS). 
According to Haugen et al. the prevalence of Sjögren’s syndrome (in a large Norwegian 
study) is 0.2 % for people between 40-44 years and 1.4 % for people between 71-74 years 
[66]. Women are affected by Sjögren’s syndrome 9x more frequently than men with the 
most common age of onset around menopause, however the disease may occur in patients 
of all ages [67, 68].
1.5.3 Extra glandular manifestations
For 40% of Sjögren’s syndrome patients, fatigue has been described as the most severe 
symptom [69]. It often varies from day to day, may come on very suddenly and usually 
increases during the course of the day and improves after a rest. It is estimated that over 
50% of patients suffer from extreme fatigue, in many cases leading to inability to work, and 
a strong decrease in quality of life [70-74]. 
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Other frequent extraglandular manifestations are found in the joints and muscles. About 
53% of pSS patients complain of arthralgia. Myalgias are reported in 22% of the pSS patients 
[75] and 7% of patients with fibromyalgia have pSS [76]. 
Skin problems are also a common feature of pSS. According to Bernacchi et al. [77] 
xerosis (skin dryness) and angular cheilitis (chronic inflammatory condition of the corners 
of the mouth) are the most frequent skin diseases in pSS. Bernacchi et al. also found a 
significant connection between xerosis erythema and the presence of anti-SSA and anti-SSB 
antibodies in pSS  patients. Other manifestations include cutaneous Raynaud’s phenomenon, 
vitiligo, anetoderma, alopecia, cutaneous lymphomas and vasculitis [78]. Vasculitis is an 
inflammation of small blood vessels and concerns mainly the blood vessels of the skin in the 
case of pSS [79-81]. Besides dryness of the skin, increased mucosal dryness is found in many 
pSS patients, in particular the vagina, resulting in an increased risk of local infections [67]. 
Cough due to tracheobronchial sicca and interstitial pneumonitis are the most 
common presentation of pulmonary involvement in pSS [82]. Other potential pulmonary 
complications include MALT (mucosa-associated lymphoid tissue) lymphoma or other types 
of lymphoma of the lung [83]. 
Renal manifestations include mostly interstitial nephritis, with or without renal tubular 
acidosis [84]. Unlike in other autoimmune diseases, the glomeruli in pSS are spared [85] and 
renal injury is due to lymphocyte infiltration of the interstitial space rather than immune 
complex deposition [86]. Symptoms indicating an interstitial cystitis are common in pSS and 
can be severe [87, 88].
Gastrointestinal manifestations include dysphagia (difficulty in swallowing) that is partly 
a result of xerostomia but also of oesophageal dysmotility. pSS patients can also suffer 
from functional dyspepsia (indigestion) causing symptoms of epigastric pain, early satiety, 
postprandial fullness and epigastric burning [89]. Coeliac disease is found in 10-14.7% of pSS 
patients [90, 91]. 
Neurological manifestations are reported in a relatively large subset of pSS patients. 
About 20% of patients suffer from neurological problems including central-nervous-
system involvement, cranial neuropathies, myelopathy and peripheral (primarily sensory) 
neuropathies [92-94]. Sensory peripheral neuropathy is the most common form of 
neuropathy in pSS. Psychiatric disorders like depression and anxiety are reported in many 
pSS patients [95, 96]. The high frequency suggests that they are part of the underlying 
process rather than simply a response to the stress of a chronic disease [97]. 
Hypothyroidism is more common in pSS compared with the general population [98, 
99]. In addition, pSS is present in about 10% of patients with autoimmune thyroid disease 
[100]. These patients are usually seropositive for anti-thyroid peroxidase (ant-TPO) and 
anti-thyroglobulin (ATG) antibodies [101]. In addition, in family members of pSS patients 
increased prevalence of thyroid diseases has been documented, suggesting genetic 
susceptibility [101].
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Hematological abnormalities are not uncommon in pSS, although they rarely have 
clinical significance. Lymphopenia has been reported in 35.3% of pSS patients, leukopenia in 
26.2% and thromobocytopenia in 7.1% [102].  
Finally, a lack of control of inflammatory processes may lead to the formation of 
lymphomas. Malignant lymphoma is the only cause of premature mortality for which 
pSS patients are at increased risk [103]. Compared with the general population, patients 
with pSS have a 16-44 times higher relative risk for the development of a Non-Hodgkin 
lymphoma [104, 105]. Lifetime risk for the development of lymphoma is approximately 5%-
10% in patients with pSS [106-108]. A retrospective study showed that the following factors 
could predict the development of Non-Hodgkin lymphoma: neutropenia, cryoglobulinemia, 
splenomegaly, lymphadenopathy and low C4 levels [109]. Furthermore, the detection of 
germinal centre-like structures in pSS diagnostic salivary biopsies is proposed as a highly 
predictive marker for the development of Non-Hodgkin lymphoma [110]. 
1.5.4 Diagnosis
An early, precise diagnosis of pSS can help to prevent or ensure timely treatment of many of 
the complications associated with the disease. Early recovery of salivary function can relieve 
oral dryness symptoms for example and may prevent or slow the progress of dental caries, 
oral candidiasis and periodontal disease. Since many symptoms in accordance with pSS 
develop gradually over a period of time, are deceptively non-specific and are frequently seen 
in middle-aged women, these symptoms may initially be unjustly attributed to menopause 
[67]. Until 2002 several sets of diagnostic criteria for pSS were used. The discrepancy in 
these different diagnostic criteria led to substantial confusion in research publications and 
clinical-trial reports. 
Therefore an international consensus group suggested the latest set of criteria, the 
2002 European-American classification criteria to confirm and unify the diagnosis of pSS 
[111]. This set consists of six criteria, both subjective and objective in nature (Figure 5). 
The subjective criteria contain symptoms of dry eyes and dry mouth. The objective criteria 
include clinical tests of lacrimal (eye tests) and salivary function (imaging or function 
investigation of the salivary glands) and two laboratory measurements. These laboratory 
measurements contain the presence of antibodies against Ro/SSA and La/SSB and the 
presence of focal lymphocytic infiltrates in biopsy material of the minor salivary glands. 
Establishment of the diagnosis of pSS requires four of these six criteria, including a positive 
minor-salivary-gland biopsy sample (focus score ≥ 1, defined as a number of lymphocytic 
foci which contain more than 50 lymphocytes per 4 mm² of glandular tissue) or antibody to 
SSA/SSB. All other possible causes of oral and ocular dryness such as previous radiotherapy 
to the head and neck, lymphoma, sarcoidosis, graft-versus-host disease and hepatitis C 
infection must be excluded. 
General introduction
Ch
ap
te
r 
1
21
1. Ocular symptoms—A positive response to at least one of the following questions:
a) Have you had daily, persistent, troublesome dry eyes for more than 3 months?
b) Do you have a recurrent sensation of sand or gravel in the eyes?
c) Do you use tear substitutes more than three times a day?
2. Oral symptoms—A positive response to at least one of the following questions:
a) Have you had a daily feeling of dry mouth for more than 3 months?
b) Have you had recurrently or persistently swollen salivary glands as an adult?
c) Do you frequently drink liquids to aid in swallowing dry food?
3. Ocular signs—Objective evidence of ocular involvement defined as a positive result for at least one of the following tests:
a) Schirmer’s test for tear function, performed without anaesthesia (positive result ≤5 mm in 5 minutes)
b) Rose Bengal score or other ocular dye score (positive result score ≥4 on the van Bijsterveld scoring system)
4. Histopathology—In minor salivary glands (obtained through normal appearing mucosa) focal lymphocytic sialoadenitis, evaluated by
an expert histopathologist, with a focus score of 1 (defined as the number of lymphocytic foci (which are adjacent to normal appearing
mucous acini and contain >50 lymphocytes) per 4 mm2 of glandular tissue)
5. Salivary gland involvement—Objective evidence of salivary gland involvement defined by a positive result for at least one of the
following tests:
a) Unstimulated whole salivary flow (<1.5 mL in 15 minutes)
b) Parotid sialography showing presence of diffuse sialectasias (punctate, cavitary, or destructive pattern) without evidence of obstruction
in the major ducts
c) Salivary scintigraphy showing delayed uptake, reduced concentration, or delayed excretion of tracer
6. Autoantibodies to Ro/SS-A or La/SS-B antigens, or both
Presence of primary Sjögren syndrome
Patients are classified as having primary Sjögren syndrome when they fulfil ≥4 of the 6 criteria; either criterion 4 (salivary gland pathology)
or 6 (autoantibodies) is mandatory
Exclusion criteria—Past head and neck radiation treatment, hepatitis C infection, AIDS, pre-existing lymphoma, sarcoidosis, graft versus
host disease, use of anticholinergic drugs
Figure 5. Adapted from Ramos-Casals M. et al (2012)[112]. 2002 American-European classification criteria for 
Sjögren’s syndrome.
Although these criteria result in more homogeneous and comparable patient populations 
in research, almost 60% of patients diagnosed by experienced clinicians as having pSS do not 
completely fulfil these criteria, even though the symptoms cannot be attributed to another 
disease [112]. The patients that do not fulfil the criteria but have pSS symptoms,  frequently 
do not receive the proper treatment. Although it is a point of discussion, this group might be 
considered as pSS for clinical practice since this group is likely to benefit from the common 
treatment for pSS.
1.5.5 Treatment
Stimulation of salivary and lacrimal glands
Despite recent knowledge the treatment of pSS is rather symptomatic than causal. 
Treatment is aimed at recognizing and treating complications of the disease early. When 
patients still have some salivary and lacrimal function present, initial therapy is directed 
toward stimulating flow by sucking on flavoured lemon lozenges for example and chewing 
gum [113]. In patients where this type of stimulation is not sufficient, pharmacological 
intervention like muscarinic agonists such as pilocarpine may be needed.
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Acetylcholine binds to muscarinic 3 receptors (M3Rs), which are present in the salivary 
and lacrimal glands, to stimulate saliva and tear flow. It has been proposed that acetylcholine 
does not bind successfully to M3Rs in pSS patients due to blocking antibodies against the 
M3R [114-117], although these findings are a matter of debate. Pilocarpine is a muscarin 
agonist that stimulates M3Rs to produce more saliva and tear flow. Two placebo-controlled 
trials showed pilocarpine induced improvement of both dry eye and dry mouth symptoms 
[118, 119], while a third trial found a similar improvement in solely dry mouth symptoms 
[120]. When pharmacological intervention does not suffice to increase tear flow, temporary 
or permanent occlusion can be used to block tear drainage and thus retain existing tears. 
Replacement fluids 
The use of replacement fluids may be helpful when pSS patients do not have sufficient 
remaining salivary and lacrimal function. Flushing water or using artificial saliva can alleviate 
oral dryness and artificial tears can be used to treat persistent symptoms of dry eyes [113]. 
Systemic therapy
Systemic manifestations such as arthralgia are generally treated with salicylates, non-
steroidal anti-inflammatory drugs (NSAIDs) and hydroxychloroquine (HCQ). HCQ is an 
anti-inflammatory and disease-modifying drug and its inhibitory activity in autoimmune 
diseases has been attributed to the inhibition of endosomal acidification, since acidic pH is a 
prerequisite of endosomal TLR activation [121-123]. Strong interactions of nucleic acid TLR 
ligands with TLR occur only under pH 4.5-6.5. Recently Kuznik et al. showed that inhibition 
of pH acidification is not the underlying cause of inhibitory effect of HCQ in autoimmunity 
[124]. Instead, a direct binding of HCQ to nucleic acid TLR ligands was found, masking the 
TLR binding epitope and possibly explaining the efficiency of HCQ in autoimmune diseases. 
Only 1 double-blind placebo-controlled study on HCQ in pSS has been performed [125]. In 
this 2-year crossover trial 19 patients were treated with 400 mg HCQ per day. No significant 
differences in HCQ vs. placebo were found for clinical symptoms. In the HCQ group an 
improvement of hyperglobulinaemia, erythrocyte sedimentation rate (ESR) and IgM was 
found. An open label study of HCQ in 14 patients showed no effects on sicca symptoms 
and fatigue but significant reduction in ESR, C-reactive protein and IgG levels [126]. A 
retrospective study of 50 pSS patients showed improvement of painful eye and mouth 
symptoms, improvement of arthralgias and myalgias and a significant improvement in ESR 
and IgG levels [127]. Finally, a more recent retrospective analysis on 14 pSS patients showed 
beneficial effects of HCQ on xerostomia [128].     
Corticosteroids are effective but limited by their common side effects and are therefore 
preserved for visceral involvement like vasculitis, pneumonitis, neuropathy and nephritis. 
There is limited evidence on the use of immunosuppressive agents, since controlled and 
prospective studies are small and are specifically designed to evaluate sicca features [113].  
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Biologicals 
It is justified to use expensive biologic therapies in pSS patients with severe systemic 
involvement who fail to respond to conventional immunosuppression, despite the rare but 
potentially serious side effects of biologic therapy [129]. In the last decade anti-TNFs have 
taken the central stage for the treatment of rheumatic and autoimmune diseases. In contrast 
to the enormous success of anti-TNF agents in rheumatoid arthritis (RA), these agents have 
been found inefficacious in pSS [130-133]. Inefficacious results might be due to increased IFN 
type I response [134, 135], increased BAFF production [135] and increased Th17 response 
[136] upon anti-TNF therapy. The levels of circulating TNFα were even reported significantly 
increased in pSS patients after anti-TNF treatment [137]. How an antagonist of TNF might 
augment its levels has remained a puzzle. One explanation of diminished IL-10 in pSS, which 
is an inhibitor of TNFα production, has been suggested. 
Rituximab, a monoclonal antibody against CD20 causing B cell depletion, has been 
considered to be effective in pSS. This antibody used for the treatment of B cell lymphoma, 
resulted in significant improvement in salivary gland function, decreased rheumatoid factor, 
improvement of extra-glandular manifestations and general well-being of treated pSS patients 
[138]. However after 36-48 weeks post treatment there is a reappearance of circulating B 
cells [139, 140] and relapse of clinical symptoms [138, 141-144]. The first reappearing B cells 
in the peripheral blood displayed a phenotype pointing toward transitional B cells, indicating 
that these cells are newly generated bone marrow derived B cells [145]. Contradicting data 
exist concerning the presence of CD20+ B cells in the salivary gland biopsies after rituximab 
[140, 146]. One group finds despite full depletion of circulating CD20+ B cells by rituximab 
still B cells present in parotid biopsies 12 weeks after initial treatment [146], while others 
demonstrated a complete absence of B cells in labial salivary gland biopsies up to one year 
after rituximab treatment [140]. Regarding retreatment with rituximab, most patients that 
were retreated reported a beneficial effect comparable to that of the initial treatment 
[138, 141, 142, 144]. Interestingly, following B cell depletion therapy with rituximab, BAFF 
protein levels were found elevated in pSS patients [147, 148]. Higher baseline BAFF levels 
were shown to lead to a shorter period of B cell depletion after rituximab treatment [140]. 
Moreover persistently elevated BAFF levels are also associated with resistance to rituximab 
treatment in pSS patients with lymphoma [149].   
For this reason a new treatment for pSS has been proposed: Belimumab, a fully human 
IgG1 antibody directed against BAFF. pSS patients show an increased expression of BAFF 
in both serum [150, 151] and salivary glands [152], suggesting a critical role for BAFF in 
pSS. BAFF expression was furthermore found increased in peripheral blood mononuclear 
cells (PBMCs), epithelial cells, T cells and B cells within the salivary glands of pSS patients 
[151, 153, 154]. Belimumab  was successful in clinical trials in SLE and is already in clinical 
use [155]. Although Belimumab trials in pSS have been registered (www.clinicalstudies.gov), 
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results of these studies are not known up till now. Another BAFF-blocking agent is Atacicept, 
which is a recombinant fusion protein designed to block the activity of both BAFF and APRIL. 
Initial study of Atacicept with mycophenolate in SLE patients had to be prematurely stopped 
due to infections in 3/6 SLE patients [156]. 
Epratuzumab, recombinant humanized monoclonal antibody, targets another B cell 
surface protein namely CD22. In contrast to anti-CD20 agents, Epratuzumab appears to 
function more by modulation of B cells rather than by their depletion capacity. Epratuzumab 
has been investigated in an open-label study of 16 pSS patients and showed clinical 
response in 52% to 67% of patients [157]. Further studies are needed to determine whether 
Epratuzumab is a promising therapy for pSS.
Abatacept is a fusion protein consisting of CTLA-4 linked to the Fc portion of IgG1. It is 
similar to CD28 in the way that it contains a high-affinity binding site for CD80 and CD86. 
For T cell activation next to binding of the T cell receptor to  the MHC complex on APCs, a 
costimulatory signal is necessary as well. This costimulatory signal is provided by the binding 
of the T cell’s CD28 protein to the CD80/86 protein on APCs. Abatacept binds to the CD80/86 
protein on APCs and prevents the delivery of a costimulatory signal to T cells, resulting 
in prevention of T cell activation. Abatacept is licensed for the treatment of rheumatoid 
arthritis [158] and recently a pilot study with Abatecept was performed in 11 pSS patients. 
This study showed that Abatacept treatment significantly increased saliva production, 
reduced glandular inflammation, induced expansion of naive B cells, total lymphocytes and 
CD4+ cells in the peripheral blood [159].  
1.5.6 Pathogenesis 
The pathogenesis of pSS is multifactorial. A complex interplay exists between genetic factors, 
hormonal mechanisms and environmental events that involve innate and adaptive immunity 
including autoantibodies [160]. The first stages in the pathogenesis are still unclear.
Genetic factors
Some familial clustering of pSS has been identified, suggesting a genetic component of the 
disease. In fact, a family history of autoimmune diseases causes a seven fold increased risk of 
developing pSS [161]. The genetics of pSS involve HLA and non-HLA genes. pSS is associated 
with increased frequencies of HLA-B8, HLA-Dw3 and HLA-DR3 [162, 163]. Polymorphisms of 
non-HLA genes occur in  the IFN type I pathway such as STAT4 and IRF5 [164-166]. A strong 
additive effect between the risk alleles of IRF5 and STAT4 was found for pSS [165].
Hormonal mechanisms
A role for sex steroids has been proposed given the female predominance among pSS 
patients and the fact that the most common age of onset is around menopause. Estrogen 
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receptor (ER) and mRNA of ER have been detected in salivary gland tissue and cultured 
salivary gland epithelial cells [167-169]. Mouse studies have shown that estrogen suppresses 
the development of pSS, while ovariectomy leads to a Sjögren-like disease [170]. Estrogen 
can ameliorate recruitment of T cells in the gland [171] and prevent cell apoptosis in the 
lacrimal glands in a murine model for pSS [172]. Interestingly, another group proposed 
that a defect in the synthesis of androgens in the salivary glands of pSS patients plays an 
important role and that the increased risk is due to a change in the androgen-estrogen ratio 
rather than absolute levels of estrogens [173] . Ovaries produce low levels of testosterone, 
which decrease at the time of menopause. The other significant source of androgens is the 
adrenal cortex, which produces dehydroepiandrosterone (DHEA) and its metabolite DHEA 
sulfate (DHEA-S) [160]. DHEA concentrations reach their peak in early adulthood and decline 
with age and are 40-50% lower in pSS compared with age and sex matched controls [174]. 
DHEA is a prohormone which can be converted to either androgens or estradiol locally 
in target organs including the salivary glands. Women may be particularly vulnerable to 
local androgen deficiency in the salivary gland in pSS as their local dihydrotestosterone 
production is completely dependent on local conversion of DHEA, whereas in men, systemic 
androgens may satisfy the local requirement [160]. Dillon et al. presented during the 11th 
international symposium in Athens data showing 4 times higher prevalence of pSS among 
females carrying the triple X chromosome (47XXX) compared with normal females (46XX). 
This would imply that genes on the X chromosome are responsible for the female bias of pSS 
rather than the sex hormones. 
Environmental factors
The initial trigger that causes salivary gland injury is presently unknown, though one of the 
postulated triggers is a viral infection [175]. In this case, the infection provides antigens to 
TLRs that are expressed by DCs and epithelial cells of the salivary glands, initiating MHC class 
II presentation and secretion of chemokines  and cytokines like IFN type I. Although no strict 
correlation has been found between pSS and one virus in particular, a few reports describe 
an association between pSS and EBV [176], HTLV1 [177], coxsackievirus [178] and HIV and 
hepatitis C viruses   (HCV) [179]. Infections with HCV or HIV are associated with development 
of sialoadenitis resembling pSS, however they are not characterized by production of anti-
SSA and anti-SSB autoantibodies nor by sex preference [180, 181].
Epithelial involvement
Several lines of evidence indicate that the target organ and in particular epithelial cells are 
not solely the innocent bystander targets of autoimmune responses but probably have 
their role as amplifiers of the inflammatory response [182]. In the salivary glands of the 
nonobese diabetic (NOD) mouse, which is a murine model for pSS, DCs were detected 
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before lymphocytic infiltration [183]. This suggests abnormalities in the exocrine gland itself 
that may contribute to the initiation of the autoimmune reaction. 
The expression ‘autoimmune epithelitis’ has been proposed as an alternative for 
Sjögren’s syndrome by Moutsopoulos back in 1994 [184]. Several studies show that salivary 
gland epithelial cells (SGEC) are activated in pSS and capable to function as non-professional 
APCs [185]. SGEC are reported to express MHC class I and class II as well as costimulatory 
molecules CD80 and CD86, thus providing both signals necessary for T cell activation [186-
189] (Figure 6). SGEC also express intercellular adhesion molecules ICAM1 and VCAM [190, 
191] and functional TLRs [192]. 
In addition, SGEC produce proinflammatory cytokines such as TNFα, IL-1 and IL-6 [193] 
and a number of chemokines involved in the recruitment of lymphocytes as well as the 
induction of germinal centers (GC). In 20% of pSS patients GC-like structures are found in 
the salivary glands [194, 195]. CXCL13, important for GC formation by attracting B and T 
cells through the receptor CXCR5, is reported to be elevated in pSS [196]. CCL19 and CCL21, 
involved in directing lymphocytes to lymphoid structures are also increased in pSS salivary 
glands. Furthermore, CXCL9 and CXCL10 are produced by SGEC from pSS patients, while 
most of CD3+ lymphocytes express CXCR3 (the common receptor for CXCL9 and CXCL10) 
[197]. CXCL12, constitutively expressed by SGEC, is the most efficient chemoattractant 
for pDCs and also synergizes with CXCL9 and CXCL10 [198]. Next to these chemokines, 
BAFF is expressed by SGEC in pSS after stimulation with IFN type I and type II, suggesting 
hypersensitivity of the salivary epithelial cells possibly after stimulation by innate immunity 
[153] (Figure 6). 
Finally, SGEC may serve as a source of Ro/SSA and La/SSB autoantigens by virtue of 
increased apoptosis. The Ro/La proteins are intracellular and therefore normally not 
exposed to immune cells. To expose  these proteins either elevated apoptotic death is 
required or the secretion of small endosomal vesicles, called exosomes [185]. Indeed, it has 
been shown that Ro/SSA and La/SSB undergo a redistribution during apoptosis and relocate 
to the surface of apoptotic cells [199, 200]. The pro-apoptotic molecules Fas and Fas ligand 
(Fas-L) are expressed by epithelial cells as well as by infiltrating mononuclear cells of the 
salivary and lacrimal glands of pSS patients [201-205]. Perforin and granzyme B expression 
was also observed in mononuclear cell infiltrates in pSS in contrast to HC [202] (Figure 6). 
Interestingly, X-chromosome-linked factors might influence apoptosis in salivary glands of 
patients with pSS [206]. The X-chromosome-linked inhibitor of apoptosis (XIAP) was found 
present in both pSS acinar and ductal epithelial cells and downregulated by TNFα. Next to 
apoptosis, the secretion of exosomes has been involved in the transfer of autoantigens to 
APCs [207]. Indeed, SGEC have been shown to release exosomes containing Ro/SSA and La/
SSB [208]. 
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Autoantibodies
In pSS patients a spectrum of autoantibodies to RNA binding proteins such as SSA, SSB, 
RNP, or SM can be found [209] (Figure 6). The anti-Ro/SSA and anti-La/SSB antibodies are 
considered typical and have been included in the American-European 2002 criteria. Other 
autoantibodies encountered in pSS patients are anti-nuclear antibodies (ANA), rheumatoid 
factor (RF), cryoglobulins and the less typical anti-mitochondrial antibodies (AMA), anti-
centromere antibodies (ACA), anti-smooth muscle antibodies (ASMA), antibodies against 
cyclic citrullinated peptides (anti-CCP) and anti-parietal cell antibodies [210]. 
Anti-Ro/SSA and anti-La/SSB antibodies are directed against ribonucleoprotein 
complexes, comprising small RNAs non-covalently associated with the proteins Ro52, 
Ro60 and the La protein [211]. Ro-52, also denoted TRIM21 and SSA1, is a member of the 
TRIM family of single-protein E3 ligases and is known to be IFN inducible [212]. Ro52 was 
described to negatively regulate IFNβ production following TLR3/4 stimulation by promoting 
the ubiquitination and proteasomal degradation of IFN regulatory factor 3 (IRF3) [213]. 
Subsequent study demonstrated that Ro52 is also able to degrade IRF7 following TLR7 and 
TLR9 stimulation [212]. It was postulated that Ro52 is central to a negative feedback loop 
which protects the host from prolonged exposure to IFN type I. Ro60 protein, having a shape 
that resembles a doughnut, binds to misfolded, noncoding RNAs in vertebrate cells and acts 
as a quality checkpoint for misfolded RNA [214]. The misfolded RNAs are recognized and 
then tagged by Ro60 for degradation. Mice lacking Ro60 are found to develop autoantibodies 
and membrano-proliferative glomerulonephritis. The La protein is a polypeptide that exists 
abundantly in both the nucleus and cytoplasm and plays fundamental roles in diverse 
processes of RNA metabolism [215]. 
Anti-Ro/SSA and anti-La/SSB antibodies are of both IgA and IgG and can be found in 
33-74% and 23-52% of pSS patients respectively, depending on the identification method 
used [210, 216-220]. Next to being systemically present in the serum, a striking local 
production of anti-SSA/SSB antibodies in pSS salivary glands has been reported [195]. In 
addition, autoantibodies to Ro and La have been detected both in whole saliva [221] and 
in parotid saliva [222] from pSS patients.  Anti-Ro/SSA antibodies are found either solely 
or together with anti-La/SSB, while sole anti-La/SS antibodies are only rarely detected. An 
association was reported between the presence of SSA/SSB autoantibodies and younger age 
at diagnosis, recurrent parotidmegaly, cutaneous vasculitis, Raynaud phenomenon, renal 
involvement, pulmonary involvement, peripheral neuropathy, ESR 50 mm/h, arthralgia, 
arthritis, leukopenia, thrombocytopenia and increased skin’s sensitivity to sunlight [210, 
217, 220, 223]. Finally, when women with these antibodies are pregnant, the antibodies 
can also cross the placenta causing in 10% of the cases neonatal lupus [224, 225]. The 
biggest risk of neonatal lupus is congenital heart block that occurs in 1-2% of the offspring 
of pregnant women positive for anti-SSA/SSB [226]. 
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Autoantibodies not used in the everyday clinical practice, but associated with pSS are 
anti-α-fodrin antibodies. α-fodrin is a 240 kDa cytoskeletal protein which is cleaved during 
apoptosis into smaller fragments of 150 kDa and 120kDa. α-fodrin of 120 kDa is found in 
the salivary glands of pSS patients, but not in healthy controls (HC) and antibodies against 
120 kDa α-fodrin are formed in pSS [227]. Prevalence of anti-α-fodrin is between 50% and 
95%, depending on the detection method used [228]. Immunization of neonatal mice 
with the 120 kDa α-fodrin antigen prevents disease development in a pSS mouse model 
[229]. Furthermore immunization with 120 kDa α-fodrin into normal recipients induced 
autoimmune lesions similar to pSS, suggesting a role for the anti-α-fodrin response in the 
pathogenesis of pSS. 
As previously mentioned, the major stimulus for saliva production is provided by 
acetylcholine through M3R. Autoantibodies against M3R have been reported in pSS patients 
and since M3Rs are expressed on salivary and lacrimal glands, it has been suggested that 
immune reaction to M3R plays a key role in the generation of pSS [114-117]. Interestingly, 
the decreased salivary flow in pSS patients does not correlate with the degree of 
lymphocytic infiltration in the salivary glands, suggesting that tissue destruction is not the 
only explanation for the sicca symptoms. In this light, anti-M3R antibodies might provide an 
alternative explanation for the lack of salivary flow. 
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Figure 6. Hypothetical scheme on the molecular interactions  in the salivary gland of pSS patients based on data 
from the literature. SGEC are reported to express TLRs, MHC class I and class II as well as costimulatory molecules 
CD80 and CD86. In addition, SGEC produce proinflammatory cytokines and a number of chemokines and may serve 
as a source of Ro/SSA and La/SSB autoantigens by increased apoptosis. pDCs, conventional DCs, T cells and B cells 
are attracted to the gland where for example autoantibody production can take place.
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Interferon type I
Development of Sjögren-like symptoms has been described upon treatment with IFN type I 
in patients with malignancies and Hepatitis C [230-232] supporting the role for IFN type I in 
the pathogenesis of pSS. 
Gene array studies showed an increased IFN type I activation in salivary glands of pSS 
patients [233, 234]. Moreover, in 2 studies with a limited number of pSS patients, pDCs 
were detected in salivary glands but not in healthy controls [233, 235]. Given that there 
are 17 different IFN type I subtypes, it is difficult to measure serum protein levels using an 
Enzyme-Linked Immuno Sorbent Assay (ELISA). Therefore microarray studies on peripheral 
blood were conducted to study the systemic effect of IFN type I in pSS. A set of IFIGs, the 
so-called IFN type I signature, was detected in whole blood, PBMCs and monocytes from pSS 
patients [236, 237]. The number of pDC was found decreased in the blood of pSS patients 
and the remaining pDC showed signs of increased activation, pointing to these cells as a 
possible source for the increased systemic IFN type I activity in pSS [237]. Interestingly, IFN 
type I induction was much higher in PBMCs using pSS sera that contained antibodies to RNA-
binding proteins such as SSA, SSB, RNP or Sm [235]. Finally when SGECs were stimulated with 
an RNA virus or TLR3 ligands, production of large amounts of BAFF mRNA and protein was 
induced. This production could be blocked to some extent by an IFNAR antagonist, suggesting 
at least a contributory role for the IFN pathway in the generation of BAFF in pSS [153]. 
B cells
In pSS the presence of autoantibodies, hypergammaglobulinemia, development of GC-
like structures in the glands and increased occurrence of lymphomas all point to B cell 
hyperactivity [238]. A decrease in frequencies and numbers of CD27+ memory B cells in pSS 
peripheral blood compared with HC and an increase in naive and CD27- memory B cells have 
been shown [139, 239-242]. Also a higher percentage of plasma cells has been described 
in the peripheral blood of pSS patients with a focus score ≥2 compared with patients with 
focus score ≤1 [243]. In this same study a higher ratio of CD19- plasma cells/CD19+ plasma 
cells was detected in pSS compared with HC. Studies on the different B cell subsets present 
in the salivary glands of pSS patients are few and not very definitive [238]. 
BAFF
The first indications that BAFF might play an important role in the pathogenesis of pSS 
originate from the BAFF transgenic mouse model. BAFF transgenic mice develop next to 
lupus-like disease also infiltrates in their salivary glands accompagnied by reduction of 
saliva [244]. pSS patients show an increased expression of BAFF in both serum [150, 151] 
and salivary glands [152]. The level of serum BAFF has been shown to correlate with the 
autoantibody titer in pSS [150]. The BAFF-R receptor, located on B cells and activated T cells, 
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is decreased in pSS and especially in patients with extraglandular involvement. In addition 
serum BAFF was found to correlate inversely with BAFF-R [245]. Finally, BAFF levels are 
found increased after Rituximab treatment [147]. It is hypothesized that a negative signal 
might be delivered from B cells to monocytes, thus inhibiting BAFF production. Therefore, 
B cell depletion could abolish this negative signal, leading to an increased transcription of 
BAFF mRNA. 
T cells
T cells constitute more than 75% of lymphocytes infiltrating the salivary gland [246]. 
Activated T cells expressing MHC class II and CD38 are elevated in the glands compared 
to the peripheral blood T cells [247]. In many aspects, the role of T cells in pSS remains 
cryptic, despite recent knowledge [248]. The production of Th1 cytokines is reported in the 
glands [193, 249], together with increased levels in saliva from pSS patients [250]. Yet a role 
for Th2- derived cytokines is reported in pSS as well [251]. Several studies have shown a 
decrease in Treg cells in Sjögren’s syndrome [252-254]. This is in contrast with other reports 
demonstrating an increase in Treg cells in peripheral blood and salivary gland tissue of pSS 
patients [255, 256].
Recent years, Th17 cells have been implicated in the pathogenesis of pSS. In the infiltrates 
in glands of both pSS patients and mouse models for pSS, IL-17 and IL-17 producing cells 
were observed, and IL-17A is thought to play an important role in the development of 
lymphocytic infiltrates [257-261]. In peripheral blood of pSS patients the number of IL-
17 producing CD4+ T cells [259] and IL-17 plasma levels were increased [260]. Moreover, 
induction of IL-17A expression in salivary glands of pSS-non-susceptible C57BL/6J mice by 
an adenovirus resulted in pSS-like disease supporting a role for IL-17 in disease development 
[262]. In addition, IL-21 has been detected in the serum and within the salivary glands of 
pSS patients, and levels correlated with hypergammaglobulinemia and autoantibody levels 
[263]. Also higher serum IL-22 levels were observed, correlating with higher anti-SSA/SSB 
antibodies, hypergammaglobulinemia and rheumatoid factor [264].
1.6 AIM OF THE THESIS
The role of IFN type I has been implicated in the pathogenesis of generalized autoimmune 
diseases such as pSS. The aim of this thesis was to determine the prevalence of the increased 
IFN type I activity in pSS and to elucidate the relation between the increased IFN type I 
activity and: 
a) disease manifestations 
b) other immunological parameters such as BAFF and Th17 cells
Chapter 2 demonstrates a monocyte IFN type I inducible signature as a tool for assessment 
of systemic IFN type I activity. Moreover, the prevalence of the IFN type I signature in pSS 
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is described and the correlation with disease manifestations and BAFF protein and BAFF 
mRNA expression. Since the IFN type I activity is assessed via laborious expression profiles 
of multiple IFN type I inducible genes, an easy and practical assay for identifying systemic 
IFN type I bioactivity in pSS is described in Chapter 3. 
IFN type I has also been implicated in diseases like SLE and systemic sclerosis. Systemic 
sclerosis (SSc) is a complex autoimmune disease with extensive fibrosis, vascular alterations 
and immune activation among its principal features [265]. With an incidence of 1-2 per 
100.000 it is a rare disease in which chronic oxidative stress and inflammation lead to organ 
failure ending up in severe fibrosis of skin and internal organs including kidney, lung and 
heart. IFN type I activity has been observed either in the affected skin or in immune cells 
isolated from the circulation [266-268]. Clinically, the expression of the IFN type I induced 
genes Siglec-1 and IFI44 in skin biopsies correlated well with the mean Rodnan Skin Score 
(mRSS), currently the only available disease progression marker [269]. In addition, a positive 
correlation was observed between IFN type I genes and the appearance of digital ulcers 
and a negative correlation with the presence of anti-centromere antibodies (ACA)[270]. 
Increased BAFF has been detected in the skin and serum of SSc patients and correlates 
positively to the extent of skin fibrosis [271-273]. 
The prevalence of the increased IFN type I activity in SSc patients has not been 
established yet. In Chapter 4 the prevalence of the monocyte IFN type I signature is assessed 
in SSc patients. Also the association between IFN type I and disease manifestations, BAFF 
expression and collagen metabolism is studied. In addition, the possible role of the IFN type 
I signature as a biomarker for progressive disease is investigated. 
Imatinib mesylate is used as a treatment for therapy-refractory SSc with high variability 
in therapeutic outcomes ranging from ineffective/toxic responses to extremely encouraging 
clinical improvement. This high variability in treatment outcomes stresses the need for 
a biomarker identifying SSc patients likely to respond to Imatinib treatment. Chapter 5 
describes the IFN type I signature as a possible predictor for SSc patients responding to 
Imatinib treatment.
 
SLE is a debilitating systemic autoimmune disease characterized by the production of auto-
reactive antibodies and multi- organ inflammation [274]. Also lupus like symptoms were 
observed after IFN type I treatment in patients with malignancies [275]. About half of the SLE 
patients exhibit upregulation of IFN type I induced genes which has been found to correlate 
with disease activity and severity as well as with the presence of autoantibodies against 
RNA binding proteins [25, 26, 276, 277]. IC’s containing both RNA and DNA are found to be 
IFN type I inducers in SLE [278, 279]. This occurs through FcγR-dependent internalization 
of the IC’s by pDCs, followed by TLR7 and 9 activation [280-282]. Increased expression of 
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BAFF protein has been observed in SLE patients, correlating with increased disease activity 
[283-285]. Finally, in SLE patients increased plasma levels of IL-17A are present and IL-17 
producing cells in the peripheral blood, correlating with disease severity [286-288]. IL-17-
producing cells have also been found in several effected organs of SLE patients [287, 289]. 
A possible co-activity between the pathogenic IFN type I and IL-17/Th17 pathway has 
been suggested in autoimmune diseases. Data about co-occurrence of these 2 pathways in 
patients has not been shown yet. In Chapter 6 chemokine receptor defined Th17 cells have 
been assessed and compared between IFN+ and IFN- pSS patients. Chapter 7 compares 
the IL-17A and IL-17F producing CCR6+ T memory cell percentages between IFN+ and IFN- 
SLE patients. Finally, Chapter 8 discusses the significance and implications of the studies 
described, and provides directions for future research. 
General introduction
Ch
ap
te
r 
1
33
REFERENCES
[1] Geutskens SB, Otonkoski T, Pulkkinen MA, Drexhage HA, Leenen PJ. Macrophages in the murine pancreas and 
their involvement in fetal endocrine development in vitro. J Leukoc Biol, 2005;78:845-52.
[2] Welzen-Coppens JM, van Helden-Meeuwsen CG, Drexhage HA, Versnel MA. Abnormalities of dendritic cell 
precursors in the pancreas of the NOD mouse model of diabetes. Eur J Immunol, 2012;42:186-94.
[3] Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annual review 
of biochemistry, 1998;67:227-64.
[4] Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. 
Journal of leukocyte biology, 2009;86:23-32.
[5] Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci, 1957;147:258-67.
[6] Ronnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Upsala journal of 
medical sciences, 2011;116:227-37.
[7] Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature reviews Immunology, 
2005;5:375-86.
[8] Krause CD, Pestka S. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and 
relatives. Pharmacology & therapeutics, 2005;106:299-346.
[9] Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annual 
review of immunology, 2005;23:275-306.
[10] Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren’s syndrome. Journal 
of autoimmunity, 2010;35:225-31.
[11] Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune 
responses. Annals of the New York Academy of Sciences, 2010;1183:89-103.
[12] Barber GN. Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production 
and inflammatory responses. Current opinion in immunology, 2011;23:10-20.
[13] Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory 
factor family of transcription factors. Immunity, 2006;25:349-60.
[14] Gauzzi MC, Del Corno M, Gessani S. Dissecting TLR3 signalling in dendritic cells. Immunobiology, 
2010;215:713-23.
[15] Ronnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Seminars in 
immunology, 2011;23:113-21.
[16] Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. International immunology, 
2009;21:317-37.
[17] Kalliolias GD, Ivashkiv LB. Overview of the biology of type I interferons. Arthritis research & therapy, 2010;12 
Suppl 1:S1.
[18] Gao S, von der Malsburg A, Dick A, Faelber K, Schroder GF, Haller O et al. Structure of myxovirus resistance 
protein a reveals intra- and intermolecular domain interactions required for the antiviral function. Immunity, 
2011;35:514-25.
[19] Ronni T, Melen K, Malygin A, Julkunen I. Control of IFN-inducible MxA gene expression in human cells. J 
Immunol, 1993;150:1715-26.
[20] Haller O, Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral 
activity. J Interferon Cytokine Res, 2011;31:79-87.
[21] Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR et al. Interferons at age 50: past, current 
and future impact on biomedicine. Nature reviews Drug discovery, 2007;6:975-90.
[22] Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. Journal of leukocyte 
biology, 2002;71:565-81.
[23] Karlsson-Parra A, Burman P, Hagberg H, Oberg K, Alm G, Klareskog L et al. Autoantibodies to epithelial cells in 
patients on long-term therapy with leucocyte-derived interferon-alpha (IFN-alpha). Clinical and experimental 
immunology, 1990;81:72-5.
[24] Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha 
treatment in a patient with a malignant carcinoid tumour. Journal of internal medicine, 1990;227:207-10.
[25] Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures 
in systemic lupus erythematosus blood. The Journal of experimental medicine, 2003;197:711-23.
[26] Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al. Interferon-inducible gene 
expression signature in peripheral blood cells of patients with severe lupus. Proceedings of the National 
Academy of Sciences of the United States of America, 2003;100:2610-5.
Chapter 1
34
[27] Strandberg L, Ambrosi A, Espinosa A, Ottosson L, Eloranta ML, Zhou W et al. Interferon-alpha induces up-
regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific 
monoclonal antibodies. Journal of clinical immunology, 2008;28:220-31.
[28] Varin MM, Le Pottier L, Youinou P, Saulep D, Mackay F, Pers JO. B-cell tolerance breakdown in Sjogren’s 
syndrome: focus on BAFF. Autoimmunity reviews, 2010;9:604-8.
[29] Daridon C, Youinou P, Pers JO. BAFF, APRIL, TWE-PRIL: who’s who? Autoimmun Rev, 2008;7:267-71.
[30] Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annual review of 
immunology, 2003;21:231-64.
[31] Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N et al. BAFF, a novel ligand of the tumor 
necrosis factor family, stimulates B cell growth. The Journal of experimental medicine, 1999;189:1747-56.
[32] Shu HB, Hu WH, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. 
Journal of leukocyte biology, 1999;65:680-3.
[33] Mukhopadhyay A, Ni J, Zhai Y, Yu GL, Aggarwal BB. Identification and characterization of a novel cytokine, 
THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. 
The Journal of biological chemistry, 1999;274:15978-81.
[34] Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P et al. BLyS: member of the tumor necrosis factor 
family and B lymphocyte stimulator. Science, 1999;285:260-3.
[35] Schaumann DH, Tuischer J, Ebell W, Manz RA, Lauster R. VCAM-1-positive stromal cells from human bone 
marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L, and BAFF. Molecular 
immunology, 2007;44:1606-12.
[36] Hase H, Kanno Y, Kojima M, Hasegawa K, Sakurai D, Kojima H et al. BAFF/BLyS can potentiate B-cell selection 
with the B-cell coreceptor complex. Blood, 2004;103:2257-65.
[37] Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA et al. Fibroblast-like synoviocytes of mesenchymal 
origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J 
Immunol, 2005;174:864-70.
[38] Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM et al. BAFF is produced by astrocytes 
and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. The Journal of 
experimental medicine, 2005;201:195-200.
[39] Daridon C, Pers JO, Devauchelle V, Martins-Carvalho C, Hutin P, Pennec YL et al. Identification of transitional 
type II B cells in the salivary glands of patients with Sjogren’s syndrome. Arthritis and rheumatism, 
2006;54:2280-8.
[40] Lahiri A, Pochard P, Le Pottier L, Tobon GJ, Bendaoud B, Youinou P et al. The complexity of the BAFF TNF-
family members: implications for autoimmunity. Journal of autoimmunity, 2012;39:189-98.
[41] Le Pottier L, Bendaoud B, Renaudineau Y, Youinou P, Pers JO, Daridon C. New ELISA for B cell-activating factor. 
Clinical chemistry, 2009;55:1843-51.
[42] Meyer-Bahlburg A, Andrews SF, Yu KO, Porcelli SA, Rawlings DJ. Characterization of a late transitional B 
cell population highly sensitive to BAFF-mediated homeostatic proliferation. The Journal of experimental 
medicine, 2008;205:155-68.
[43] Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F et al. Excess BAFF rescues self-reactive B cells 
from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity, 
2004;20:785-98.
[44] Gavin AL, Ait-Azzouzene D, Ware CF, Nemazee D. DeltaBAFF, an alternate splice isoform that regulates 
receptor binding and biopresentation of the B cell survival cytokine, BAFF. The Journal of biological chemistry, 
2003;278:38220-8.
[45] Gavin AL, Duong B, Skog P, Ait-Azzouzene D, Greaves DR, Scott ML et al. deltaBAFF, a splice isoform of BAFF, 
opposes full-length BAFF activity in vivo in transgenic mouse models. J Immunol, 2005;175:319-28.
[46] Martin F, Dixit VM. Unraveling TACIt functions. Nat Genet, 2005;37:793-4.
[47] Afkarian M, Sedy JR, Yang J, Jacobson NG, Cereb N, Yang SY et al. T-bet is a STAT1-induced regulator of IL-12R 
expression in naive CD4+ T cells. Nature immunology, 2002;3:549-57.
[48] Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 
lineage commitment. Cell, 2000;100:655-69.
[49] Oestreich KJ, Weinmann AS. Transcriptional mechanisms that regulate T helper 1 cell differentiation. Current 
opinion in immunology, 2012;24:191-5.
[50] Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for 
development of Th2 cells. Immunity, 1996;4:313-9.
General introduction
Ch
ap
te
r 
1
35
[51] Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene 
expression in CD4 T cells. Cell, 1997;89:587-96.
[52] Deenick EK, Tangye SG. Autoimmunity: IL-21: a new player in Th17-cell differentiation. Immunol Cell Biol, 
2007;85:503-5.
[53] McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T et al. TGF-beta and IL-6 drive 
the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nature immunology, 
2007;8:1390-7.
[54] Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al. IL-23 drives a pathogenic T cell 
population that induces autoimmune inflammation. The Journal of experimental medicine, 2005;201:233-
40.
[55] Zhou L, Ivanov, II, Spolski R, Min R, Shenderov K, Egawa T et al. IL-6 programs T(H)-17 cell differentiation by 
promoting sequential engagement of the IL-21 and IL-23 pathways. Nature immunology, 2007;8:967-74.
[56] Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annual review of immunology, 2009;27:485-
517.
[57] Gaffen SL. Structure and signalling in the IL-17 receptor family. Nature reviews Immunology, 2009;9:556-67.
[58] Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C et al. T cell interleukin-17 induces stromal 
cells to produce proinflammatory and hematopoietic cytokines. The Journal of experimental medicine, 
1996;183:2593-603.
[59] Spolski R, Wang L, Wan CK, Bonville CA, Domachowske JB, Kim HP et al. IL-21 promotes the pathologic 
immune response to pneumovirus infection. J Immunol, 2012;188:1924-32.
[60] Rangel-Moreno J, Carragher DM, de la Luz Garcia-Hernandez M, Hwang JY, Kusser K, Hartson L et al. The 
development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nature immunology, 
2011;12:639-46.
[61] Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood, 2013;121:2402-14.
[62] Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV et al. Therapeutic efficacy of IL-17 
neutralization in murine experimental autoimmune encephalomyelitis. Cellular immunology, 2005;237:123-
30.
[63] Ambrosi A, Espinosa A, Wahren-Herlenius M. IL-17: a new actor in IFN-driven systemic autoimmune diseases. 
European journal of immunology, 2012;42:2274-84.
[64] Fox RI, Howell FV, Bone RC, Michelson P. Primary Sjogren syndrome: clinical and immunopathologic features. 
Semin Arthritis Rheum, 1984;14:77-105.
[65] Soto-Rojas AE, Villa AR, Sifuentes-Osornio J, Alarcon-Segovia D, Kraus A. Oral manifestations in patients with 
Sjogren’s syndrome. J Rheumatol, 1998;25:906-10.
[66] Haugen AJ, Peen E, Hulten B, Johannessen AC, Brun JG, Halse AK et al. Estimation of the prevalence of primary 
Sjogren’s syndrome in two age-different community-based populations using two sets of classification 
criteria: the Hordaland Health Study. Scand J Rheumatol, 2008;37:30-4.
[67] Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern 
Med, 2004;164:1275-84.
[68] Bayetto K, Logan RM. Sjogren’s syndrome: a review of aetiology, pathogenesis, diagnosis and management. 
Aust Dent J, 2010;55 Suppl 1:39-47.
[69] Meijer JM, Meiners PM, Huddleston Slater JJ, Spijkervet FK, Kallenberg CG, Vissink A et al. Health-related 
quality of life, employment and disability in patients with Sjogren’s syndrome. Rheumatology (Oxford), 
2009;48:1077-82.
[70] Bax HI, Vriesendorp TM, Kallenberg CG, Kalk WW. Fatigue and immune activity in Sjogren’s syndrome. Ann 
Rheum Dis, 2002;61:284.
[71] Strombeck B, Ekdahl C, Manthorpe R, Jacobsson LT. Physical capacity in women with primary Sjogren’s 
syndrome: a controlled study. Arthritis Rheum, 2003;49:681-8.
[72] Godaert GL, Hartkamp A, Geenen R, Garssen A, Kruize AA, Bijlsma JW et al. Fatigue in daily life in patients 
with primary Sjogren’s syndrome and systemic lupus erythematosus. Ann N Y Acad Sci, 2002;966:320-6.
[73] Barendregt PJ, Visser MR, Smets EM, Tulen JH, van den Meiracker AH, Boomsma F et al. Fatigue in primary 
Sjogren’s syndrome. Ann Rheum Dis, 1998;57:291-5.
[74] Bjerrum K, Prause JU. Primary Sjogren’s syndrome: a subjective description of the disease. Clin Exp 
Rheumatol, 1990;8:283-8.
[75] Lindvall B, Bengtsson A, Ernerudh J, Eriksson P. Subclinical myositis is common in primary Sjogren’s syndrome 
and is not related to muscle pain. J Rheumatol, 2002;29:717-25.
Chapter 1
36
[76] Bonafede RP, Downey DC, Bennett RM. An association of fibromyalgia with primary Sjogren’s syndrome: a 
prospective study of 72 patients. J Rheumatol, 1995;22:133-6.
[77] Bernacchi E, Amato L, Parodi A, Cottoni F, Rubegni P, De Pita O et al. Sjogren’s syndrome: a retrospective 
review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. Clin Exp 
Rheumatol, 2004;22:55-62.
[78] Roguedas AM, Misery L, Sassolas B, Le Masson G, Pennec YL, Youinou P. Cutaneous manifestations of primary 
Sjogren’s syndrome are underestimated. Clin Exp Rheumatol, 2004;22:632-6.
[79] Alexander EL, Arnett FC, Provost TT, Stevens MB. Sjogren’s syndrome: association of anti-Ro(SS-A) antibodies 
with vasculitis, hematologic abnormalities, and serologic hyperreactivity. Ann Intern Med, 1983;98:155-9.
[80] Tsokos M, Lazarou SA, Moutsopoulos HM. Vasculitis in primary Sjogren’s syndrome. Histologic classification 
and clinical presentation. Am J Clin Pathol, 1987;88:26-31.
[81] Ramos-Casals M, Cervera R, Yague J, Garcia-Carrasco M, Trejo O, Jimenez S et al. Cryoglobulinemia in primary 
Sjogren’s syndrome: prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum, 
1998;28:200-5.
[82] Quismorio FP, Jr. Pulmonary involvement in primary Sjogren’s syndrome. Curr Opin Pulm Med, 1996;2:424-8.
[83] Constantopoulos SH, Tsianos EV, Moutsopoulos HM. Pulmonary and gastrointestinal manifestations of 
Sjogren’s syndrome. Rheum Dis Clin North Am, 1992;18:617-35.
[84] Maripuri S, Grande JP, Osborn TG, Fervenza FC, Matteson EL, Donadio JV et al. Renal involvement in primary 
Sjogren’s syndrome: a clinicopathologic study. Clinical journal of the American Society of Nephrology : CJASN, 
2009;4:1423-31.
[85] Gamron S, Barberis G, Onetti CM, Strusberg I, Hliba E, Martellotto G et al. Mesangial nephropathy in Sjogren’s 
syndrome. Scand J Rheumatol, 2000;29:65-7.
[86] Fujimoto T, Dohi K. [Renal involvement in Sjogren’s syndrome--interstitial nephritis and glomerulonephritis]. 
Nihon rinsho Japanese journal of clinical medicine, 1995;53:2495-502.
[87] Leppilahti M, Tammela TL, Huhtala H, Kiilholma P, Leppilahti K, Auvinen A. Interstitial cystitis-like urinary 
symptoms among patients with Sjogren’s syndrome: a population-based study in Finland. Am J Med, 
2003;115:62-5.
[88] Shibata S, Ubara Y, Sawa N, Tagami T, Hosino J, Yokota M et al. Severe interstitial cystitis associated with 
Sjogren’s syndrome. Intern Med, 2004;43:248-52.
[89] Ohlsson B, Scheja A, Janciauskiene S, Mandl T. Functional bowel symptoms and GnRH antibodies: common 
findings in patients with primary Sjogren’s syndrome but not in systemic sclerosis. Scand J Rheumatol, 
2009;38:391-3.
[90] Iltanen S, Collin P, Korpela M, Holm K, Partanen J, Polvi A et al. Celiac disease and markers of celiac disease 
latency in patients with primary Sjogren’s syndrome. Am J Gastroenterol, 1999;94:1042-6.
[91] Luft LM, Barr SG, Martin LO, Chan EK, Fritzler MJ. Autoantibodies to tissue transglutaminase in Sjogren’s 
syndrome and related rheumatic diseases. J Rheumatol, 2003;30:2613-9.
[92] Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D et al. Neurologic manifestations in 
primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore), 2004;83:280-91.
[93] Urban PP, Keilmann A, Teichmann EM, Hopf HC. Sensory neuropathy of the trigeminal, glossopharyngeal, and 
vagal nerves in Sjogren’s syndrome. J Neurol Sci, 2001;186:59-63.
[94] Barendregt PJ, van den Bent MJ, van Raaij-van den Aarssen VJ, van den Meiracker AH, Vecht CJ, van der 
Heijde GL et al. Involvement of the peripheral nervous system in primary Sjogren’s syndrome. Ann Rheum 
Dis, 2001;60:876-81.
[95] Stevenson HA, Jones ME, Rostron JL, Longman LP, Field EA. UK patients with primary Sjogren’s syndrome are 
at increased risk from clinical depression. Gerodontology, 2004;21:141-5.
[96] Valtysdottir ST, Gudbjornsson B, Lindqvist U, Hallgren R, Hetta J. Anxiety and depression in patients with 
primary Sjogren’s syndrome. J Rheumatol, 2000;27:165-9.
[97] Utset TO, Golden M, Siberry G, Kiri N, Crum RM, Petri M. Depressive symptoms in patients with systemic 
lupus erythematosus: association with central nervous system lupus and Sjogren’s syndrome. J Rheumatol, 
1994;21:2039-45.
[98] D’Arbonneau F, Ansart S, Le Berre R, Dueymes M, Youinou P, Pennec YL. Thyroid dysfunction in primary 
Sjogren’s syndrome: a long-term followup study. Arthritis Rheum, 2003;49:804-9.
[99] Perez B, Kraus A, Lopez G, Cifuentes M, Alarcon-Segovia D. Autoimmune thyroid disease in primary Sjogren’s 
syndrome. Am J Med, 1995;99:480-4.
[100] Tektonidou MG, Anapliotou M, Vlachoyiannopoulos P, Moutsopoulos HM. Presence of systemic autoimmune 
disorders in patients with autoimmune thyroid diseases. Ann Rheum Dis, 2004;63:1159-61.
General introduction
Ch
ap
te
r 
1
37
[101] Jara LJ, Navarro C, Brito-Zeron Mdel P, Garcia-Carrasco M, Escarcega RO, Ramos-Casals M. Thyroid disease in 
Sjogren’s syndrome. Clin Rheumatol, 2007;26:1601-6.
[102] Aoki A, Ohno S, Ueda A, Ideguchi H, Ohkubo T, Hagiwara E et al. [Hematological abnormalities of primary 
Sjogren’s syndrome]. Nihon Rinsho Meneki Gakkai Kaishi, 2000;23:124-8.
[103] Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren’s syndrome: a 
prospective cohort study. Arthritis Rheum, 2004;50:1262-9.
[104] Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR et al. Increased risk of 
lymphoma in sicca syndrome. Ann Intern Med, 1978;89:888-92.
[105] Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other 
malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. 
Ann Rheum Dis, 2006;65:796-803.
[106] Pariente D, Anaya JM, Combe B, Jorgensen C, Emberger JM, Rossi JF et al. Non-Hodgkin’s lymphoma 
associated with primary Sjogren’s syndrome. Eur J Med, 1992;1:337-42.
[107] Kauppi M, Pukkala E, Isomaki H. Elevated incidence of hematologic malignancies in patients with Sjogren’s 
syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control, 1997;8:201-4.
[108] Voulgarelis M, Moutsopoulos HM. Malignant lymphoma in primary Sjogren’s syndrome. Isr Med Assoc J, 
2001;3:761-6.
[109] Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of 
lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine 
(Baltimore), 2009;88:284-93.
[110] Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R et al. Lymphoid organisation in 
labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary 
Sjogren’s syndrome. Ann Rheum Dis, 2011;70:1363-8.
[111] Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al. Classification criteria 
for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European 
Consensus Group. Ann Rheum Dis, 2002;61:554-8.
[112] Brun JG, Madland TM, Gjesdal CB, Bertelsen LT. Sjogren’s syndrome in an out-patient clinic: classification 
of patients according to the preliminary European criteria and the proposed modified European criteria. 
Rheumatology (Oxford), 2002;41:301-4.
[113] Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X. Treatment of primary Sjogren syndrome: a systematic 
review. JAMA, 2010;304:452-60.
[114] Bacman S, Perez Leiros C, Sterin-Borda L, Hubscher O, Arana R, Borda E. Autoantibodies against lacrimal 
gland M3 muscarinic acetylcholine receptors in patients with primary Sjogren’s syndrome. Investigative 
ophthalmology & visual science, 1998;39:151-6.
[115] Robinson CP, Brayer J, Yamachika S, Esch TR, Peck AB, Stewart CA et al. Transfer of human serum IgG to 
nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of 
exocrine tissues in Sjogren’s syndrome. Proceedings of the National Academy of Sciences of the United States 
of America, 1998;95:7538-43.
[116] Nguyen KH, Brayer J, Cha S, Diggs S, Yasunari U, Hilal G et al. Evidence for antimuscarinic acetylcholine receptor 
antibody-mediated secretory dysfunction in nod mice. Arthritis and rheumatism, 2000;43:2297-306.
[117] Bacman S, Berra A, Sterin-Borda L, Borda E. Muscarinic acetylcholine receptor antibodies as a new marker of 
dry eye Sjogren syndrome. Investigative ophthalmology & visual science, 2001;42:321-7.
[118] Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL, 3rd, Tran-Johnson TK et al. Pilocarpine tablets 
for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, 
placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med, 1999;159:174-81.
[119] Papas AS, Sherrer YS, Charney M, Golden HE, Medsger TA, Jr., Walsh BT et al. Successful Treatment of Dry 
Mouth and Dry Eye Symptoms in Sjogren’s Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-
Controlled, Dose-Adjustment Study. J Clin Rheumatol, 2004;10:169-77.
[120] Wu CH, Hsieh SC, Lee KL, Li KJ, Lu MC, Yu CL. Pilocarpine hydrochloride for the treatment of xerostomia in 
patients with Sjogren’s syndrome in Taiwan--a double-blind, placebo-controlled trial. J Formos Med Assoc, 
2006;105:796-803.
[121] Macfarlane DE, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, 
chloroquine, and structurally related compounds. J Immunol, 1998;160:1122-31.
[122] Hacker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T et al. CpG-DNA-specific activation of 
antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and 
endosomal maturation. EMBO J, 1998;17:6230-40.
Chapter 1
38
[123] Yi AK, Tuetken R, Redford T, Waldschmidt M, Kirsch J, Krieg AM. CpG motifs in bacterial DNA activate 
leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol, 1998;160:4755-61.
[124] Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by 
antimalarial drugs and imidazoquinolines. J Immunol, 2011;186:4794-804.
[125] Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L et al. Hydroxychloroquine 
treatment for primary Sjogren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis, 
1993;52:360-4.
[126] Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjogren’s syndrome: its 
effect on salivary and serum inflammatory markers. Ann Rheum Dis, 1999;58:253-6.
[127] Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjogren’s syndrome with hydroxychloroquine: a 
retrospective, open-label study. Lupus, 1996;5 Suppl 1:S31-6.
[128] Rihl M, Ulbricht K, Schmidt RE, Witte T. Treatment of sicca symptoms with hydroxychloroquine in patients 
with Sjogren’s syndrome. Rheumatology (Oxford), 2009;48:796-9.
[129] Bowman S, Barone F. Biologic treatments in Sjogren’s syndrome. Presse Med, 2012;41:e495-509.
[130] Joseph A, Brasington R, Kahl L, Ranganathan P, Cheng TP, Atkinson J. Immunologic rheumatic disorders. J 
Allergy Clin Immunol, 2010;125:S204-15.
[131] Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ, Group BS. A systematic review of the off-label use of 
biological therapies in systemic autoimmune diseases. Medicine (Baltimore), 2008;87:345-64.
[132] Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E et al. Inefficacy of infliximab in primary 
Sjogren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren’s Syndrome 
(TRIPSS). Arthritis and rheumatism, 2004;50:1270-6.
[133] Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the 
treatment of patients with primary Sjogren’s syndrome: a pilot study. The Journal of rheumatology, 
2004;31:96-101.
[134] van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, Baeten DL et al. Regulation 
of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical 
response to treatment. Arthritis research & therapy, 2010;12:R11.
[135] Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-alpha 
pathway activation in patients with Sjogren’s syndrome treated with etanercept. Arthritis and rheumatism, 
2007;56:3995-4004.
[136] Aerts NE, De Knop KJ, Leysen J, Ebo DG, Bridts CH, Weyler JJ et al. Increased IL-17 production by peripheral 
T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of 
migration-associated chemokine receptor expression. Rheumatology (Oxford), 2010;49:2264-72.
[137] Moutsopoulos NM, Katsifis GE, Angelov N, Leakan RA, Sankar V, Pillemer S et al. Lack of efficacy of etanercept 
in Sjogren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune 
activation. Ann Rheum Dis, 2008;67:1437-43.
[138] Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N et al. Effectiveness of rituximab 
treatment in primary Sjogren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis 
Rheum, 2010;62:960-8.
[139] Abdulahad WH, Meijer JM, Kroese FG, Meiners PM, Vissink A, Spijkervet FK et al. B cell reconstitution and T 
helper cell balance after rituximab treatment of active primary Sjogren’s syndrome: a double-blind, placebo-
controlled study. Arthritis and rheumatism, 2011;63:1116-23.
[140] Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A et al. BAFF-modulated repopulation 
of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren’s syndrome. 
Arthritis and rheumatism, 2007;56:1464-77.
[141] Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K et al. Rituximab treatment in 
patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum, 2005;52:2740-50.
[142] Meijer JM, Pijpe J, Vissink A, Kallenberg CG, Bootsma H. Treatment of primary Sjogren syndrome with 
rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis, 2009;68:284-5.
[143] Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S et al. Improvement of Sjogren’s 
syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum, 2007;57:310-7.
[144] Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M et al. Tolerance and efficacy of rituximab and 
changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren’s syndrome. 
Ann Rheum Dis, 2007;66:351-7.
[145] Abdulahad WH, Kroese FG, Vissink A, Bootsma H. Immune regulation and B-cell depletion therapy in patients 
with primary Sjogren’s syndrome. J Autoimmun, 2012;39:103-11.
General introduction
Ch
ap
te
r 
1
39
[146] Pijpe J, Meijer JM, Bootsma H, van der Wal JE, Spijkervet FK, Kallenberg CG et al. Clinical and histologic 
evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjogren’s syndrome. 
Arthritis Rheum, 2009;60:3251-6.
[147] Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell-activating factor of 
the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. 
Ann Rheum Dis, 2007;66:700-3.
[148] Pollard RP, Abdulahad WH, Vissink A, Hamza N, Burgerhof JG, Meijer JM et al. Serum levels of BAFF, but not 
APRIL, are increased after rituximab treatment in patients with primary Sjogren’s syndrome: data from a 
placebo-controlled clinical trial. Ann Rheum Dis, 2013;72:146-8.
[149] Quartuccio L, Fabris M, Moretti M, Barone F, Bombardieri M, Rupolo M et al. Resistance to rituximab therapy 
and local BAFF overexpression in Sjogren’s syndrome-related myoepithelial sialadenitis and low-grade 
parotid B-cell lymphoma. The open rheumatology journal, 2008;2:38-43.
[150] Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T et al. The level of BLyS (BAFF) correlates with the titre 
of autoantibodies in human Sjogren’s syndrome. Annals of the rheumatic diseases, 2003;62:168-71.
[151] Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. B-cell activating factor of the tumour 
necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren’s 
syndrome. Scand J Immunol, 2008;67:185-92.
[152] Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X. Expression of BAFF (BLyS) in T cells infiltrating 
labial salivary glands from patients with Sjogren’s syndrome. The Journal of pathology, 2004;202:496-502.
[153] Ittah M, Miceli-Richard C, Eric Gottenberg J, Lavie F, Lazure T, Ba N et al. B cell-activating factor of the tumor 
necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in 
primary Sjogren’s syndrome. Arthritis research & therapy, 2006;8:R51.
[154] Daridon C, Devauchelle V, Hutin P, Le Berre R, Martins-Carvalho C, Bendaoud B et al. Aberrant expression of 
BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren’s syndrome. Arthritis 
and rheumatism, 2007;56:1134-44.
[155] van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS et al. Belimumab in the treatment 
of systemic lupus erythematosus: high disease activity predictors of response. Annals of the rheumatic 
diseases, 2012;71:1343-9.
[156] Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E et al. Atacicept in combination with MMF and 
corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis research & therapy, 
2012;14:R33.
[157] Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM et al. Epratuzumab (humanised 
anti-CD22 antibody) in primary Sjogren’s syndrome: an open-label phase I/II study. Arthritis research & 
therapy, 2006;8:R129.
[158] Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T et al. Safety and efficacy of the selective 
costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: 
a 5-year extended phase IIB study. The Journal of rheumatology, 2009;36:736-42.
[159] Adler S, Korner M, Forger F, Huscher D, Caversaccio MD, Villiger PM. Evaluation of histological, serological and 
clinical changes in response to abatacept treatment of primary Sjogren’s syndrome: A pilot study. Arthritis 
care & research, 2013.
[160] Nikolov NP, Illei GG. Pathogenesis of Sjogren’s syndrome. Current opinion in rheumatology, 2009;21:465-70.
[161] Priori R, Medda E, Conti F, Cassara EA, Sabbadini MG, Antonioli CM et al. Risk factors for Sjogren’s syndrome: 
a case-control study. Clinical and experimental rheumatology, 2007;25:378-84.
[162] Fye KH, Terasaki PI, Michalski JP, Daniels TE, Opelz G, Talal N. Relationshipp of HLA-Dw3 and HLA-B8 to 
Sjogren’s syndrome. Arthritis and rheumatism, 1978;21:337-42.
[163] Mann DL, Moutsopoulos HM. HLA DR alloantigens in different subsets of patients with Sjogren’s syndrome 
and in family members. Annals of the rheumatic diseases, 1983;42:533-6.
[164] Miceli-Richard C, Comets E, Loiseau P, Puechal X, Hachulla E, Mariette X. Association of an IRF5 gene 
functional polymorphism with Sjogren’s syndrome. Arthritis and rheumatism, 2007;56:3989-94.
[165] Nordmark G, Kristjansdottir G, Theander E, Eriksson P, Brun JG, Wang C et al. Additive effects of the major risk 
alleles of IRF5 and STAT4 in primary Sjogren’s syndrome. Genes and immunity, 2009;10:68-76.
[166] Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW et al. STAT4 and the risk of rheumatoid 
arthritis and systemic lupus erythematosus. The New England journal of medicine, 2007;357:977-86.
[167] Leimola-Virtanen R, Salo T, Toikkanen S, Pulkkinen J, Syrjanen S. Expression of estrogen receptor (ER) in oral 
mucosa and salivary glands. Maturitas, 2000;36:131-7.
Chapter 1
40
[168] Tsinti M, Kassi E, Korkolopoulou P, Kapsogeorgou E, Moutsatsou P, Patsouris E et al. Functional estrogen 
receptors alpha and beta are expressed in normal human salivary gland epithelium and apparently mediate 
immunomodulatory effects. European journal of oral sciences, 2009;117:498-505.
[169] Kassi E, Moutsatsou P, Sekeris CE, Moutsopoulos HM, Manoussakis MN. Oestrogen receptors in cultured 
epithelial cells from salivary glands of Sjogren’s syndrome patients. Rheumatology (Oxford), 2003;42:1120-2.
[170] Ishimaru N, Arakaki R, Watanabe M, Kobayashi M, Miyazaki K, Hayashi Y. Development of autoimmune 
exocrinopathy resembling Sjogren’s syndrome in estrogen-deficient mice of healthy background. The 
American journal of pathology, 2003;163:1481-90.
[171] Carlsten H, Nilsson N, Jonsson R, Backman K, Holmdahl R, Tarkowski A. Estrogen accelerates immune complex 
glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL lpr/lpr 
mice. Cellular immunology, 1992;144:190-202.
[172] Ishimaru N, Saegusa K, Yanagi K, Haneji N, Saito I, Hayashi Y. Estrogen deficiency accelerates autoimmune 
exocrinopathy in murine Sjogren’s syndrome through fas-mediated apoptosis. The American journal of 
pathology, 1999;155:173-81.
[173] Porola P, Laine M, Virkki L, Poduval P, Konttinen YT. The influence of sex steroids on Sjogren’s syndrome. 
Annals of the New York Academy of Sciences, 2007;1108:426-32.
[174] Valtysdottir ST, Wide L, Hallgren R. Low serum dehydroepiandrosterone sulfate in women with primary 
Sjogren’s syndrome as an isolated sign of impaired HPA axis function. The Journal of rheumatology, 
2001;28:1259-65.
[175] Peri Y, Agmon-Levin N, Theodor E, Shoenfeld Y. Sjogren’s syndrome, the old and the new. Best practice & 
research Clinical rheumatology, 2012;26:105-17.
[176] Toussirot E, Roudier J. Epstein-Barr virus in autoimmune diseases. Best practice & research Clinical 
rheumatology, 2008;22:883-96.
[177] Hida A, Imaizumi M, Sera N, Akahoshi M, Soda M, Maeda R et al. Association of human T lymphotropic virus 
type I with Sjogren syndrome. Annals of the rheumatic diseases, 2010;69:2056-7.
[178] Triantafyllopoulou A, Tapinos N, Moutsopoulos HM. Evidence for coxsackievirus infection in primary Sjogren’s 
syndrome. Arthritis and rheumatism, 2004;50:2897-902.
[179] Haddad J, Deny P, Munz-Gotheil C, Ambrosini JC, Trinchet JC, Pateron D et al. Lymphocytic sialadenitis of 
Sjogren’s syndrome associated with chronic hepatitis C virus liver disease. Lancet, 1992;339:321-3.
[180] Mariette X, Zerbib M, Jaccard A, Schenmetzler C, Danon F, Clauvel JP. Hepatitis C virus and Sjogren’s syndrome. 
Arthritis and rheumatism, 1993;36:280-1.
[181] Kordossis T, Paikos S, Aroni K, Kitsanta P, Dimitrakopoulos A, Kavouklis E et al. Prevalence of Sjogren’s-like 
syndrome in a cohort of HIV-1-positive patients: descriptive pathology and immunopathology. British journal 
of rheumatology, 1998;37:691-5.
[182] Manoussakis MN, Kapsogeorgou EK. The role of intrinsic epithelial activation in the pathogenesis of Sjogren’s 
syndrome. Journal of autoimmunity, 2010;35:219-24.
[183] van Blokland SC, van Helden-Meeuwsen CG, Wierenga-Wolf AF, Drexhage HA, Hooijkaas H, van de Merwe 
JP et al. Two different types of sialoadenitis in the NOD- and MRL/lpr mouse models for Sjogren’s syndrome: 
a differential role for dendritic cells in the initiation of sialoadenitis? Laboratory investigation; a journal of 
technical methods and pathology, 2000;80:575-85.
[184] Moutsopoulos HM. Sjogren’s syndrome: autoimmune epithelitis. Clinical immunology and immunopathology, 
1994;72:162-5.
[185] Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. Sjogren’s syndrome: why autoimmune epithelitis? Oral 
diseases, 2006;12:523-32.
[186] Moutsopoulos HM, Hooks JJ, Chan CC, Dalavanga YA, Skopouli FN, Detrick B. HLA-DR expression by labial 
minor salivary gland tissues in Sjogren’s syndrome. Annals of the rheumatic diseases, 1986;45:677-83.
[187] Manoussakis MN, Dimitriou ID, Kapsogeorgou EK, Xanthou G, Paikos S, Polihronis M et al. Expression of B7 
costimulatory molecules by salivary gland epithelial cells in patients with Sjogren’s syndrome. Arthritis and 
rheumatism, 1999;42:229-39.
[188] Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN. Functional expression of a costimulatory B7.2 
(CD86) protein on human salivary gland epithelial cells that interacts with the CD28 receptor, but has reduced 
binding to CTLA4. J Immunol, 2001;166:3107-13.
[189] Matsumura R, Umemiya K, Goto T, Nakazawa T, Kagami M, Tomioka H et al. Glandular and extraglandular 
expression of costimulatory molecules in patients with Sjogren’s syndrome. Annals of the rheumatic diseases, 
2001;60:473-82.
General introduction
Ch
ap
te
r 
1
41
[190] Kapsogeorgou EK, Dimitriou ID, Abu-Helu RF, Moutsopoulos HM, Manoussakis MN. Activation of epithelial 
and myoepithelial cells in the salivary glands of patients with Sjogren’s syndrome: high expression of 
intercellular adhesion molecule-1 (ICAM.1) in biopsy specimens and cultured cells. Clinical and experimental 
immunology, 2001;124:126-33.
[191] Tsunawaki S, Nakamura S, Ohyama Y, Sasaki M, Ikebe-Hiroki A, Hiraki A et al. Possible function of salivary 
gland epithelial cells as nonprofessional antigen-presenting cells in the development of Sjogren’s syndrome. 
The Journal of rheumatology, 2002;29:1884-96.
[192] Spachidou MP, Bourazopoulou E, Maratheftis CI, Kapsogeorgou EK, Moutsopoulos HM, Tzioufas AG et al. 
Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression 
in cells derived from patients with primary Sjogren’s syndrome. Clinical and experimental immunology, 
2007;147:497-503.
[193] Boumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues 
from patients with primary Sjogren’s syndrome. British journal of rheumatology, 1995;34:326-33.
[194] Xanthou G, Tapinos NI, Polihronis M, Nezis IP, Margaritis LH, Moutsopoulos HM. CD4 cytotoxic and dendritic 
cells in the immunopathologic lesion of Sjogren’s syndrome. Clinical and experimental immunology, 
1999;118:154-63.
[195] Salomonsson S, Jonsson MV, Skarstein K, Brokstad KA, Hjelmstrom P, Wahren-Herlenius M et al. Cellular 
basis of ectopic germinal center formation and autoantibody production in the target organ of patients with 
Sjogren’s syndrome. Arthritis and rheumatism, 2003;48:3187-201.
[196] Xanthou G, Polihronis M, Tzioufas AG, Paikos S, Sideras P, Moutsopoulos HM. “Lymphoid” chemokine 
messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands 
of Sjogren’s syndrome patients: possible participation in lymphoid structure formation. Arthritis and 
rheumatism, 2001;44:408-18.
[197] Ogawa N, Ping L, Zhenjun L, Takada Y, Sugai S. Involvement of the interferon-gamma-induced T cell-attracting 
chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-
gamma (CXCL9), in the salivary gland lesions of patients with Sjogren’s syndrome. Arthritis and rheumatism, 
2002;46:2730-41.
[198] Vanbervliet B, Bendriss-Vermare N, Massacrier C, Homey B, de Bouteiller O, Briere F et al. The inducible 
CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-
derived factor 1 (SDF-1)/CXCL12. The Journal of experimental medicine, 2003;198:823-30.
[199] McArthur C, Wang Y, Veno P, Zhang J, Fiorella R. Intracellular trafficking and surface expression of SS-A (Ro), 
SS-B (La), poly(ADP-ribose) polymerase and alpha-fodrin autoantigens during apoptosis in human salivary 
gland cells induced by tumour necrosis factor-alpha. Archives of oral biology, 2002;47:443-8.
[200] Ohlsson M, Jonsson R, Brokstad KA. Subcellular redistribution and surface exposure of the Ro52, Ro60 
and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the 
pathogenesis of Sjogren’s syndrome. Scandinavian journal of immunology, 2002;56:456-69.
[201] Kong L, Ogawa N, Nakabayashi T, Liu GT, D’Souza E, McGuff HS et al. Fas and Fas ligand expression in the 
salivary glands of patients with primary Sjogren’s syndrome. Arthritis and rheumatism, 1997;40:87-97.
[202] Polihronis M, Tapinos NI, Theocharis SE, Economou A, Kittas C, Moutsopoulos HM. Modes of epithelial cell 
death and repair in Sjogren’s syndrome (SS). Clinical and experimental immunology, 1998;114:485-90.
[203] Matsumura R, Umemiya K, Goto T, Nakazawa T, Ochiai K, Kagami M et al. Interferon gamma and tumor 
necrosis factor alpha induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line. 
Clinical and experimental rheumatology, 2000;18:311-8.
[204] Abu-Helu RF, Dimitriou ID, Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN. Induction of salivary 
gland epithelial cell injury in Sjogren’s syndrome: in vitro assessment of T cell-derived cytokines and Fas 
protein expression. Journal of autoimmunity, 2001;17:141-53.
[205] Tsubota K, Fujita H, Tsuzaka K, Takeuchi T. Quantitative analysis of lacrimal gland function, apoptotic figures, Fas 
and Fas ligand expression of lacrimal glands in dry eye patients. Experimental eye research, 2003;76:233-40.
[206] Nakamura H, Kawakami A, Yamasaki S, Nakashima T, Kamachi M, Migita K et al. Expression and function of X 
chromosome-linked inhibitor of apoptosis protein in Sjogren’s syndrome. Laboratory investigation; a journal 
of technical methods and pathology, 2000;80:1421-7.
[207] Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nature reviews 
Immunology, 2002;2:569-79.
[208] Kapsogeorgou EK, Abu-Helu RF, Moutsopoulos HM, Manoussakis MN. Salivary gland epithelial cell exosomes: 
A source of autoantigenic ribonucleoproteins. Arthritis and rheumatism, 2005;52:1517-21.
Chapter 1
42
[209] Bournia VK, Vlachoyiannopoulos PG. Subgroups of Sjogren syndrome patients according to serological 
profiles. Journal of autoimmunity, 2012;39:15-26.
[210] Nardi N, Brito-Zeron P, Ramos-Casals M, Aguilo S, Cervera R, Ingelmo M et al. Circulating auto-antibodies 
against nuclear and non-nuclear antigens in primary Sjogren’s syndrome: prevalence and clinical significance 
in 335 patients. Clinical rheumatology, 2006;25:341-6.
[211] Routsias JG, Tzioufas AG. Sjogren’s syndrome--study of autoantigens and autoantibodies. Clinical reviews in 
allergy & immunology, 2007;32:238-51.
[212] Higgs R, Lazzari E, Wynne C, Ni Gabhann J, Espinosa A, Wahren-Herlenius M et al. Self protection from anti-
viral responses--Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like 
receptors. PloS one, 2010;5:e11776.
[213] Higgs R, Ni Gabhann J, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA. The E3 ubiquitin ligase Ro52 
negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation 
of IRF3. J Immunol, 2008;181:1780-6.
[214] Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmunity 
reviews, 2009;8:632-7.
[215] Wolin SL, Cedervall T. The La protein. Annual review of biochemistry, 2002;71:375-403.
[216] ter Borg EJ, Risselada AP, Kelder JC. Relation of systemic autoantibodies to the number of extraglandular 
manifestations in primary Sjogren’s Syndrome: a retrospective analysis of 65 patients in the Netherlands. 
Seminars in arthritis and rheumatism, 2011;40:547-51.
[217] Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J et al. Primary Sjogren syndrome in 
Spain: clinical and immunologic expression in 1010 patients. Medicine, 2008;87:210-9.
[218] Fauchais AL, Martel C, Gondran G, Lambert M, Launay D, Jauberteau MO et al. Immunological profile in 
primary Sjogren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune 
disease. Autoimmunity reviews, 2010;9:595-9.
[219] Locht H, Pelck R, Manthorpe R. Clinical manifestations correlated to the prevalence of autoantibodies 
in a large (n=321) cohort of patients with primary Sjogren’s syndrome: a comparison of patients initially 
diagnosed according to the Copenhagen classification criteria with the American-European consensus 
criteria. Autoimmunity reviews, 2005;4:276-81.
[220] Martel C, Gondran G, Launay D, Lalloue F, Palat S, Lambert M et al. Active immunological profile is associated 
with systemic Sjogren’s syndrome. Journal of clinical immunology, 2011;31:840-7.
[221] Horsfall AC, Rose LM, Maini RN. Autoantibody synthesis in salivary glands of Sjogren’s syndrome patients. 
Journal of autoimmunity, 1989;2:559-68.
[222] Hammi AR, Al-Hashimi IH, Nunn ME, Zipp M. Assessment of SS-A and SS-B in parotid saliva of patients 
with Sjogren’s syndrome. Journal of oral pathology & medicine : official publication of the International 
Association of Oral Pathologists and the American Academy of Oral Pathology, 2005;34:198-203.
[223] Kawakami T, Saito R. The relationship between facial annular erythema and anti-SS-A/Ro antibodies in three 
East Asian women. The British journal of dermatology, 1999;140:136-40.
[224] Franco HL, Weston WL, Peebles C, Forstot SL, Phanuphak P. Autoantibodies directed against sicca syndrome 
antigens in the neonatal lupus syndrome. Journal of the American Academy of Dermatology, 1981;4:67-72.
[225] Reichlin M, Wasicek CA. Clinical and biologic significance of antibodies to Ro/SSA. Human pathology, 
1983;14:401-5.
[226] Brucato A, Cimaz R, Caporali R, Ramoni V, Buyon J. Pregnancy outcomes in patients with autoimmune 
diseases and anti-Ro/SSA antibodies. Clinical reviews in allergy & immunology, 2011;40:27-41.
[227] Haneji N, Nakamura T, Takio K, Yanagi K, Higashiyama H, Saito I et al. Identification of alpha-fodrin as a 
candidate autoantigen in primary Sjogren’s syndrome. Science, 1997;276:604-7.
[228] Witte T. Antifodrin antibodies in Sjogren’s syndrome: a review. Annals of the New York Academy of Sciences, 
2005;1051:235-9.
[229] Saegusa K, Ishimaru N, Yanagi K, Mishima K, Arakaki R, Suda T et al. Prevention and induction of autoimmune 
exocrinopathy is dependent on pathogenic autoantigen cleavage in murine Sjogren’s syndrome. J Immunol, 
2002;169:1050-7.
[230] Oishi A, Miyamoto K, Kashii S, Yoshimura N. Abducens palsy and Sjogren’s syndrome induced by pegylated 
interferon therapy. Br J Ophthalmol, 2007;91:843-4.
[231] Ojha J, Bhattacharyya I, Islam N, Cohen DM, Stewart CM, Katz J. Xerostomia and lichenoid reaction in a 
hepatitis C patient treated with interferon-alpha: a case report. Quintessence Int, 2008;39:343-8.
[232] Onishi S, Nagashima T, Kimura H, Matsuyama Y, Yoshio T, Minota S. Systemic lupus erythematosus and 
Sjogren syndrome induced in a case by interferon-{alpha} used for the treatment of hepatitis C. Lupus, 2010.
General introduction
Ch
ap
te
r 
1
43
[233] Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T et al. Activation of IFN pathways and 
plasmacytoid dendritic cell recruitment in target organs of primary Sjogren’s syndrome. Proceedings of the 
National Academy of Sciences of the United States of America, 2006;103:2770-5.
[234] Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary 
glands clearly distinguishes primary Sjogren’s syndrome patients from healthy control subjects. Arthritis and 
rheumatism, 2005;52:1534-44.
[235] Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML et al. Activation of the type I interferon 
system in primary Sjogren’s syndrome: a possible etiopathogenic mechanism. Arthritis and rheumatism, 
2005;52:1185-95.
[236] Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM et al. Peripheral blood gene 
expression profiling in Sjogren’s syndrome. Genes and immunity, 2009;10:285-96.
[237] Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA. Systemic increase 
in type I interferon activity in Sjogren’s syndrome: a putative role for plasmacytoid dendritic cells. European 
journal of immunology, 2008;38:2024-33.
[238] Hamza N, Bos NA, Kallenberg CG. B-cell populations and sub-populations in Sjogren’s syndrome. Presse Med, 
2012;41:e475-83.
[239] Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood 
B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell 
subpopulations in patients with primary Sjogren’s syndrome. J Immunol, 2001;167:3610-8.
[240] Bohnhorst JO, Bjorgan MB, Thoen JE, Jonsson R, Natvig JB, Thompson KM. Abnormal B cell differentiation 
in primary Sjogren’s syndrome results in a depressed percentage of circulating memory B cells and elevated 
levels of soluble CD27 that correlate with Serum IgG concentration. Clin Immunol, 2002;103:79-88.
[241] Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J et al. Diminished peripheral blood memory B 
cells and accumulation of memory B cells in the salivary glands of patients with Sjogren’s syndrome. Arthritis 
and rheumatism, 2002;46:2160-71.
[242] Binard A, Le Pottier L, Devauchelle-Pensec V, Saraux A, Youinou P, Pers JO. Is the blood B-cell subset profile 
diagnostic for Sjogren syndrome? Annals of the rheumatic diseases, 2009;68:1447-52.
[243] Szyszko EA, Brun JG, Skarstein K, Peck AB, Jonsson R, Brokstad KA. Phenotypic diversity of peripheral blood 
plasma cells in primary Sjogren’s syndrome. Scandinavian journal of immunology, 2011;73:18-28.
[244] Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P et al. Association of BAFF/BLyS 
overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest, 2002;109:59-68.
[245] Sellam J, Miceli-Richard C, Gottenberg JE, Ittah M, Lavie F, Lacabaratz C et al. Decreased B cell activating 
factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary 
Sjogren’s syndrome and systemic lupus erythematosus. Ann Rheum Dis, 2007;66:790-7.
[246] Fox RI, Adamson TC, 3rd, Fong S, Young C, Howell FV. Characterization of the phenotype and function of 
lymphocytes infiltrating the salivary gland in patients with primary Sjogren syndrome. Diagnostic immunology, 
1983;1:233-9.
[247] Adamson TC, 3rd, Fox RI, Frisman DM, Howell FV. Immunohistologic analysis of lymphoid infiltrates in primary 
Sjogren’s syndrome using monoclonal antibodies. J Immunol, 1983;130:203-8.
[248] Singh N, Cohen PL. The T cell in Sjogren’s syndrome: force majeure, not spectateur. Journal of autoimmunity, 
2012;39:229-33.
[249] Roescher N, Tak PP, Illei GG. Cytokines in Sjogren’s syndrome. Oral diseases, 2009;15:519-26.
[250] Kang EH, Lee YJ, Hyon JY, Yun PY, Song YW. Salivary cytokine profiles in primary Sjogren’s syndrome differ 
from those in non-Sjogren sicca in terms of TNF-alpha levels and Th-1/Th-2 ratios. Clinical and experimental 
rheumatology, 2011;29:970-6.
[251] Bertorello R, Cordone MP, Contini P, Rossi P, Indiveri F, Puppo F et al. Increased levels of interleukin-10 in 
saliva of Sjogren’s syndrome patients. Correlation with disease activity. Clinical and experimental medicine, 
2004;4:148-51.
[252] Liu MF, Wang CR, Fung LL, Wu CR. Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic 
lupus erythematosus. Scandinavian journal of immunology, 2004;59:198-202.
[253] Li XM, Li XP, Qian L, Wang GS, Zhang H, Wang XQ et al. [Expression of forkhead box protein P3 in peripheral 
blood and salivary gland of patients with Sjogren’s syndrome]. Zhonghua nei ke za zhi [Chinese journal of 
internal medicine], 2007;46:544-6.
[254] Li XM, Li XP, Qian L, Wang GS, Zhang H, Zhei ZM et al. [Expression of CD4+ CD25+ regulatory T cells in 
peripheral blood and salivary gland of patients with primary Sjogren’s syndrome]. Zhonghua yi xue za zhi, 
2007;87:1034-6.
Chapter 1
44
[255] Gottenberg JE, Lavie F, Abbed K, Gasnault J, Le Nevot E, Delfraissy JF et al. CD4 CD25high regulatory T cells 
are not impaired in patients with primary Sjogren’s syndrome. J Autoimmun, 2005;24:235-42.
[256] Sarigul M, Yazisiz V, Bassorgun CI, Ulker M, Avci AB, Erbasan F et al. The numbers of Foxp3 + Treg cells are 
positively correlated with higher grade of infiltration at the salivary glands in primary Sjogren’s syndrome. 
Lupus, 2010;19:138-45.
[257] Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB. Salivary gland tissue expression of interleukin-23 and interleukin-17 
in Sjogren’s syndrome: findings in humans and mice. Arthritis and rheumatism, 2008;58:734-43.
[258] Reksten TR, Jonsson MV, Szyszko EA, Brun JG, Jonsson R, Brokstad KA. Cytokine and autoantibody profiling 
related to histopathological features in primary Sjogren’s syndrome. Rheumatology (Oxford), 2009;48:1102-6.
[259] Kwok SK, Cho ML, Her YM, Oh HJ, Park MK, Lee SY et al. TLR2 ligation induces the production of IL-23/IL-17 
via IL-6, STAT3 and NF-kB pathway in patients with primary Sjogren’s syndrome. Arthritis research & therapy, 
2012;14:R64.
[260] Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM. Systemic and local interleukin-17 and linked 
cytokines associated with Sjogren’s syndrome immunopathogenesis. The American journal of pathology, 
2009;175:1167-77.
[261] Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of 
patients with Sjogren’s syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines 
from salivary gland cells by IL-18. J Immunol, 2008;181:2898-906.
[262] Nguyen CQ, Yin H, Lee BH, Carcamo WC, Chiorini JA, Peck AB. Pathogenic effect of interleukin-17A in 
induction of Sjogren’s syndrome-like disease using adenovirus-mediated gene transfer. Arthritis research & 
therapy, 2010;12:R220.
[263] Kang KY, Kim HO, Kwok SK, Ju JH, Park KS, Sun DI et al. Impact of interleukin-21 in the pathogenesis of primary 
Sjogren’s syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. 
Arthritis research & therapy, 2011;13:R179.
[264] Lavoie TN, Stewart CM, Berg KM, Li Y, Nguyen CQ. Expression of interleukin-22 in Sjogren’s syndrome: 
significant correlation with disease parameters. Scand J Immunol, 2011;74:377-82.
[265] Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med, 2009;360:1989-2003.
[266] Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C et al. Signatures of differentially regulated 
interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. 
Rheumatology (Oxford), 2006;45:694-702.
[267] York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R. A macrophage marker, Siglec-1, is 
increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and 
toll-like receptor agonists. Arthritis Rheum, 2007;56:1010-20.
[268] Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA et al. Combined analysis of monocyte and 
lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis 
Rheum, 2008;58:1465-74.
[269] Farina G, Lafyatis D, Lemaire R, Lafyatis R. A four-gene biomarker predicts skin disease in patients with diffuse 
cutaneous systemic sclerosis. Arthritis and rheumatism;62:580-8.
[270] Bos CL, van Baarsen LG, Timmer TC, Overbeek MJ, Basoski NM, Rustenburg F et al. Molecular subtypes 
of systemic sclerosis in association with anti-centromere antibodies and digital ulcers. Genes Immun, 
2009;10:210-8.
[271] Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients 
with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis and 
rheumatism, 2006;54:192-201.
[272] Matsushita T, Fujimoto M, Hasegawa M, Tanaka C, Kumada S, Ogawa F et al. Elevated serum APRIL levels in 
patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. The 
Journal of rheumatology, 2007;34:2056-62.
[273] Wutte N, Kovacs G, Berghold A, Reiter H, Aberer W, Aberer E. CXCL13 and BAFF as Putative Biomarkers in 
Systemic Sclerosis. The British journal of dermatology, 2013.
[274] Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus-an update. Current opinion in 
immunology, 2012;24:651-7.
[275] Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid 
tumors. Annals of internal medicine, 1991;115:178-83.
[276] Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway 
identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active 
disease. Arthritis and rheumatism, 2005;52:1491-503.
General introduction
Ch
ap
te
r 
1
45
[277] Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA. Association of a gene expression profile 
from whole blood with disease activity in systemic lupus erythaematosus. Annals of the rheumatic diseases, 
2008;67:1069-75.
[278] Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. Patients with systemic lupus erythematosus (SLE) 
have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling 
immature dendritic cells. Clinical and experimental immunology, 1999;115:196-202.
[279] Vallin H, Perers A, Alm GV, Ronnblom L. Anti-double-stranded DNA antibodies and immunostimulatory 
plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J 
Immunol, 1999;163:6306-13.
[280] Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. Fc gamma RIIa is expressed on natural 
IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced 
by apoptotic cells combined with lupus IgG. J Immunol, 2003;171:3296-302.
[281] Ronnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis 
and rheumatism, 2006;54:408-20.
[282] Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha production in plasmacytoid 
dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and 
lupus IgG. Arthritis and rheumatism, 2004;50:1861-72.
[283] Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus 
and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus, 2006;15:570-6.
[284] Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J et al. Association of plasma B lymphocyte 
stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum, 2008;58:2453-9.
[285] Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D et al. B lymphocyte stimulator overexpression in 
patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum, 2003;48:3475-86.
[286] Chen XQ, Yu YC, Deng HH, Sun JZ, Dai Z, Wu YW et al. Plasma IL-17A is increased in new-onset SLE patients 
and associated with disease activity. Journal of clinical immunology, 2010;30:221-5.
[287] Yang J, Chu Y, Yang X, Gao D, Zhu L, Wan L et al. Th17 and natural Treg cell population dynamics in systemic 
lupus erythematosus. Arthritis and rheumatism, 2009;60:1472-83.
[288] Shah K, Lee WW, Lee SH, Kim SH, Kang SW, Craft J et al. Dysregulated balance of Th17 and Th1 cells in 
systemic lupus erythematosus. Arthritis research & therapy, 2010;12:R53.
[289] Wang Y, Ito S, Chino Y, Goto D, Matsumoto I, Murata H et al. Laser microdissection-based analysis of cytokine 
balance in the kidneys of patients with lupus nephritis. Clinical and experimental immunology, 2010;159:1-10.

CHAPTER 2
PREVALENCE OF INTERFERON TYPE I SIGNATURE IN CD14+ 
MONOCYTES OF SJÖGREN’S SYNDROME PATIENTS AND 
ASSOCIATION WITH DISEASE ACTIVITY 
AND BAFF GENE EXPRESSION
Zana Brkic, Naomi I. Maria, Cornelia G. van Helden-Meeuwsen, Joop P. van de Merwe, 
Paul L. van Daele, Virgil A. Dalm, Manon E. Wildenberg, Wouter Beumer, 
Hemmo A. Drexhage, Marjan A. Versnel 
Annals of the Rheumatic Diseases, 2013 May; 72(5):728-735.
Chapter 2
48
ABSTRACT
Objective To determine the prevalence of upregulation of Interferon (IFN) type I 
inducible genes, the so called “IFN type I signature”, in CD14+ monocytes in 69 primary 
Sjögren’s syndrome (pSS) patients and 44 healthy controls (HC) and correlate it to disease 
manifestations and expression of B cell activating factor (BAFF).
Methods Expression of IFI44L, IFI44, IFIT3, LY6E and MX1 was measured using Real time 
Quantitative Polymerase Chain Reaction (RQ-PCR) in monocytes. Expression values were 
used to calculate IFN type I scores per subject. pSS patients positive for IFN type I signature 
(IFN score≥10) and patients negative for the signature (IFN score<10) were then compared 
for clinical disease manifestations and BAFF expression. A bioassay using a monocytic cell 
line was performed to study whether BAFF mRNA expression was inducible by IFN type I 
activity in serum of pSS patients.
Results IFN type I signature was present in 55% of pSS patients compared to 4.5% of HC. 
Patients with the IFN type I signature showed:
a) higher EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) scores; higher anti-
Ro52, anti-Ro60 and anti-La autoantibodies; higher rheumatoid factor; higher serum 
IgG; lower C3, lower absolute lymphocyte and neutrophil counts
b) higher BAFF gene expression in monocytes. In addition serum of signature positive 
patients induced BAFF gene expression in monocytes.
Conclusions The monocyte IFN type I signature identifies a subgroup of pSS with a higher 
clinical disease activity together with higher BAFF mRNA expression. Such patients might 
benefit from treatment blocking IFN type I production and activity.
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2INTRODUCTION
Primary Sjögren’s syndrome (pSS) is an autoimmune disease characterized by lymphocytic 
infiltrates in salivary and lachrymal glands. After rheumatoid arthritis, pSS is the second most 
common generalized autoimmune disease [1]. Nevertheless, establishment of the diagnosis 
is difficult due to heterogeneity of the disease and lack of a specific diagnostic test. The 
diagnosis of pSS is based on 2002 American-European classification criteria [2]. Treatment is 
mainly symptomatic and the efficacy differs across patients. If new biomarkers based upon 
underlying pathogenic pathways can be identified, then more effective, evidence-based 
treatments for pSS might be developed.
 Previously we were the first to describe a systemic upregulation of IFN type I inducible 
genes in CD14+ monocytes of pSS patients [3]. This was in line with described local 
increased activation of IFN type I in salivary glands of pSS patients [4-6] and confirmed in 
peripheral blood mononuclear cells (PBMCs) [7]. IFN type I plays important role in the innate 
immunity by inhibiting viral replication, activating natural killer cells, boosting generation 
and activation of dendritic cells and enhancing antibody responses [8-12]. Given that there 
are 17 different IFN type I subtypes, however, it is difficult to measure protein levels using 
an Enzyme-Linked Immuno Sorbent Assay (ELISA). For diseases as hepatitis C, IFN type I is 
part of the conventional treatment. Interestingly, development of Sjögren-like symptoms 
has been described upon treatment with IFN type I in patients with Hepatitis C [13-15] 
supporting the role for IFN type I in the pathogenesis of pSS.
 Another factor known to be involved in the pathogenesis of pSS is B cell activating factor of 
the tumour necrosis factor family (BAFF). An increased expression of BAFF, which correlates 
with autoantibody level in both serum [16, 17] and salivary glands [18], has been described 
for pSS [16]. BAFF-transgenic mice develop Sjögren-like symptoms [19]. IFN type I has been 
shown to induce BAFF expression in cultured monocytes and salivary gland epithelial cells of 
pSS patients [20, 21] and a correlation between IFN type I and BAFF has been shown in IFN 
type I treated multiple sclerosis patients [22]. Furthermore BAFF-dependence of IFN type I 
functioning mechanisms has been observed in SLE-prone mice [23].
 Previously we found a significant upregulation of 23 IFN type I inducible genes using 
whole genome analysis on pooled monocyte samples of pSS patients. Further assessment 
of the prevalence of the monocyte IFN type I inducible gene overexpression in pSS and 
correlations with disease manifestations have yet to be performed. In the current study, 
we therefore first measured the expression of 11 IFN type I inducible genes, which were 
previously detected by us, in CD14+ monocytes from 69 pSS patients and 44 healthy 
controls (HC). Results of factor analysis showed 5 genes (IFI44, IFI44L, IFIT3, LY6E and MX1) 
to explain 95% of the total variance of the 11 genes, and we therefore decided to adopt 
overexpression of these 5 genes as our operational definition of positivity for an “IFN type 
I signature”. The relationship between this IFN type I signature in monocytes and various 
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disease manifestations was then studied. Given the data suggesting that BAFF is an IFN 
type I inducible factor, we further decided to measure the in vivo BAFF mRNA expression in 
monocytes of pSS patients and to correlate the expression level with the IFN type I signature.
PATIENTS AND METHODS
Patients
69 patients with a positive diagnosis for pSS according to 2002 American-European criteria 
[2] were recruited. Patients treated with prednisone >10 mg daily, immunosuppressants or 
biologicals were excluded. The level of disease activity was assessed using EULAR Sjögren’s 
Syndrome Disease Activity Index (ESSDAI) [24]. 44 healthy controls neither suffering from 
autoimmune diseases nor using corticosteroids were included. Characteristics of patients 
and controls are summarized in Table 1. Medical Ethical Review Committee of the Erasmus 
MC approved the study and written informed consent was obtained. 
Table 1. Demographics, laboratory and clinical characteristics of participants
Controls
(n=44)
pSS
(n=69)
Demographic characteristics
Female (n) 40/44 (91%) 62/69 (90%)
Mean age (years) 51±15 58±13
Disease duration (years) - 10.8±7.7
2002 American-European criteria - 4.2±0.4
Sjögren manifestations (n)
Ocular symptoms - 69/69 (100%)
Oral symptoms - 66/69 (96%)
Positive ocular tests - 53/69 (77%)
Positive histopathology - 39/69 (57%)
Positive salivary gland tests - 2/69 (3%)
Anti-SSA - 58/69 (84%)
Anti-Ro52 - 54/56 (96%)
Anti-Ro60 - 47/56 (84%)
Anti-SSB - 38/69 (55%)
2002 American-European criteria: number of criteria fulfilled out of the six criteria items.
Positive histopathology: focus score≥1, defined as a number of lymphocytic foci containing more than 50 
lymphocytes per 4 mm². 
Positive salivary gland tests: sialography showing the presence of diffuse sialectasias or salivary scintigraphy 
showing delayed uptake, reduced concentration and/or delayed excretion of tracer.  
pSS, primary Sjögren’s syndrome
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Blood was collected in clotting tubes for serum preparation (stored at -80°C) and in sodium-
heparin tubes for PBMC preparation as described previously [25]. CD14 positive monocytes 
were isolated as described [25].
RQ-PCR
Total RNA was isolated from purified monocytes followed by cDNA preparation and RQ-
PCR analysis using predesigned primer/probe sets (Applied Biosystems) [25]. For calculation 
of relative expression, all samples were normalized against expression of the household 
gene Abl [26]. Fold change values were determined from normalized CT values using 2ΔΔCT 
method (User Bulletin , Applied Biosystems, Foster City, California).
Measurement of complement, immunoglobulin levels and autoantibodies
C3 and C4 were measured using Immage nephelometer (Beckman Coulter, Woerden, The 
Netherlands).
 IgG, IgA, IgM were measured via turbidimetry using an Modular P800 (Roche, Almere, 
The Netherlands).
 Anti-SSA and anti-SSB were determined by EliA (Thermo Scientific) and confirmed with 
ANA profile immunoblot (EuroImmun). When discrepant, QUANTA Lite ELISA-kit from INOVA 
was used for confirmation.
Bio-assay for BAFF activity in serum and ELISA
To assess whether BAFF mRNA expression could be induced by IFN type I activity in serum 
of pSS patients, THP-1 cells were cultured in 250 μl medium as described previously [3]. 250 
μl of serum from pSS patients positive or negative for the IFN type I signature, was added 
to THP-1 cells and incubated for 6 hours. As positive control, recombinant human IFN-alpha 
was added (5ng/ml, Peprotech, London, UK). HC serum was added as negative control and 
for blocking anti-IFN type I receptor (PBL Interferon Source, Piscataway, USA) was added (5 
μg/ml).
 BAFF protein in serum was assessed by ELISA (improved Quantikine Human BAFF/BLyS, 
R&D systems, Minneapolis, United States).
Factor analysis
Expression levels of 11 IFN type I inducible genes were submitted to a principal component 
analysis to identify correlated groups of genes to reduce data complexity. Kaiser-Meyer-
Olkin measure of sampling adequacy was 0.833 with significant Bartlett’s test of sphericity 
(P< 0.001). Eigenvalues were derived to assess the amount of variance explained by each 
component factor.
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Statistical analyses
Statistical analyses were performed using SPSS 17.0 package. When data were not 
normally distributed, values were expressed as medians with interquartile ranges (IQRs) 
and comparisons were made using the non-parametric Mann-Whitney U test. For normally 
distributed data, independent T test was used to compare means. Correlations were 
assessed either using Pearson correlation test for normally distributed data or Spearman’s 
rho when data were not normally distributed. Linear regression was performed on ESSDAI 
components with the IFN score as the dependent variable. Differences were considered 
statistically significant if p<0.05.
RESULTS
Increased IFN type I inducible gene expression in pSS monocytes
In whole genome analyses of pooled monocytes, we previously showed 23 IFN type 
I inducible genes to be upregulated in pSS relative to HC [3]. On the basis of their high, 
intermediate or low levels of upregulation in the whole genome analysis, 11 of the 23 IFN 
type I inducible genes were selected for analysis in the present study using RQ-PCR in CD14+ 
monocytes and found to be significantly upregulated in the pSS group relative to the HC 
group (Figure 1A). The 11 IFN type I inducible genes analyzed in the monocytes were: IFI27, 
IFI44L, IFIT3, IFITM1, SERPING1, IFIT1, IFIT2, LY6E, IFI44, XAF1 and MX1.
Prevalence of “IFN type I signature” in pSS monocytes
The results of a principal component analysis showed a subset of 5 genes (IFI44, IFI44L, 
IFIT3, LY6E and MX1) to explain 95% of the total variance of the 11 IFN type I inducible 
genes. Given that the expression of these 5 IFN type I inducible genes was not normally 
distributed, log transformations of expression values were performed and IFN scores were 
calculated as described for SLE [27]. The mean and SD level of each IFN inducible gene in the 
HC group were used to standardize expression levels of each gene for each study subject. 
The standardized expression levels were subsequently summed for each patient to provide 
an IFN type I expression score.
 The distribution of the IFN scores for the 69 patients was bimodal with an overlap at a 
score of 10. We therefore set the threshold for a positive IFN type I signature at 10. Adoption 
of this threshold showed 55% of pSS group to have an IFN type I signature and only 4.5% of 
the HC group (Figure 1B,1C).
 To determine if the IFN type I signature possibly changes over time, we assessed IFN 
scores at two different time points in 24 pSS patients. Average period between the two 
measurement points was 3.6 ± 2.5 years. A significant difference in the scores over time was 
not detected (Figure 1C,1D), which shows a stability of the signature over time. 
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Figure 1 (A) Gene expression of 11 IFN type I inducible genes in pSS patients (n=69) and healthy controls (n=44). 
To compare means the Mann-Whitney U test was applied. (B) Heatmap showing gene expression of 5 IFN type 
I inducible genes in monocytes of pSS patients (n=69) and healthy controls (n=44). On the left the pSS patients 
are depicted and subdivided into IFN type I signature positive patients and IFN type I signature negative patients. 
On the right the healthy controls are depicted. Red colour indicates high gene expression (C) Distribution of IFN 
scores in IFN type I signature positive and negative patients and healthy controls. In red IFN type I positive cases 
are depicted. Blue lines depict medians. (D) Heatmap showing gene expression of IFN type I inducible genes in 
monocytes of pSS patients (n=24) at two different timepoints (average period between two measurements 3.6 ± 
2.5 years). (E) No significant differences detected between two timepoints using the dependent T test.
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Correlation of IFN type I signature with disease parameters
To investigate whether IFN type I activation, as reflected by a high IFN score, is associated 
with disease activity, we assessed ESSDAI disease activity scores in 38 pSS patients. Significant 
positive correlation was observed between IFN type I scores and ESSDAI scores (r=0.458, 
P=0.003). The pSS patients were next stratified according to their IFN type I signature status 
(IFN score<10 vs. IFN score≥10) and the disease activity scores were compared. Patients 
with a positive IFN type I signature (IFN score>10) showed significantly higher ESSDAI scores 
than those with a negative signature (Figure 2A). The high disease activity for patients 
with a positive IFN type I signature was mostly attributable to the presence of glandular, 
cutaneous and haematological manifestations (Table 2). Linear regression analysis showed 
glandular, cutaneous and articular manifestations - despite the nonsuggestive P value in the 
univariate analysis - to be associated with high IFN type I scores (Beta Coefficients with 95% 
C.I respectively: 5.90 (1.78, 10.01), 5.00 (1.66, 8.35) and 7.54 (2.38, 12.71). 
Table 2. Comparison of IFN scores for pSS patients with or without different ESDDAI features
Present Absent
ESSDAI feature No. of patients Median (IQR) No. of patients Median (IQR) P
Constitutional 6 6.28 (-1.74,14.92) 32 5.19 (0.10,13.97) NS
Lymphadeno-pathy - 38 5.19 (-0.26,14.43) ND
Glandular 9 14.7 (4.10,16.22) 29 2.65 (-1.16,12.41) 0.029
Articular 16 8.73 (1.02,14.94) 22 3.53 (-2.02,13.33) NS
Cutaneous 6 15.26 
(11.85,15.90)
32 3.53 (-2.02,13.33) <0.001
Pulmonary - - 38 5.19 (-0.26-14.43) ND
Renal - - 38 5.19 (-0.26-14.43) ND
Muscular - - 38 5.19 (-0.26-14.43) ND
PNS 3 15.20 (-5.27-15.58) 35 4.40 (-0.16,12.87) NS
CNS - - 38 5.19 (-0.26-14.43) ND
Hematological 2 16.09 
(15.32,16.85)
36 4.40 (-0.46,12.83) <0.001
Biological 20 10.21 (1.80,14.94) 18 3.97 (-3.21,12.88) NS
CNS, central nervous system; PNS, peripheral nervous sytem, NS, nonsignificant; ND, not determined
 
In addition to the ESSDAI, demographic, laboratory and clinical parameters were collected. 
Comparison of IFN type I signature positive patients with IFN type I signature negative 
patients revealed significant differences in anti-SSA autoantibodies (anti-Ro52 and anti-
Ro60), anti-SSB autoantibodies, rheumatoid factor, C3, IgG, lymphocyte and neutrophil 
count (Table 3). 
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Table 3. Comparison of pSS patients with or without a positive IFN type I signature
IFN type I signature category 
Variable n Positive Negative P
Demographics
  Female gender (n) 69 34/38 (89%) 28/31 (90%) 0.908
  Age (years) 69 56.7±12.5 59.5±13.3 0.376
  Disease duration (years) 67 11.2±8.2 10.3±7.1 0.631
Laboratory parameters
  Anti-SSA (n) 69 37/38 (97%) 21/31 (68%) 0.001
  Anti-Ro52 (n) 69 35/38 (92%) 19/31 (61%) 0.002
  Anti-Ro60 (n) 69 34/38 (89%) 13/31 (42%) <0.001
  Anti-SSB (n) 69 32/38 (84%) 6/31 (19%) <0.001
  Rheumatoid factor (IE/ml) 50 25 (0,100) 0 (0,44) 0.048
  C3 (g/l) 46 1.06±0.20 1.27±0.33 0.012
  C4 (g/l) 46 0.18 (0.13,0.20) 0.18 (0.14,0.25) 0.261
  IgG (g/l) 68 16.10 (13.15,18.55) 11.60 (10.6,15.00) 0.001
  IgA (g/l) 54 3.20 (2.18,4.25) 2.44 (1.69,4.20) 0.179
  IgM (g/l) 54 1.22 (0.78,1.97) 1.36 (1.07,1.67) 0.876
  CRP (mg/l) 61 1.0 (0.0,5.5) 3.0 (1.0,7.0) 0.068
  Hb (mmol/l) 60 7.95 (7.58,8.33) 8.25 (7.78,8.80) 0.159
  Thrombocytes (*10E9/l) 51 219.5 (199.3,284.8) 257 (221,298) 0.190
  Lymphocytes (*10E9/l) 42 1.32±0.55 1.85±0.57 0.005
  Neutrophiles (*10E9/l) 41 3.09±1.18 4.42±1.78 0.014
Medical therapy
  Pilocarpine (n)  69 15/38 (39%) 12/31 (39%) 0.949
  Plaquenil (n) 69 23/38 (61%) 17/31 (55%) 0.636
  Corticosteroids (n) 69 3/38 (8%) 1/31 (3%) 0.412
Values are the mean ± SD, median (25% quartile-75% quartile), or number (%) of patients, depending on whether 
the data are normally distributed or not, and whether the data are continuous or dichotomous. When the data 
followed normal distribution, the independent t-test was conducted; otherwise the Mann-Whitney U test was 
conducted. CRP, C-reactive protein; Hb, haemoglobin
 When patients were next stratified according to their autoantibody status (autoantibody 
positive vs. autoantibody negative) for comparison of their IFN scores, patients with 
autoantibodies showed higher IFN scores than patients without autoantibodies (Figure 
2B). Rheumatoid factor and higher IgG levels were more often present in the IFN signature 
positive patients compared to IFN type I signature negative patients (Figure 2C, 2D). C3, 
lymphocytes and neutrophils were lower in IFN type I signature positive pSS patients (Figure 
2E, 2F and 2G). No differences were found with respect to demographic characteristics or 
medication status (Table 3). 
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Figure 2 (A) ESSDAI scores in IFN type I signature positive and negative pSS patients (n=38). (B) IFN scores in pSS 
patients positive or negative for anti-SSA (both Ro52 and Ro60) and anti-SSB (n=69). (C) Rheumatoid factor levels 
in IFN type I signature positive and negative pSS patients (n=50). (D) IgG levels in IFN type I signature positive and 
negative pSS patients (n=68). (E) C3 levels in IFN type I signature positive and negative pSS patients (n=46). (F)
Absolute lymphocyte levels in IFN type I signature positive and negative pSS patients (n=42). (G) Absolute neutrophil 
levels in IFN type I signature positive and negative pSS patients (n=41). Independent T-test was used to compare 
means in E-G where horizontal bars represent the means. Mann-Whitney U test was used to compare means in 
A-D where horizontal bars represent the medians. In B medians and interquartile range (IQR) are depicted; ** 
represents P value<0.01 and **** represents P value <0.0001.
Correlation between BAFF expression and IFN type I signature
As already mentioned, a factor also known to be involved in the pathogenesis of pSS and 
found to correlate with elevated serum levels of IgG, anti-SSA and anti-SSB is BAFF [16]. BAFF 
mRNA expression was increased in monocytes of the pSS group relative to the HC group 
(Figure 3A). Significant positive correlation between IFN score and BAFF mRNA expression 
was also thus found (Figure 3B).
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Figure 3 (A) BAFF mRNA expression in monocytes in pSS patients (n=69) and healthy controls (n=44). BAFF mRNA 
expression was determined by RQ-PCR. (B) Correlation between IFN type I score and BAFF mRNA expression 
in monocytes in pSS patients (n=69). (C) Induction of BAFF mRNA expression in THP-1 cells by incubation with 
50% serum of IFN type I signature positive pSS patients (n=9) and IFN type I signature negative pSS patients 
(n=7) in the presence of a blocking IFN type I receptor antibody. Expression is relative compared to the mean 
expression in healthy controls (n=8) (D) BAFF protein levels in serum of pSS patients (n=68) and healthy controls 
(n=42) measured by ELISA. (E) Correlation between serum BAFF protein and IFN scores in pSS patients (n=68). (F) 
Correlation between serum BAFF protein and BAFF mRNA expression in monocytes in pSS patients (n=68). The 
correlation coefficients (r) and P values are shown. For correlations Spearman’s rho correlation test was used and 
to compare means the Mann-Whitney U test was used.
We therefore next investigated if BAFF mRNA expression could be induced in monocytes by 
IFN type I serum activity. A bioassay was performed for this purpose using THP-1 monocytic 
cell line exposed to 50% by volume serum of pSS patients who were either positive or negative 
for the IFN type I signature with and without a blocking antibody against the IFN type I 
receptor. After incubation with serum from IFN type I signature positive patients (n=9), BAFF 
mRNA expression was indeed induced in THP-1 cells. Blocking IFN type I receptor diminished 
BAFF mRNA expression in THP-1 (Figure 3C). Serum of IFN type I signature negative patients 
did not induce higher BAFF mRNA expression relative to that found for the HC group.
 To assess BAFF protein in serum, we performed an ELISA on 68 pSS samples and 42 HC. 
A statistical difference between pSS and HC was observed (Figure 3D). After stratification for 
positive versus negative IFN signature, however, no differences and no correlations between 
the IFN scores and serum BAFF protein were found (Figure 3E). Noteworthy serum BAFF 
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protein does not correlate with BAFF mRNA in monocytes (Figure 3F) and we also found in 
a smaller series that BAFF mRNA in monocytes does not correlate to BAFF mRNA in PBMC 
(see online supplementary Figure S1). This suggests that production of BAFF is differently 
regulated in different circulating leucocytes, however this needs further investigation.
DISCUSSION
This study shows increased IFN type I activity for 55% of a group of pSS patients versus 
to 4.5% of a HC group. The presence of such an “IFN type I signature” in monocytes of 
pSS patients was further shown to be associated with the ESSDAI, biological markers of 
activity and BAFF mRNA in monocytes. BAFF expression could also be induced in cultured 
monocytes by serum from pSS patients with a positive IFN signature.
 Taken together, these results suggest the following scenario: A raised level of IFN type 
I, present in the serum of a significant number of pSS patients, induces in monocytes 
overexpression of IFN type I inducible genes amongst which is BAFF. After production, 
this cytokine can induce polyclonal B cell stimulation which results in higher autoantibody 
production and enhanced autoantigen-autoantibody reaction with complement 
consumption. This scenario fits with our observation of a correlation between the presence 
of a positive IFN type I signature in monocytes and cutaneous manifestations in the ESSDAI 
index. Moreover the biological domain of the ESSDAI includes markers for B cell activation 
such as IgG, cryoglobulinemia, decrease of complement. Thus part of the association 
between the IFN signature and the ESSDAI may be related to the role of IFN type I in B cell 
activation.
 A similar scenario resulting in vasculitis has been described for SLE, systemic sclerosis 
and dermatomyositis. For subgroups of these diseases overexpression of IFN type I induced 
genes has also been observed. In SLE the overexpressed genes were associated – similar to 
the findings of our studies – with nuclear autoantibodies, glomerulonephritis and higher 
disease activity [28-30], again indicating the relationship of IFN activity to B cell activation 
and immune complex vasculitis. While these studies used PBMCs, we examined monocytes, 
as our focus of previous work was on the role of monocytes and dendritic cells in pSS. 
The IFN type I signature which we report for pSS monocytes is similar to the IFN inducible 
gene expression profile observed for pSS PBMCs [7]. Furthermore, we assessed the IFN 
type I signature in PBMCs of 12 pSS and 6 HC in supplementary analyses and found a high 
correlation with the IFN type I signature identified for monocytes in the same sample (see 
online supplementary Figure S2).
 There was surprisingly no correlation of monocyte activation related to an IFN type I 
signature with other hallmarks of pSS (i.e. sicca symptoms and fatigue) (unpublished results). 
This is surprising as there are different reports of sicca syndrome and fatigue being induced 
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the sicca syndrome all patients scored positive and these symptoms are not quantified in 
the ESSDAI. Quantification using a Schirmer test or analogous test is therefore merited in 
future studies. With regard to fatigue this might be explained by the fact that we assessed 
fatigue using the VAS-score and not by the Multidimensional Fatigue Inventory, which 
covers different dimensions of fatigue. There are also reports that immune activation is not 
the only determinant of fatigue in IFN type I treated patients, but also the induction of IDO 
(indoleamine 2,3-dioxygenase) and the catabolism of tryptophan to quinolinic acid at the 
expense of serotonin [33]. More in-depth research into the relations between fatigue and 
IFN type I signature in pSS is thus essential.
 Previously, we showed that although the number of plasmacytoid dendritic cells (pDC) 
was lowered in the blood of pSS patients - possibly due to migration into the glands - the 
remaining pDC showed increased activation [3]. There are indications that pDC are the 
source of the high IFN type I serum levels in SLE [34]. pDC are the most powerful producers 
of IFN type I. Stimuli for the pDC to produce IFN type I can be either exogenous (viral 
DNA/RNA) or endogenous, such as immune complexes of nuclear antigens and antibodies 
(hallmarks of pSS) which bind to FcγRIIa on the pDC, followed by internalization and binding 
to intracellular TLR7 and TLR9 [35]. This IFN type I production by pDC upon immune complex 
binding could be a potential explanation for the association we found between IFN type I 
scores and autoantibodies, IgG and lowered C3. The absence of modification of the IFN type 
I signature in patients treated with Plaquenil is surprising as Plaquenil is known to inhibit the 
activation of intracellular TLR. This could be explained by the fact that patients in our cohort 
are using Plaquenil for years. Assessment of IFN scores in patients before and after initiation 
of Plaquenil treatment in future research could therefore be informative.
 At this point 2 limitations on our study should be mentioned. First, the patient group did 
not completely match the HC group with regard to age. In the statistical analysis we took that 
into account and could not find a significant influence of age on outcomes. A second possible 
limitation is the use of multiple parameters for our correlations between the presence of 
an IFN type I signature and clinical manifestations. Although it is questionable whether a 
Bonferroni correction is needed, when we applied such correction for n=22 (resulting in a 
P value of 0.002), the differences in rheumatoid factor, C3 and lymphocyte and neutrophil 
counts lost significance. In fact to reach significance after such correction for C3 for example, 
88 patients would have to be studied. Our study of 69 pSS patients is relatively large, but 
new validation studies with larger numbers of participants are called for — also in light of 
the fact that the ESSDAI was measured in only 38 patients and laboratory parameters were 
not available for all patients.
 To conclude, the findings of the present study suggest that determining the presence of 
an “IFN type I signature” in monocytes of pSS patients can be done to identify subgroups 
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of patients for specific treatment. Patients identified in such a manner may benefit from 
treatment aimed at blocking the IFN type I activity and thereby counteracting B cell activation 
and autoantibody production.
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Supplemental Figure 1 BAFF mRNA expression was assessed in PBMCs of 6 IFN signature+ pSS patients (monocyte 
data), 6 IFN signature- pSS patients (monocyte data) and 6 HC. BAFF mRNA in PBMCs of these cases does not 
correlate to BAFF mRNA in monocytes of the same cases. Spearman’s rho correlation test was used and correlation 
coefficient (r) and P value are shown.
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Supplemental Figure 2 Expression of the 11 IFN type I inducible genes was assessed in PBMCs of 6 IFN signature+ 
pSS patients (monocyte data), 6 IFN signature- pSS patients (monocyte data) and 6 HC. The results of a principal 
component analysis showed a subset of 4 genes (IFI44L, IFIT1, IFI44 and MX1) to explain 98% of the total variance 
of the 11 IFN type I inducible genes. The IFN scores based on these 4 genes in PBMCs correlate with the IFN scores 
in monocytes of the same cases. Spearman’s rho correlation test was used and correlation coefficient (r) and P 
value are shown.
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ABSTRACT
Objective  To establish an easy and practical assay for identifying systemic Interferon (IFN) 
type I bioactivity in primary Sjögren’s syndrome (pSS). The IFN type I signature is present in 
over half of pSS patients and identifies a subgroup with higher disease activity. This signature 
is currently assessed via laborious expression profiles of multiple IFN type I inducible genes.
Methods  In a cohort of 35 pSS patients, Myxovirus resistance protein A (MxA) was 
assessed as a potential biomarker for IFN type I activity, using an enzyme immunoassay 
(EIA) on whole blood and flow cytometric analyses (FACS) of isolated CD14+ monocytes. 
In addition, potential biomarkers CD64, CD169 and BAFF were simultaneously analysed in 
CD14+ monocytes using FACS. The IFNscore, a measure for total IFN type I bioactivity, was 
calculated using expression values of the IFN type I signature genes – IFI44, IFI44L, IFIT3, 
LY6E, MX1 – in CD14+ monocytes, determined by real-time quantitative PCR.
 
Results  IFNscores correlated strongest with monocyte MxA-protein (r=0.741, p<0.001) and 
whole blood MxA-levels (r=0.764, p<0.001), weaker with CD169 (r=0.495, p<0.001) and 
CD64 (r=0.436, p=0.007), and not at all with BAFF protein. In particular, whole blood MxA-
levels correlated with ESSDAI scores and numerous clinical pSS parameters. Interestingly, 
patients on hydroxychloroquine showed reduced MxA-levels (EIA, p=0.04; FACS p=0.001).
Conclusion  The MxA-assays were excellent tools to assess IFN type I activity in pSS, MxA-
EIA being the most practical. MxA-levels associate with features of active disease and are 
reduced in hydroxychloroquine-treated patients, suggesting the clinical applicability of MxA 
in stratifying patients according to IFN-positivity.
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INTRODUCTION
Primary Sjögren’s syndrome (pSS), the second most common systemic autoimmune 
disease, is characterized by lymphocytic infiltrates in the salivary and lachrymal glands. 
Clinical manifestations range amongst others from ocular and oral dryness to vasculitis and 
severe fatigue. To date, effective therapy is not available and treatment has been mainly 
symptomatic. The etiology of pSS is largely unknown, but evidence for a role of Interferon 
(IFN) type I in the pathogenesis of pSS has been emerging [1-12]. Further unraveling the 
complex pathophysiology of pSS is essential for finding disease-related biomarkers and 
identifying new treatment targets.  
 Previously, we described systemic upregulation of IFN type I inducible genes (IFIGs) in 
CD14+ monocytes of pSS patients, the so-called IFN type I signature [7]. The signature is 
not restricted to monocytes, as a similar IFN type I signature has been observed in pSS 
peripheral blood mononuclear cells (PBMCs) [12, 13]. Assessment of the IFN type I signature 
is however a laborious real-time-PCR technique for the expression of multiple IFIGs and at 
present, another reliable immunoassay for detection of type I IFNs in blood or serum is not 
available. The latter is mainly due to the presence of multiple subtypes of IFN type I [5, 14, 
15]. An easy and functional assay to determine the presence of IFN type I activity in the 
circulation would facilitate the identification of pSS patients with an IFN type I signature and 
further contribute to unraveling the role of IFN type I in pSS. 
The IFN type I signature, as defined by us, resulted from a factor analysis of multiple tested 
IFIGs and showed five genes – IFI44L, IFI44, IFIT3, LY6E and MX1– to predict 95% of the total 
variance of a larger set of IFIGs. These 5 genes were used to calculate an IFN type I expression 
score (IFNscore) per subject. Recently, we showed this IFN type I signature in pSS monocytes 
to be associated with higher EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) scores 
as well as higher auto-antibody production, rheumatoid factor and serum IgG, lower C3 
complement levels, and higher B cell activating factor (BAFF) gene expression [13].  
The IFN type I signature is also displayed by subgroups of patients with systemic sclerosis 
(SSc), systemic lupus erythematosus (SLE), dermatomyositis and rheumatoid arthritis 
(RA), and several biomarkers for IFN type I activity have been proposed, amongst others 
MxA, CD64 and CD169 [15-24]. However, these protein markers have never been tested 
systematically and simultaneously in a single (pSS) patient group. 
MxA (Myxovirus-resistance protein 1) is a key mediator of the IFN-induced antiviral 
response and is tightly regulated by type I IFNs [25-27]. In SSc, MxA gene expression was 
proposed as biomarker for IFN type I bioactivity and found to correlate with disease activity 
[15]. Several methods for detection of MxA have been previously described [15, 19, 28, 
29]. Vallittu et al. evaluated their enzyme immunoassay (EIA) for MxA in whole blood for 
monitoring IFN type I bioactivity in multiple sclerosis (MS) patients treated with IFN-β. The 
MxA-EIA was considered by the authors to be a faster and more reliable method compared 
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to flow cytometric analysis of MxA in PBMCs [19]. To our knowledge, MxA-EIA has never 
been used for the detection of IFN type I activity in systemic autoimmune diseases. 
In this study, we tested MxA as a candidate biomarker for systemic IFN type I activity in 
pSS using EIA and flow cytometry in whole blood lysates and CD14+ monocytes, respectively. 
In addition, the expression of CD64 (FcγRI), CD169 (Siglec-1), and BAFF proteins were 
simultaneously assessed in CD14+ monocytes, as these markers have also been proposed as 
biomarkers for IFN type I bioactivity in systemic autoimmunity [21-23, 30]. 
PATIENTS AND METHODS 
Patients 
Thirty-five patients positively diagnosed with pSS, according to the 2002 American-European 
criteria were recruited [2]. Patients treated with high doses of prednisone (>10mg daily), 
immunosuppressants, or biologicals were excluded. Level of disease activity was assessed 
using EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) [31]. Twenty-seven HC, 
neither suffering from autoimmune diseases nor using corticosteroids, were included. Study 
subjects were screened to be free of symptoms of underlying viral infections at inclusion 
(Table 1). The Medical Ethical Review Board of the Erasmus MC Rotterdam approved the 
study and written informed consent was obtained.  
Blood collection, preparation and monocytes isolation
Blood was collected in clotting tubes for serum preparation (stored at -80°C) and in sodium-
heparin tubes (Greiner Bio-One, Germany). From heparinized blood, PBMCs and consecutively 
CD14+ peripheral blood monocytes, were isolated as previously described [32]. 
Measurement of complement, immunoglobulin levels and autoantibodies
C3 and C4 complement, IgG, IgM and IgA immunoglobulin and anti-SSA/B autoantibody 
levels were measured as described previously [13]. 
Real-time quantitative PCR 
Total RNA was isolated from purified CD14+ monocytes using RNAeasy columns Qiagen, 
Hilden, Germany), subsequently reverse-transcribed to cDNA using a High-Capacity cDNA 
Reverse Transcription Kit and RQ-PCR analysis using predesigned primer/probe sets 
(Applied Biosystems, Foster City, California, USA) [32]. For calculation of relative expression, 
all samples were normalized to expression of the household gene Abl [33]. Fold change 
values were determined from normalized CT values using 2-ΔΔCT method (User Bulletin, 
Applied Biosystems).
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Table 1. Patient and control characteristics
 
         pSS
 Controls (n=27) IFNpos (n=21) IFNneg (n=14)
Demographics
Female (%) 24/27 (89) 16/21 (76) 12/14 (86)
Mean age (years)* 53 ± 11  57(30-85) 55 (37-76)
Disease duration (years)* NA 13.8 ± 6.4 10.9 ± 7.7
pSS manifestations (%)
Ocular symptoms NA 20/21 (95)  14/14 (100)
Oral symptoms NA  21/21 (100) 13/14 (93)
Positive ocular tests NA 15/21 (71) 12/14 (86)
Positive histopathology NA 11/21 (52)  7/14 (50)
Positive salivary gland tests NA 1/21 (5) 1/14 (7)
Anti-SSA NA 20/21 (95) 10/14 (71)
Anti-SSB NA 17/21 (81)  6/14 (43)
Medication status (%)
Pilocarpine NA  5/21 (24)  4/14 (29)
Hydroxychloroquine NA 13/21 (62) 13/14 (93)
Corticosteroids NA 1/21 (5) 1/14 (7)
*Data are presented as means with corresponding range or SD.
IFNpos, IFN type I signature positive; IFNneg, IFN type I signature negative; NA, not
applicable; pSS, primary Sjögren’s syndrome.
Flow Cytometry
FACS (fluorescence-activated cell sorting) analysis was used to determine surface expression 
and intracellular cytokine content in purified CD14+ monocytes. Membrane staining was 
performed with fluorescently labeled antibodies: anti-CD14 (APC/Cy7; BD Biosciences, CA, 
USA), and either anti-CD64 (PE; Serotech, Toronto, Canada) or CD169 (AF; Serotech), 20 
min in the dark. Subsequently cells were fixed (paraformaldehyde), permeabilized (0.5% 
saponin), and stained with either anti-BAFF (FITC; R&D Systems, PHL, USA) or unconjugated 
anti-MxA (ProteinTech group, IL, USA), incubated in the dark 30 min on ice; secondary 
antibody goat-anti rabbit-FITC (Supertech). Unstained cells and appropriate isotype-
matched controls (BD Biosciences) were used to confirm antibody-specificity. Fluorescence 
was assayed using four-colour flow cytometry (FACS® Calibur, Beckon&Dickinson, USA) and 
analysed using FlowJo Software (TreeStar Inc., USA). 
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MxA Enzyme immunoassay (EIA)
MxA-EIA was executed as previously described [19]. Heparinised blood (25μl) was lysed 
1:20 and stored at -70°C until assayed [19]. Briefly (see online supplementary Figure S1 
for full description), lysed whole blood samples and biotinylated detector-monoclonal 
antibody (MAb) were loaded onto MAb-coated micortiter strips and incubated overnight 
at 8°C, color-reaction was stopped, absorbance
450
 was measured and [MxA] read from a 
master standard-curve. Detection-limit was 10μg/l, determined as three times the standard 
deviations (SD) of 8 negative control replicates [26].
IFN score
Monocyte IFN type I signature was defined by the relative expression of 5 IFIGs – IFI44L, 
IFI44, IFIT3, LY6E and MxA [13]. Mean
HC
 and SD
HC
 of each gene in the HC-group were used to 
standardize expression levels. IFNscores per subject represent the sum of these standardized 
scores, calculated as previously described [34, 35]. IFNscore-distribution for the 35 patients 
was bimodal, with an overlap at a score of 10. Furthermore HC only occasionally show 
IFNscore≥10; consequently values≥10 represent IFN type I signature positivity [13].
Statistical analysis
Comparisons were analyzed using the non-parametric Mann-Whitney U test to compare 
medians, as an independent T-test was used to compare means (for normally distributed 
data). For correlation studies the Spearman’s rho (rs) or Pearson correlation coefficient (rp) 
were calculated. Values of p<0.05 were considered statistically significant. For multiple 
variable testing, values of p<0.01 (p<0.05/5) were considered statistically significant after 
applying a Bonferroni correction (n=5). Multiple group comparisons were analyzed using the 
Kruskal-Wallis test; Statistical analysis performed using SPSS17.0.
RESULTS
Stratification of pSS patients into IFN type I signature positive and negative patients
We utilized our previously described definition for the IFN type I signature [13] and 
reconfirmed the presence of the signature in the current cohort – using the 5 indicator 
genes IFI44L, IFI44, IFIT3, LY6E and MX1 (Figure 1A). We stratified the patient group as 
previously described in patients positive for the IFN type I signature (IFNpos; IFNscore≥10) 
and patients negative for the signature (IFNneg; IFNscore<10). Using this paradigm, none 
of the HC scored above 10 whereas 21 out of 35 pSS patients were IFNpos – a prevalence 
of 60% (Figure 1B). In Figure 1C gene expression for the 5 signature genes is depicted in a 
heatmap. 
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Figure 1 (A) Relative mRNA gene expression is shown for the 5 IFN type I inducible genes of the IFN type I signature 
in CD14+ monocytes of pSS patients (n=35) and healthy controls (HC) (n=27). Patient group is stratified in patients 
negative for the IFN type I signature (IFNneg) (n=14) and patients positive for signature (IFNpos) (n=21). (B) The 
IFNscore is shown for HC and pSS patients. A cutoff value of 10 is used as threshold: IFNneg (IFNscore <10) and 
IFNpos (IFNscore≥10) pSS patients. Each symbol represents an individual sample; horizontal lines represent the 
median. P values are shown, and to compare medians the Mann-Whitney U test was used. (C) Heatmap depicting 
gene expression of IFN type I inducible genes. Individual study subjects sorted according to increasing IFNscore 
(scale from blue to red) and stratified in HC (left), IFNneg (right upper panel) and IFNpos pSS patients (lower panel). 
MxA correlates strongly to IFN type I bioactivity in pSS
To assess MxA protein as a potential biomarker for the IFN type I signature, intracellular 
MxA was measured in CD14+ monocytes using flow cytometry and in whole blood lysates 
using MxA-EIA. 
Significant positive correlation was observed between the IFNscore and intracellular 
MxA-levels, as assessed by flow cytometry (Figure 2B). Relative mean fluorescence intensity 
(MFI) scores of MxA were next compared between HC, IFNneg and IFNpos pSS patients. 
Quantification of CD14+ monocyte MxA-levels showed a significant increase in IFNpos 
patients compared to both IFNneg patients and HC, whereas IFNneg patients showed MxA-
levels indistinguishable from HC (Figure 2C,D). 
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Utilizing the MxA enzyme immunoassay (EIA), MxA protein-levels (μg/l) were assessed in 
lysed whole blood of the same study subjects. Correlating whole blood MxA-levels to IFNscores 
showed a significant positive correlation (Figure 2E). IFNpos patients showed significantly 
elevated MxA protein-levels, compared to both IFNneg patients and HC. An increase was not 
observed in IFNneg patients, again showing MxA-levels equal to HC (Figure 2F). 
Figure 2 Flow cytometric analysis of MxA protein expression in CD14+ monocytes from HC (n=27) and pSS patients 
stratified in IFNneg (n=14) and IFNpos (n=21) patients. (A) Representative dot plots show CD14 and MxA protein 
expression on monocytes from study subjects.  (B) Correlation plot shown between IFN scores for all study subjects 
and relative mean fluorescent intensity (MFI) of MxA. (C) Relative MFI of MxA is shown for HC, IFNneg and IFNpos 
pSS patients. (D) MxA levels are shown for IFNneg (left) and IFNpos (right) pSS patients. Representative histograms 
are depicted; Shaded histogram represents the isotype control, dotted line represents the HC and the solid line the 
pSS patients. Relative expression was calculated as MxA-specific staining (MFI)/ isotype control (MFI). 
MxA levels (µg/l) determined by MxA-enzyme immunoassay (EIA) in whole blood lysates of HC and pSS patients. 
(E) Correlation plot between IFN scores for all study subjects and intracellular MxA-EIA (µg/l) levels. (F) MxA-EIA 
(µg/l) levels shown for HC and pSS patients, stratified in IFNneg and IFNpos patients. Each symbol represents an 
individual sample (duplicates of 2 separate EIA-measurements per study subject); horizontal lines represent the 
median. The correlation coefficients (r) and P values are shown. For correlations Spearman’s rho correlation test 
was used and to compare medians the Mann-Whitney U test was used.
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CD64 and CD169 correlate weakly to IFN type I bioactivity in pSS
We also assessed surface protein levels of CD64 and CD169 (other proposed biomarkers of 
IFN activity) on CD14+ monocytes using flow cytometry (see online supplementary Figure 
S2). A significant positive correlation was observed between the IFNscore and surface 
expression of both CD64 (Figure 3A) and CD169 (Figure 3B) respectively, though with 
considerably lower correlation coefficients as found for MxA (Fig.2). 
Figure 3D shows CD64 upregulation on monocytes of pSS patients irrespective of their 
IFN positivity. For CD169 surface expression this was not the case as the marker was solely 
upregulated in IFNpos pSS patients (Figure 3E). 
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Figure 3 Flow cytometric analysis of CD14+ monocytes from HC and pSS patients. Correlation plots shown between 
IFN scores for all study subjects and (A) CD64, (B) CD169 and (C) BAFF protein levels, respectively. Relative mean 
fluorescent intensity (MFI) for (D) CD64 (E) CD169 and (F) BAFF protein levels shown for CD14+ monocytes from 
HC (n=27) and pSS patients, stratified in IFNneg (n=14) and IFNpos (n=21) patients. Each symbol represents an 
individual sample; horizontal lines represent the median. Relative expression was calculated as protein-specific 
staining (MFI)/ isotype control (MFI). The correlation coefficients (r) and P values are shown. For correlations on 
CD64 and CD169, Spearman’s rho correlation test was used and to compare medians the Mann-Whitney U test was 
used. For BAFF a Pearson correlation test was used and to compare means the independent T-test.
BAFF does not correlate to IFN type I bioactivity in pSS
Previously we established a positive correlation for the presence of the IFN type I signature 
and BAFF mRNA gene expression in CD14+ monocytes[13]. This observation was confirmed 
in our current cohort (Figure S3). We therefore assessed intracellular BAFF protein in CD14+ 
monocytes as a candidate biomarker for IFN type I, using flow cytometry. Intracellular BAFF 
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levels showed no correlation with the IFNscore (Figure 3C, S2). Moreover, BAFF protein 
levels were not significantly elevated in pSS patients compared to HC, neither in IFNpos nor 
IFNneg patients (Figure 3F). 
MxA correlates with disease manifestations of pSS
Previously observed association of the IFN type I signature with higher ESSDAI disease 
activity scores [13] (reconfirmed in this study (Figure 4A)), gave rise to the question whether 
this also holds true for the here described potential biomarkers MxA, CD64 and CD169. 
We were able to assess ESSDAI disease activity scores in 23 pSS patients of this cohort. 
Significant correlation was observed between ESSDAI scores and MxA-levels measured by 
either assay, though the correlation was strongest when the EIA was used (Table 2, Figure 
4B,C). For the other biomarkers no correlation was found (Table S1). 
Table 2. Comparisons of the MxA biomarker – assessed by MxA-EIA and MxA-FACS - with clinical and 
laboratory parameters of pSS patients.
 MxA-EIA MxA-Facs
Variable N r p value N r p value
ESSDAI score 24 0.65 0.00 28 0.45 0.02
Laboratory parameters
  Rf (IE/ml) 22 0.57 0.01 26 0.33 n.s.
  C3 (g/l)a 27 0.03 n.s. 33 -0.17 n.s.
  C4 (g/l) 27 -0.07 n.s. 33 -0.43 n.s.
  IgG (g/l)a 29 0.52 0.00 35 0.40 0.02
  IgA (g/l) 27 0.44 0.02 33 0.41 0.02
  IgM (g/l) 27 0.46 0.02 33 0.18 n.s.
  CRP (mg/l) 26 0.09 n.s. 31 0.22 n.s.
  Hb (mmol/l) 29 -0.45 0.02 35 -0.61 n.s.
  Thrombocytes (*10E9/l)a 28 0.20 n.s. 34 0.03 n.s.
  Lymphocytes (*10E9/l)a 26 0.03 n.s. 32 -0.11 n.s.
  Neutrophiles (*10E9/l) 26 -0.40 0.05 32 -0.18 n.s.
Variable N (%) Z p value N (%) Z p value
Auto-antibodies
  Anti-SSA 24/29 (83) -3.07 0.00 30/35 (86) -2.40 0.02
  Anti-Ro52 16/22 (73) -2.26 0.02 21/27 (78) -1.98 0.05
  Anti-Ro60 15/22 (68) -3.02 0.00 19/27 (70) -2.76 0.01
  Anti-SSB 19/29 (66) -3.20 0.00 23/35 (66) -1.63 n.s.
Medical therapy
  Pilocarpine  7/29 (24) -1.36 n.s. 9/35 (26) -1.47 n.s.
  Plaquenil 23/29 (79) -2.05 0.04 26/35 (74) -3.25 0.00
  Corticosteroids 2/29 (7) -1.64 n.s.  3/35 (9) -0.59 n.s.
Data are presented as Spearman’s rho (r) or according to κ2 test (Z), unless otherwise mentioned
aData normally distributed are presented as Pearson’s rho (r )
Rf, Rheumatoid factor; CRP, C-reactive protein; Hb, Hemoglobin; ns, not significant
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We subsequently determined whether the potential biomarkers were associated with 
classical aberrant immune parameters of pSS, such as anti-SSA and anti-SSB autoantibodies, 
rheumatoid factor, immunoglobulin levels and neutrophil counts (Table 2). In particular 
whole blood MxA-levels showed the strongest and most significant correlations with many 
of these parameters; patients with autoantibodies showed higher whole blood MxA-levels 
compared to patients free of autoantibodies (Figure 4D). Significant positive correlations 
were also found between whole blood MxA and rheumatoid factor, and immunoglobulin 
levels (IgG, IgA and IgM) (Table 2, Figure 4E). Significant negative correlations were found 
between whole blood MxA, hemoglobin levels and neutrophil counts. Monocyte MxA(-
Facs) and CD169-levels performed less well in these comparisons (Table 2, Table S1). 
Patients on hydroxychloroquine (Plaquenil®) treatment had significantly reduced 
biomarkers of IFN activity (Figure 4F,G); Table 2 and Figure 4G show patients on 
hydroxychloroquine treatment to have reduced levels of MxA, measured by both EIA and 
FACS. Hydroxychloroquine was however found to have no significant effect on ESSDAI levels 
(Figure 4H).
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Figure 4 EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) scores stratified in (A) IFNneg and IFNpos pSS 
patients (B) MxA (μg/l) levels as measured by the MxA-EIA; MxA<100μg/l (low) and MxA>100μg/l (high). Cut-off 
determined as mean
HC 
+ 2 x SD
HC
 (C) Correlation plot shown between ESSDAI scores and MxA (μg/l) levels. (D) 
MxA (μg/l) levels in pSS patients in presence (+) or absence (-) of auto-antibodies; anti-SSA (divided in Ro52 and 
Ro60) and anti-SSB (E) Immunoglobulin - IgG, IgA and IgM - levels (g/l) in pSS patients stratified in MxA<100μg/l 
and MxA>100μg/l. Comparisons for pSS patients in presence (+) or absence (-) of hydroxychloroquine (Plaquenil®) 
treatment plotted for (F) the IFNscore; line represents IFNscore cut-off ≥10, (G) MxA (μg/l), as measured by the 
MxA-EIA and (H) ESSDAI scores. Each symbol represents an individual sample; horizontal lines represent the 
median. The correlation coefficient (r) and P values (*p>0.05; **p>0.01; ***p>0.001) are shown, Spearman’s rho 
correlation test was used and to compare medians the Mann-Whitney U test was used.
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DISCUSSION
Our study is the first to simultaneously assess protein levels of MxA, CD64, CD169 and BAFF 
as biomarkers for IFN type I detection. Herein MxA was distinguished as the best functional 
biomarker for systemic IFN type I activity in pSS.  
 MxA protein is considered an important mediator of early innate immune defense and 
its expression has been used as a marker for IFN bioactivity in experimental as well as clinical 
settings [19, 27]. The MxA gene, in contrast to other IFIGs, is not directly inducible by viruses 
and depends strictly on IFN signaling [27]. Furthermore, the stability of MxA protein in cells 
was observed to be higher than corresponding mRNA levels [26]. We assessed intracellular 
MxA protein using an EIA-method on whole blood and flow cytometric analysis on circulating 
CD14+ monocytes. In our patients, flow cytometric detection of MxA in monocytes showed 
a slightly better distinction between IFNpos and IFNneg patients within this pSS group, 
relative to the EIA in whole blood. Nevertheless, the MxA-EIA was a more practical assay as 
it requires only 25µl of whole blood – obtained during routine blood collection and easily 
stored at -70°C to the time of assessment – without necessity of laborious PBMC- and 
subsequent monocyte-isolation. Vallittu et al., who previously validated the MxA-EIA for 
monitoring MS patients treated with IFN-β, concluded the EIA favourable for large scale 
clinical application due to its high level of standardization and reproducibility [19]. We also 
experienced the EIA to be less variable than FACS (data not shown). This report shows 
whole blood MxA-levels measured by EIA to have the strongest correlation with features 
of active pSS: i.e with higher ESSDAI scores, anti-SSA/SSB antibodies, rheumatoid factor, 
immunoglobulin levels, lower hemoglobulin levels and neutrophil counts. We found no 
association with complement consumption, as previously found for the IFNscore [13]. On 
the basis of these observations, we propose to use the MxA-EIA for identification of IFN type 
I bioactivity in pSS. 
Alongside MxA, we also considered CD64, CD169 and BAFF as candidates, observing a 
significant correlation between CD64 and CD169 and the IFNscore, be it with a relatively low 
correlation-coefficient. 
CD64, the high affinity Fc-gamma receptor I (FcγRI) recognizing Fc portion of IgG, is 
exclusively expressed on myeloid cells and found to correlate to IFIG-expression in SLE 
[21, 23]. Levels of CD64 on monocytes did neither correlate with IFN-activity, nor with the 
clinical and laboratory parameters. In contrast, the surface marker was overexpressed in all 
pSS patients. We therefore consider it a marker of systemic autoimmunity in general [36].   
 CD169, also termed sialoadhesin (Siglec-1), previously identified as a biomarker for 
IFN type I activation in SLE, was found to correlate with disease severity [16]. Also in SSc, 
elevated CD169 levels were found on monocytes [17]. In our hands, CD169 was elevated in 
IFNpos pSS patients and correlated to several clinical and laboratory parameters, although 
not as strongly as the MxA assays.
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 BAFF overexpression has been observed in serum, salivary glands, and monocytes in 
pSS [18, 20, 37, 38]. We previously observed a strong correlation between the IFN type I 
signature and BAFF mRNA in pSS monocytes [13]. Moreover we found BAFF serum protein 
increased in pSS compared to HC but did not find a correlation with the IFNscore, additionally 
BAFF serum protein did not correlate with BAFF mRNA. We here report that BAFF protein 
levels showed a slight but not significant increase in IFNpos patients, while BAFF mRNA was 
indeed significantly increased in IFNpos patients. This again indicates the lack of correlation 
between BAFF mRNA and protein. 
Some limitations of our study are for one, the relatively small sample size for CD64. 
Assessing this surface marker in a larger set of patients is warranted to better understand its 
role in systemic autoimmunity. Secondly, MxA-EIA levels were not assessed for all subjects 
due to whole blood necessity. Furthermore, absence of viral infections was defined as ‘no 
symptoms of underlying viral infections’ at inclusion, whereas no viral screening was done 
to confirm. In HC with relatively high MxA-levels however, ENA-profiles were run to rule out 
autoantibody-presence. Third, the ESSDAI as well as some clinical and laboratory parameters 
were not assessed in all pSS patients.
In this study we reconfirmed a monocyte IFN type I signature prevalence in over half 
of pSS patients, a subgroup with higher disease activity [13]. We proposed identification 
of these subgroups useful in establishing patient-eligibility for specific treatments. Indeed, 
an interesting finding here was patients on hydroxychloroquine (HCQ)-treatment to have 
considerably reduced MxA-levels, indicating HCQ to perhaps interfere with IFN-production. 
A recent report shows HCQ to impair systemic IFNα-production [39]. Our data suggests that 
identifying IFN type I signature by performing MxA-assays might prove useful in predicting 
HCQ-treatment responsiveness. In this cohort there are more HCQ-users in the IFNneg group 
compared to IFNpos. However it is not likely that increased ESSDAI levels in the IFNpos group 
are an effect of less HCQ-use in this group, since in IFNpos group still 62% of patients use 
HCQ and are nevertheless IFNpos. Moreover, we previously showed 61% (23/38) of IFNpos 
patients to use HCQ compared to 55% (17/31) of IFNneg patients. In addition HCQ-use did 
not significantly affect ESSDAI scores (Figure 4H). Larger studies are however warranted to 
fully elucidate the effect of HCQ on IFN type I, thus on MxA-levels. 
The association between the IFN type I signature, MxA protein and disease activity levels 
in pSS needs to be further assessed, by for one looking longitudinally, in order to validate 
MxA as a disease activity marker. The same holds true for association between IFN type 
I polymorphisms and MxA, as these polymorphisms have been linked to increased IFNα-
sensitivity [40, 41].
To determine applicability of the MxA-EIA in other IFN type I related-diseases, MxA-
levels were assessed in a small SLE-cohort (see online supplemental Figure S4) and showed 
results similar to pSS – a significant correlation between IFNscores and MxA-levels (r=0.885, 
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p<0.0001) – suggesting a broad applicability of MxA-EIA in systemic autoimmunity. 
In conclusion, we identify MxA protein expression by EIA and FACS analysis as practical 
and rapid approaches for assessment of IFN type I bioactivity in pSS. MxA-EIA is the simplest 
and most reliable of these assays and indicates clinical applicability in stratifying pSS patients 
according to IFN-positivity. Use of MxA as a biomarker for identifying patients eligible for 
therapy in pSS clearly requires further research.
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Table S1
 CD169 CD64
Variable N r p value N r p value
ESSDAI score 28 0.28 n.s. 18 0.03 n.s.
Laboratory parameters
  Rf (IE/ml) 26 0.19 n.s. 18 0.39 n.s.
  C3 (g/l)a 33 0.13 n.s. 20 0.14 n.s.
  C4 (g/l) 33 0.07 n.s. 20 -0.161 n.s.
  IgG (g/l)a 34 0.40 0.02 20 0.18 n.s.
  IgA (g/l) 33 0.10 n.s. 20 0.37 n.s.
  IgM (g/l) 33 0.36 0.04 20 0.18 n.s.
  CRP (mg/l) 31 0.14 n.s. 19 0.16 n.s.
  Hb (mmol/l) 34 -0.29 n.s. 20 -0.04 n.s.
  Thrombocytes (*10E9/l)a 33 -0.01 n.s. 19 -0.31 n.s.
  Lymphocytes (*10E9/l)a 31 0.00 n.s. 19 0.23 n.s.
  Neutrophiles (*10E9/l) 31 -0.24 n.s. 19 -0.11 n.s.
Variable N (%) Z p value N (%) Z p value
Auto-antibodies
  Anti-SSA 29/34 (85) -2.16 0.03 16/20 (80) -0.95 n.s.
  Anti-Ro52 21/27 (78) -0.99 n.s. 15/19 (79) -1.20 n.s.
  Anti-Ro60 19/27 (70) -1.97 0.05 14/19 (74) -1.94 n.s.
  Anti-SSB 22/34 (65) -2.05 0.04 13/20 (65) -0.83 n.s.
Medical therapy
  Pilocarpine  9/34 (26) -2.25 0.03 6/20 (30) -0.17 n.s.
  Plaquenil 25/34 (74) -1.93 n.s. 13/20 (65) -0.20 n.s.
  Corticosteroids 3/34 (9) -1.12 n.s.  2/20 (10) -0.25 n.s.
Data are presented as Spearman’s rho (r) or according to κ2 test (Z), unless otherwise mentioned
aData normally distributed are presented as Pearson’s rho (r )
Rf, Rheumatoid factor; CRP, C-reactive protein; Hb, Hemoglobin
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Figure S1. MxA Enzyme immunoassay (EIA)
MxA-EIA was executed as previously described with new monoclonal antibodies and recombinant MxA as standard, 
subsequent to validation for corresponding results [19]. Mouse MAbs AFI-7B3 and AFI-10G10 (Institute of Clinical 
Medicine, University of  Eastern Finland) were used as capture and biotinylated detector-antibody, respectively. 
MAbs were used as IgG, purified from cell culture supernatants by using FPLC with CIM protein G monolithic column 
(BIA separations, Ljubljana, Slovenia). Detector antibody was biotinylated with NHS-PEO
4
-Biotin reagent (Pierce, 
Rockford, IL) according to manufacturer’s instructions. Recombinant MxA, produced with baculovirus expression 
system, was kindly provided by Ilkka Julkunen and Krister Melen (National Institute of Health and Welfare, 
Helsinki, Finland) [26]. The heparinized whole blood samples (25μl) were lysed by diluting 1:20 in hypotonic buffer 
containing 1.5% bovine serum albumin (BSA), 1% ascorbic acid, 0.5% NaHCO
3
 and 0.05% NaN3 and stored at -70°C 
until assayed. Standard dilutions for the assay were prepared in hypotonic buffer. Microtitre strip wells were coated 
by overnight incubation with 0.4 μg per well of AFI-7B3 IgG in 0.1 M carbonate, pH 9.6. The strips were washed 
twice with 5 mm Tris, 0.15 M NaCl, 0.05% Tween 20, pH 7.75 and saturated for 1 h with the assay buffer containing 
0.5% BSA, 0.05% Tween 20 and 0.1 mM merthiolate in PBS. Strips were washed four times, and 50 μl each of the 
sample and 0.8 μg/ml biotinylated AFI-10G10 IgG, in the assay buffer, were added into the duplicate wells. After 
overnight incubation with shaking at 8°C, the strips were washed six times, and 100 μl of streptavidin–peroxidise-
HRP (Pierce, #21127) diluted 1:15.000 in assay buffer was added into the wells. Strips were shaken for 75±15 min, 
washed eight times and incubated with 100 μl of tetramethylbenzidine (TMB) peroxidise substrate solution (Ani 
Labsystems, Vantaa, Finland) for 10–30 min in the dark. Color development was stopped by adding 100μl of 0.5 
N H
2
SO
4
 and absorbance values were measured at 450 nM using Victor3 multilabel counter (PerkinElmer, Turku, 
Finland). MxA concentrations (μg/l) of the specimens were read from a master curve (50-800μg/l) plotted with the 
standard values using Mutlicalc software with spline smoothed fitting algorithm. Hypotonic buffer was used as the 
negative control. The limit of detection of the MxA EIA assay was 10μg/l, which was determined as three times the 
standard deviations (SD) of eight negative control replicates. One negative and one positive control sample were 
also included in each assay.
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Figure S2. Flow cytometric analysis was performed on 
CD14+ cells isolated from HC and pSS patients (stratified 
in IFNneg and IFNpos). (A) Representative dot plots show 
CD14 and consecutive CD64, CD169 and BAFF protein 
expression (top to bottom) on monocytes from study 
subjects. Appropriate isotype-matched controls were 
used to confirm antibody-specificity. (B) CD64 (C) CD169 
and (D) BAFF protein expression for IFNneg (left) and 
IFNpos (right) pSS patients are shown. Representative 
histograms are depicted; Shaded histogram represents 
the isotype control, dotted line represents the HC and 
the solid line the pSS patients.
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Figure S3. For relative BAFF mRNA gene expression (A) a correlation plot shown with IFNscores for all study subjects 
and (B) BAFF mRNA gene expression levels stratified in HC (n=27), IFNneg (n=14) and IFNpos (n=21) pSS patients. 
Each symbol represents an individual sample; horizontal lines represent the mean. The correlation coefficient (r) 
and P values are shown. For BAFF a Pearson correlation was used and to compare means the independent T-test 
was used.
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Figure S4. In a small cohort of systemic lupus erythemathosis (SLE) patients (A) a correlation plot is shown between 
IFNscores (for all age and gender matched study subjects) and intracellular MxA (µg/l) levels, as assessed by 
the MxA-EIA. (B) IFNscores shown for HC (n=12) and SLE patients (n=12), stratified in IFNneg and IFNpos by red 
dotted line at 10; Red dots represent IFNpositivity (IFNscore≥10). (C) MxA-EIA (µg/l) levels shown for HC (n=12) 
and SLE patients (n=12). Each symbol represents an individual sample; horizontal lines represent the median. The 
correlation coefficients (r) and P values are shown. For correlations Spearman’s rho correlation test was used and 
to compare medians the Mann-Whitney U test was used.
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ABSTRACT
Objective
To determine the prevalence of the monocyte Interferon (IFN) type I inducible signature in 
58 systemic sclerosis (SSc) patients and 27 healthy controls (HC) and to relate the IFN type I 
activity to disease manifestations. 
Methods
IFN type I scores were calculated based on the mRNA expression levels of IFI44L, IFIT3, 
IFITM1, IFIT1 and MXA in monocytes. SSc patients with IFN type I activity, as reflected by 
a positive IFN type I signature (IFN score≥10) were compared with patients negative for 
the IFN type I signature (IFN score<10) for clinical phenotype, auto-antibody profile, mRNA 
expression of B cell activating factor (BAFF) and type III procollagen N-terminal propeptide 
(PIIINP) in serum. 
Results 
IFN type I signature was expressed in 29.3% of SSc patients. No significant differences could 
be found between limited and diffuse SSc. SSc patients with the IFN type I signature were 
characterized by the presence of anti-RNP autoantibodies and absence of anti-centromere 
antibodies. Moreover, in these IFN type I positive patients the time between the onset of 
Raynaud’s phenomenon and development of the first non-Raynaud symptom was markedly 
shorter. Along with these observations, monocyte BAFF mRNA levels and PIIINP levels in 
serum were increased in the IFN type I signature positive SSc patients.
Conclusions                                                                                                                         
Increased IFN type I activity is present in monocytes of about one third of SSc
patients. The presence of the IFN type I signature might be useful as a marker for predicting 
progression of patients with Raynaud’s phenomenon to SSc. 
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INTRODUCTION
Systemic sclerosis (SSc) is a complex autoimmune disease with extensive fibrosis, vascular 
alterations and immune activation among its principal features [1]. With an incidence of 
1-2 per 100.000 it is a rare disease in which chronic oxidative stress and inflammation lead 
to organ failure ending up in severe fibrosis of skin and internal organs including kidney, 
lung and heart. Ultimately, these disease hallmarks culminate in profound decline in the 
quality of life and premature death. SSc represents a particularly difficult disease to unravel, 
partly due to the intricacies of the genetics and partly by virtue of complicated nature of 
the disease process. Despite extensive efforts to understand the underpinnings of this 
devastating disease, our current knowledge of the causal pathways driving SSc and related 
mechanisms involved in fibrosis and accelerated ageing is still limited. A unique feature of 
SSc that distinguishes it from other fibrotic disorders is that inflammation, autoimmunity and 
vasculopathy characteristically precede the development of tissue remodeling and fibrosis. 
This latter implicates a window of opportunity in which patients with more progressive 
disease and/or worse prognosis can be selected for early and aggressive therapy. In line 
with this, in those patients with less severe prognosis, side-effects and therapy induced co-
morbidity might be prevented.
In SSc accumulating evidence suggests the implication of an aberrant immune system in 
the development of the disease. This is supported by studies on genetic risk factors for SSc 
that revealed genes involved in the immune system [2], and amongst others STAT4 and IRF5, 
which are both involved in the Interferon (IFN) type I signalling pathway [3-6]. A substantial 
part of the SSc patients display IFN type I activation either in the affected skin or in immune 
cells isolated from the circulation [7-9]. Clinically, the expression of the IFN type I induced 
genes Siglec-1 and IFI44 in skin biopsies correlated well with the mean Rodnan Skin Score 
(mRSS), currently the only available disease progression marker [10]. It is widely accepted 
that plasmacytoid dendritic cells (pDCs) are the main source of IFN type I. Upon activation of 
toll-like receptors (TLRs) by so-called danger signals, pDCs start to secrete marked amounts 
of IFN type I, which in turn probably is reflected by the IFN type I induced gene expression 
pattern, the so called IFN type I signature, observed now in multiple autoimmune diseases 
[11, 12]. 
Previously, microarray studies showed increased expression of IFN type I inducible 
genes in peripheral blood mononuclear cells (PBMCs), monocytes and skin biopsies from 
SSc patients [7-9, 13, 14]. Some studies showed clinical associations with the IFN type I 
expression, such as a positive correlation between IFN type I genes and the appearance of 
digital ulcers and a negative correlation with the presence of anti-centromere antibodies 
(ACA) [13]. However, there is discrepancy when it comes to other autoantibodies such as 
anti-topoisomerase I (ATA), anti-RNP and anti-SSA antibodies. Recently Wuttge et al. showed 
that 27% of early SSc sera were able to induce increased IFN type I expression in a reporter 
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cell line. This increased IFN type I activity correlated with higher IgG levels, lower leucocytes 
and higher amount of antibodies against extractable nuclear antigens [14]. 
One of the most important cell types affected by IFN type I are the monocytes. 
Monocytes stimulated by IFN type I differentiate into activated DCs and macrophages and 
in combination with other triggers will direct the immune system into potentially harmful 
conditions like autoimmune diseases. Previously we found in 55% of primary Sjögren’s 
syndrome (pSS) patients a monocyte IFN type I signature compared to 4.5% of healthy 
controls (HC) [15]. One of the genes that strongly correlated to the presence of the IFN type 
I signature was B cell activating factor of the tumour necrosis factor family (BAFF) [15]. 
Taken together, further unravelling the clinical implications of the IFN type I gene signature 
is highly justified. In this study we replicated findings from the literature and analyzed for 
the first time the prevalence of the monocyte IFN type I signature in two independent 
cohorts of SSc patients. The presence of the IFN type I signature was correlated to disease 
manifestations, BAFF expression and collagen metabolism and thus supports a direct role 
for IFN type I in the pathogenesis of SSc.
PATIENTS AND METHODS
Patient collection
Twenty-eight patients presenting at the department of Rheumatology, Radboud University 
Nijmegen Medical Center (RUNMC) and thirty patients visiting the Erasmus Medical 
Center, Rotterdam were included in the study. All patients met the American College of 
Rheumatology preliminary criteria for the classification of SSc [16]. For analyses, patients 
were subdivided as having limited cutaneous SSc (lcSSc, n=42) or diffuse cutaneous SSc 
(dcSSc, n=16) on the basis of the extent of their skin involvement [17]. A further subdivision 
was made between early and late disease based upon the duration of disease: early SSc is 
defined as disease duration <2 years and late as SSc longer than 2 years. The presence of SSc 
specific autoantibodies, anti-topoisomerase I (ATA) and anti-centromere (ACA), were tested 
according to local laboratory standards. Pulmonary fibrosis was defined as the presence of 
significant fibrosis on high-resolution computed tomography scan combined with a restrictive 
pulmonary function pattern. Pulmonary artery hypertension was diagnosed by right heart 
catheterization and considered present if the mean pulmonary artery pressure was greater 
than 25 mmHg at rest in the presence of a normal wedge pressure. As a comparator group 
27 healthy controls were studied. Blood samples were obtained with informed consent 
under local Institutional Review Board approval. Characteristics of patients and controls are 
summarized in Table 1.
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Table 1. Demographics, laboratory and clinical characteristics of participants
SSc IFN type I signature
Variable Controls 
(n=44)
Limited  
(n=42)
Diffuse 
(n=16)
Positive
(n=17)
Negative
(n=41)
Demographic s
   N females (%) 19/27 (70%) 34/42 (81%) 10/16 (63%) 12/17 (78%) 32/41 (71%)
   Age (years) 46.0±15 52.0±14 54.0±10 48.8±11.7 54.6±12.8
Disease duration (years)  - 6.5±4.9 3.9±5.5 5.2±4.5 6.1±5.4
Rodnan skin score - 3.6±3.0 11.5±7.6 6.0 (1.0,10.5) 4.5 (2.0,9.75)
Digital ulcers - 12/42 (29%) 5/15 (33%) 3/17 (18%) 14/40 (35%)
Digital loss - 2/39 (5%) 0/3 (0%) 0/12 (0%) 2/30 (7%)
Pulmonary hypertension - 8/40 (20%) 2/16 (13%) 1/16 (6%) 9/40 (23%)
Lung fibrosis - 14/40 (35%) 11/16 (69%) 8/16 (50%) 17/40 (43%)
ACA positivity - 17/40 (43%) 2/16 (13%) 1/16 (6%) 18/40 (45%)
ATA positivity - 9/37 (24%) 4/16 (25%) 5/15 (33%) 8/38 (21%)
Anti-RNP positivity - 2/39 (5%) 2/13 (15%) 4/13 (31%) 0/39 (0%)
Anti-SSA positivity - 11/39 (28%) 2/13 (15%) 3/14 (21%) 10/38 (26%)
Medical therapies   
  Mycophenolate mofetil - 2/42 (5%) 2/15 (13%) 1/17 (6%) 3/40 (8%)
  Cyclophosphamide - 0/42 (0%) 1/15 (7%) 1/17 (6%) 0/40 (0%)
  Prednisolone - 5/42 (12%) 1/15 (7%) 2/17 (11.8%) 4/40 (10%)
  Hydroxychloroquine - 1/42 (2%) 0/15 (0%) 0/17 (0%) 1/40 (3%)
  Methotrexate - 8/42 (19%) 2/15 (13%) 7/17 (41%) 3/40 (8%)
  Azathioprine - 2/42 (5%) 0/15 (0%) 1/17 (6%) 1/40 (3%)
Values are the mean (± SD), median (25% quartile,75% quartile), or number (%) of patients, depending on whether 
the data are dichotomous or continuous following a normal distribution or not.
 
Blood collection and isolation of monocytes
Blood was collected in clotting tubes for serum preparation (stored at -80°C) and in 
sodium-heparin tubes for PBMC preparation as described previously [18]. CD14 
positive monocytes were isolated as described [18]. 
Real Time Quantitative Polymerase Chain Reaction (RQ-PCR)
Total RNA was isolated from purified monocytes followed by cDNA preparation and RQ-PCR 
analysis using predesigned primer/probe sets (Applied Biosystems, Foster City, California)
[18]. For calculation of relative expression, all samples were normalized against expression 
of the household gene Abl [19]. Fold change values were determined from normalized CT 
values using 2-ΔΔCT method (User Bulletin , Applied Biosystems, Foster City, California).
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Measurement of autoantibodies
Anti-SSA and anti-SSB were determined by EliA (Thermo Scientific, Uppsala, Sweden) and 
confirmed with ANA profile immunoblot (EuroImmun, Lubeck, Germany). When the results 
showed a discrepancy, a QUANTA Lite ELISA-kit from INOVA (San Diego, USA) was used for 
confirmation. 
Bio-assay for IFN type I activity in serum 
To assess whether the expression of IFN type I inducible genes could be induced by serum of 
SSc patients, THP-1 cells were cultured in 250 μl medium as described previously [15]. 250 
μl of serum from SSc patients positive or negative for the IFN type I signature, was added to 
THP-1 cells and incubated for 6 hours. HC serum was added as negative control. For blocking 
purposes anti-IFN type I receptor (anti-IFNAR) (PBL Interferon Source, Piscataway, USA) 
was added (5 μg/ml) and anti-IgG2a (Santa Cruz Biotechnology, Dallas, USA) as an isotype 
control. IFN type I gene expression induced by serum from IFN type I positive patients was 
compared with expression induced by serum from IFN type I negative patients, both relative 
to the expression induced by HC serum. 
Radioimmunoassay for quantitative N-terminal propeptide III
For quantitative assessment of intact N-terminal propeptide of type III (PIIINP) procollagen, 
a Radioimmunoassay (RIA-) kit was used according to manufacturer’s protocol (UniQ, Orion 
Diagnostica, Espoo, Finland). Previously frozen sera (stored at -80°C), collected at the time 
of patient-inclusion were analyzed. The kit is based on the competitive radioimmunoassay 
technique. A known amount of labeled PIIINP and an unknown amount of unlabeled PIIINP 
in the sample compete for the limited number of high affinity binding sites of the antibody. 
After separating the free antigen, the amount of labeled PIIINP in the sample tube is inversely 
proportional to the amount of PIIINP in the sample. The concentrations in unknown samples 
are obtained from a calibration curve. Measurement range: 1.0-50µg/l, detection limit: 
±0.3µg/l, defined as twice the standard deviation (SD) of the 0-binding value.
Factor analysis
Expression levels of 11 IFN type I inducible genes were submitted to a 
principal component analysis to identify correlated groups of genes to reduce data 
complexity. Kaiser-Meyer-Olkin measure of sampling adequacy was 0.843 with significant 
Bartlett’s test of sphericity (P< 0.001). Eigenvalues were derived to assess the amount of 
variance explained by each component factor. 
Statistical analyses
Statistical analyses were performed using SPSS 20.0 package. When data were not 
normally distributed, values were expressed as medians with interquartile ranges (IQRs) 
and comparisons were made using the non-parametric Mann-Whitney U test. For normally 
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distributed data, independent T test was used to compare means. In case of more than 
two samples one-way ANOVA was performed or the non-parametric Kruskal-Wallis test. For 
dichotomous data the Fisher’s Exact Test was performed. To compare survival curves the 
Gehan-Breslow-Wilcoxon Test was used. For correlations Spearman’s Rho correlation test 
was used. Differences were considered statistically significant if p<0.05.
For multiple variable testing (Rodnan skin score, vascular digital complications, pulmonary 
hyperstension, lung fibrosis, auto-antibodies, time to first non-Raynaud sytmptom, BAFF 
mRNA and PIIINP), values of p≤0.006 (p≤0.05/8) were considered statistically significant 
after applying a Bonferroni correction (n=8). 
RESULTS
The prevalence of the IFN type I signature in monocytes of SSc patients
In 58 SSc patients and 27 HCs we assessed the expression levels of 11 IFN type I inducible 
genes previously assessed in monocytes (IFI27, IFI44L, IFIT3, IFITM1, SERPING1, IFIT1, IFIT2, 
LY6E, IFI44, XAF1 and MXA) [15]. To reduce data complexity, expression levels of the 11 genes 
were submitted to a principal component analysis to identify correlated groups of genes. 
The results of the principal component analysis identified a subset of 5 genes (IFI44L, IFIT3, 
IFITM1, IFIT1 and MXA) to explain 96% of the total variance of the 11 IFN type I inducible 
genes within the SSc cohort. Given that the expression of these 5 IFN type I inducible genes 
was not normally distributed, log transformations of expression values were performed and 
IFN scores were calculated as described for pSS and SLE [15, 20]. Mean
HC
 and SD
HC
 of each 
gene in the HC-group were used to standardize expression levels. IFN scores per subject 
represent the sum of these standardized scores. When we set the threshold for a positive 
IFN type I signature at 10 [15], 29.3% of SSc patients displayed an IFN type I signature, while 
none of the subjects in the HC group (Figure 1A, B). 
 To investigate whether the increased IFN type I activity represents a systemic effect, we 
performed a bioassay using THP-1 monocytic cell line exposed to 50% by volume serum 
from SSc patients who were either positive or negative for the IFN type I signature (Figure 
S1). Serum from IFN type I signature positive patients (n=11) enhanced the expression of IFN 
type I signature genes in THP-1 monocytes, while this was not the case for serum from IFN 
type I signature negative patients (n=9). Blocking IFN type I receptor diminished significantly 
the mRNA expression of IFN type I signature genes in THP-1 monocytes. 
 To determine if the IFN type I production is higher in diffuse SSc compared to limited SSc 
as suggested by Kim et al. [21], we stratified the patients according to the extent of their skin 
involvement and compared the IFN scores. A trend for higher IFN scores was observed in 
dcSSc group in comparison to lcSSc , but this was not significant (Figure 1C). The same holds 
true when we stratified patients according to the duration of disease, defining patients as 
early SSc when having a disease duration <2 years and late when having SSc longer than 2 
years (Figure 1D, E). 
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Figure 1 (A) Heatmap showing gene expression of 5 IFN type I inducible genes in monocytes of lcSSc patients 
(n=42), dcSSc (n=16) and HC (n=27). On the left the HC are depticted and on the right the SSc patients are depticted 
and subdivided into lcSSc and dcSSC. Red colour indicates high gene expression and cases are depicted according 
to ascending IFN scores. 
Distribution of IFN scores in (B) SSc patients and HC, (C) limited and diffuse SSc patients and HC, (D) early and late 
SSc patients and HC, (E) early limited and diffuse SSc, late limited and diffuse SSc and HC. IFN type I positive cases 
are depicted in red. In case of more than two samples one-way ANOVA was performed (C-D) or the non-parametric 
Kruskal-Wallis test (E). Independent T-test was used to compare means in B-D where blue lines represent means. 
Mann-Whitney U test was used in E where blue lines represent medians. 
* respresents p-values <0.05
** respresents p-values <0.01
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IFN type I signature in SSc is associated with the presence of anti-RNP autoantibodies and 
absence of anti-centromere antibodies 
To determine whether IFN type I activity, as reflected by a positive IFN type I signature (IFN 
score≥10), is associated with specific autoantibodies, we stratified patients according to their 
autoantibody profile and compared the IFN scores. Even despite the fact that it is a small 
group, all patients positive for anti-RNP antibodies displayed the IFN type I signature and 
showed significantly higher IFN scores compared to patients without anti-RNP antibodies 
(Fisher’s Exact test p=0.003) (Figure 2A). Interestingly, almost all patients with circulating 
anti-centromere antibodies were negative for the IFN type I signature (Fisher’s Exact test 
p=0.005) (Figure 2B). There were no significant differences in IFN type I gene expression 
between patients positive or negative for ATA and anti-SSA (Figure 2C, D).
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Figure 2 IFN scores in SSc patients positive and negative for (A) anti-RNP antibodies (n=52), (B) anti-centromeric 
antibodies (ACA) (n=56), (C) anti-topoisomerase I antibodies (ATA) (n=53), (D) anti-SSA antibodies (n=52). IFN type 
I positive cases are depicted in red. Fisther’s Exact Test was performed. Only significant differences are shown.
 
IFN type I signature correlates positively with BAFF mRNA and PIIINP levels and faster 
disease development
Next we investigated whether patients positive for the IFN type I signature differ in clinical 
manifestations compared to SSc patients negative for the IFN type I signature. We did 
not observe differences between the clinical variables investigated (Table 2). Intriguingly 
however, the time between the onset of Raynaud’s phenomenon and development of the 
first non-Raynaud symptom, was markedly shorter in those individuals with a positive IFN 
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type I signature (p= 0.003) (Figure 3A). This suggests that IFN type I gene signature is a 
marker for accelerated disease development. 
Table 2. Comparison of SSc patients with or without a positive IFN type I signature
      IFN type I signature category 
Variable n Positive Negative P
ns
Rodnan skin score 33 6.0 (1.0,10.5) 4.5 (2.0,9.75) ns
Vascular digital complications
  Digital ulcers (n) 57 3/17 (18%) 14/40 (35%) ns
  Digital loss (n) 42 0/12 (0%) 2/30 (7%) ns
Pulmonary hypertension (n) 56 1/15 (7%) 9/40 (23%) ns
  DLCO (%) 54 70.3±19.3 63.5±17.3 ns
Lung fibrosis (n) 56 8/16 (50%) 17/40 (43%) ns
  FVC (%) 56 88.9±24.9 91.2±21.0 ns
Auto-antibodies
  ACA positivity (n) 56 1/16 (6%) 18/40 (45%) 0.005
  ATA positivity (n) 53 5/15 (33%) 8/38 (21%) ns
  Anti-RNP positivity (n) 52 4/13 (31%) 0/39 (0%) 0.003
  Anti-SSA positivity (n) 52 3/14 (21%) 10/38 (26%) ns
Time to first non-Raynaud symptom * 46 15.0 (3.0,24.0) 38.5 
(11.0,117.8)
0.003
BAFF mRNA monocytes 58 22.4±6.2 16.4±4.1 <0.0001
PIIINP 42 6.5 (5.8,52.5) 5.0 (3.8, 6.7) 0.007
Values are the mean (± SD), median (25% quartile,75% quartile), or number (%) of patients, depending on whether 
the data are dichotomous or continuous following a normal distribution or not. For dichotomous data the Fisher’s 
Exact Test was performed. When continuous data followed normal distribution, the independent T-test was 
conducted; otherwise the Mann-Whitney U test was conducted. For comparison of survival curves the Gehan-
Breslow-Wilcoxon Test was used (*). For multiple variable testing, values of p≤0.006 (p≤0.05/8) were considered 
statistically significant after applying a Bonferroni correction (n=8). 
Previously, we observed that BAFF levels were positively associated with IFN type 
I signature in patients with Sjögren’s syndrome [15]. In line with these observations, we 
observed that BAFF mRNA levels were significantly higher in dcSSc compared with HC 
(p=0.006) and significantly higher in IFN type I signature positive SSc patients compared 
with the signature negative patients (p<0.0001) (Figure 3B, C). 
BAFF serum levels were found to correlate with the extent of skin fibrosis in SSc [22]. 
We therefore next investigated whether an indicator of de novo collagen type III synthesis, 
namely N-terminal propeptide of type III collagen (PIIINP), is increased in SSc patients 
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positive for the IFN type I signature. We found increased PIIINP levels in SSc compared to HC 
(p=0.005) and by far the highest levels in the patients positive for the IFN type I signature 
(p=0.007) (Figure 3D, E).  After applying a Bonferroni correction for multiple variable testing 
(significance < 0.006 ( 0.05/8)) the differences in PIIINP lost significance. However when 
looking more in depth to our data, we observed that IFN type I negative patients with high 
PIIINP levels displayed also high IFN scores. IFN scores correlated significantly positive with 
the PIIINP levels (r= 0.502, p=0.0007) (Figure 3F). Together with the increased BAFF mRNA 
levels, these data indicate more extensive fibrosis in the IFN type I positive SSc patient group.
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Figure 3 (A) Survival diagram depicting the time in months between Raynaud’s phenomenon and development of 
the first non-Raynaud symptom. Red line represents SSc patients positive for the IFN type I signature (n=12) and the 
black line represents SSc patients negative for the signature (n=34). (B) BAFF mRNA expression in HC (n=27), limited 
(n=42) and diffuse SSc patients (n=16). (C) BAFF mRNA expression in monocytes from SSc patients positive for the 
IFN type I signature (n=17) and patients negative for the signature (n=41). (D) N-terminal propeptide III (PIIINP) 
(μg/l) in serum from HC (n=19) and SSc patients (n=42). (E) N-terminal propeptide III (PIIINP) (μg/l) in serum from 
SSc patients positive (n=14) and negative (n=28) for the IFN type I signature. (F), Correlation between IFN scores 
and N-terminal propeptide III (PIIINP) levels in serum. 
IFN type I positive cases are depicted in red. The correlation coefficient (r) and p values are shown. For comparison 
of survival curves the Gehan-Breslow-Wilcoxon Test was used (A). Independent T-test was used to compare means 
in (B-C) where horizontal lines represent means. Mann-Whitney U test was used in (D-E) where horizontal lines 
represent medians. Spearman’s Rho correlation test was used in (F).
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DISCUSSION
In the current study we describe the prevalence of the monocyte IFN type I signature in SSc 
patients. As main producers of IFN type I, pDCs play a role in the pathogenesis of diseases 
with the IFN type I signature. In Systemic Lupus Erythematosus (SLE) for example, the IFN 
type I signature has been associated with pDC activation either by CpG-DNA containing 
complexes [11] and/or neutrophil extracellular traps (NETS) [23]. In this light, the observation 
that IFNα is able to induce the expression of TLR3 in SSc dermal fibroblasts, leading to a self-
perpetuating inflammatory loop might directly link pDC activation, IFN type I and the onset 
of fibrotic events [24, 25]. Indeed the number of pDCs has been shown to be markedly 
increased in the skin of SSc patients, mainly in those with diffuse cutaneous disease. This is 
in line with our observations that this SSc clinical subset demonstrate a trend for higher IFN 
type I scores (this paper and unpublished data). 
SSc can be difficult to identify in the general clinic both due to its rarity and heterogeneity, 
which may give rise to marked delayed diagnosis. The onset of SSc is often heralded by 
Raynaud’s phenomenon, but Raynaud’s phenomenon is far from specific for SSc. In addition, 
primary Raynaud’s phenomenon is more common among women than men [26], and thus 
may be less likely to raise suspicion of SSc in women. Therefore, possibly the greatest 
unmet need in SSc is the lack of easy access biomarkers that would identify those Raynaud’s 
phenomenon patients at risk for disease onset and/or progression. It is generally well 
accepted that patients which present with their first non-Raynaud’s phenomenon early 
after onset of Raynaud’s have faster disease progression and worse outcome compared with 
those who have a long lag-time between these signs [27]. Therefore, markers that predict 
the development of SSc have high clinical relevance for early recognition, intensive clinical 
monitoring and possibly therapeutic interventions. Our data indicate that the presence 
of an IFN type I signature is associated with rapid progression from primary Raynaud’s 
phenomenon to full blown SSc. This justifies a role for IFN type I signature determination 
as novel biomarker alongside capillaroscopy in assessment of early disease. Taken into 
consideration that type I interferons stimulate B-cells in the generation of autoantibodies 
and in situations of hypoxic stress where there is a danger of immune complex formation 
containing self-DNA of RNA, our correlation with BAFF expression suggests a pathogenic 
pathway in the early phase of disease development. This is further supported by the elevated 
PIIINP levels in SSc patients [28, 29] and by our finding that the PIIINP levels are higher in IFN 
type I signature positive patients compared to IFN type I negative patients. 
When considering autoantibody profiles, we show a pattern of IFN type I positive patients 
being anti-RNP positive [14] and ACA negative [13]. In contrast to earlier association and 
mechanistic studies [21], we did not find an association between ATA and the IFN type I 
signature. This might be related to the limited ATA positivity in our study. However, in support 
of our findings Eloranta et al. reported that ATA did not correlate with the presence of IFN type 
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I in functional in vitro testing [30]. Furthermore, earlier literature on this subject showed a 
correlation between a positive IFN type I signature and disease severity/progression [31]. To 
quantify disease severity and activity the mRSS is the most performed assessment but also 
shows a disappointing correlation with progression towards organ involvement [27] and a 
significant interobserver variability [32]. Our present study comprised patients included in 
two different centers where the mRSS was performed by different, but a limited number of 
clinicians. This might explain the lack of correlation between the IFN type I signature and 
the mRSS in our study. In our study, the actual mRSS was noted, but the correlation between 
the maximum mRSS and IFN type I signature was not studied. In line with our findings the 
paper of York et all. showed that the expression of IFN type I inducible gene Siglec-1, does 
not correlate with the mRSS in dSSc patients [8]. We further pursued the question if the IFN 
type I signature is more frequent in dSSc, which is denied by our data in line with earlier 
studies [9, 31]. Interestingly the signature is not confined to the early phase of the disease 
but remains present in a part of all subtypes as recently shown with an IFN type I induced 
chemokine profile [31].  
In summary we show that an increased IFN type I activity is present in monocytes of 
about one third of SSc patients. Moreover the IFN type I signature is associated with the 
presence of anti-RNP autoantibodies and absence of ACA, high BAFF mRNA expression, 
high serum PIIINP levels and markedly shorter time of disease development. Therefore the 
presence of the IFN type I signature might be useful as a marker for prediction of progression 
of patients with Raynaud’s phenomenon to SSc. The lack of a clear correlation between the 
IFN type I signature and most clinical parameters leaves the intriguing question what defines 
the IFN type I positive patients unresolved. 
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Figure S1 Induction of mRNA expression of IFN type I signature genes in THP-1 monocytes by incubation with 
50% serum from IFN type I signature positive pSS patients (n=11) and IFN type I signature negative pSS patients 
(n=9) in the presence of a blocking IFN type I receptor antibody (IFNAR) and istotype control (IgG2a). Expression is 
relative compared to the mean expression induced by serum from healthy controls (n=10).  Kruskal-Wallis test was 
performed followed by the Mann-Whitney U test. 
* respresents p-values <0.05
** respresents p-values <0.01
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Systemic sclerosis (SSc) is a difficult to treat, severely debilitating, autoimmune disease 
characterized by vasculopathy, immune activation and fibrosis of the skin and internal 
organs. Imatinib mesylate (IM), is used as a treatment for therapy-refractory SSc with high 
variability in therapeutic outcomes ranging from ineffective/toxic responses to extremely 
encouraging clinical improvement [1]. This high variability in treatment outcomes stresses 
the need for a biomarker identifying SSc patients likely to respond to IM treatment. 
In this study we treated 10 therapy-refractory SSc patients with IM 400mg/day for 
one year and assessed whether gene expression patterns and serological characteristics 
could function as biomarkers for beneficial response to IM treatment. All patients included 
in this open-label trial met the American College of Rheumatology criteria [2]. Patient 
characteristics are summarized in Table 1.
Table 1. Patient characteristics
Variable Non-responders Responder 1 Responder 2
Gender 5/8 female female female
Age (years) 54 ±12.7 43 52
MRSS baseline 11 ±9.0 24 23
MRSS 12 months 10 ±8.3 16 9
TLC baseline % 78 ±22.9 77 82
TLC 12 monhts % 74 ±22.1 92 86
DLCO baseline % 66 ±13.8 74 87
DLCO 12 monhts % 59 ±11.3 88 94
MRSS, mean Modified Rodnan Skin Score; TLC, total lung capacity; DLCO, diffusing capacity for carbon monoxide
Values for non-responders are the mean±SD
 The primary endpoints for response to IM were defined as significant decrease in mean 
Modified Rodnan Skin Score (MRSS) and significant increases in total lung capacity (TLC) and 
diffusing capacity for carbon monoxide (DLCO) during treatment compared to baseline. In 
addition to these parameters, blood and serum were collected from 8 of the SSc patients 
prior to IM treatment and at 3, 6, 9 en 12 months of treatment. In terms of the primary 
endpoints, 2 of the 10 patients were identified as responders to IM (Table 1). 
Subsets of patients with various generalized autoimmune diseases have been found 
to display an IFN type I signature that correlates with increased disease activity [3-6]. We 
isolated monocytes from 8 of the SSc patients included in our study and analysed the 
IFN type I signature expression. Remarkably only the monocytes from the 2 patients who 
responded well to IM displayed a positive IFN type I signature at baseline (Figure 1A). The 
IFN type I signature remained the same during IM treatment (Figure 1A-B). 
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Previously, we found B cell activating factor (BAFF) mRNA to strongly correlate with the 
presence of the IFN type I signature in Sjögren’s syndrome patients [3] and BAFF serum 
levels were found to correlate with the extent of SSc skin fibrosis [7]. We therefore assessed 
BAFF mRNA expression in monocytes from the SSc patients in our study. The two responders 
showed the highest levels of BAFF mRNA at baseline, which decreased significantly upon IM 
treatment (Figure 1C-D). 
An indicator of de novo collagen type III synthesis, namely N-terminal propeptide of type 
III collagen (PIIINP), has been reported increased in the skin and serum of SSc patients [8, 9]. 
We assessed PIIINP in serum of 7 of the SSc patients. The 2 responders showed much higher 
baseline PIIINP levels than the other SSc patients, decreasing drastically upon 6 months of 
IM treatment (Figure 1E). In line with this, a beneficial clinical response to IM has previously 
been reported when the SSc skin displays excessive deposition of collagen type III [10]. 
In our study, we identified monocyte IFN type I signature and associated BAFF mRNA 
levels as well as serum PIIINP as potential biomarkers for the selection of SSc patients who 
are likely to respond to treatment with IM. 
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Figure 1. (A) IFN scores in monocytes from IM treated SSc patients (n=8) at baseline, 3 months, 6 months, 9 months 
and 12 months of treatment. (B) IFN scores in IM treated SSc patients (n=8) at baseline and 6 months of treatment. 
(C) BAFF mRNA expression levels in monocytes of IM treated SSc patients (n=8) at baseline, 3 months, 6 months, 
9 months and 12 months of treatment. (D) BAFF mRNA expression levels in monocytes of IM treated SSc patients 
(n=8) at baseline and 6 months of treatment. (E) PIIINP levels in serum from IM treated SSc patients (n=7) at 
baseline and 6 months of treatment. 
Data from the two patients who responded to IM is displayed in red. In A and C the Kruskal-Wallis test was 
performed followed by Mann Whitney U test in A-E. Only significant differences are shown where (*) represents 
P-values <0.05.
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ABSTRACT
Introduction The novel T helper 17 subset (Th17 cells), which produces IL-17A, IL-17F, IL-22 
and IL-21, has been implicated in the pathogenesis of primary Sjögren’s syndrome (pSS). 
Interferon (IFN) type I is yet another key player in the pathogenesis of pSS. The aim of this 
study was to determine whether Th17 cells are increased in patients with high IFN type I 
activity, as reflected by the presence of IFN type I signature. 
Methods IFN type I signature was assessed by mRNA expression of IFN type I inducible genes 
in monocytes. T helper memory (CD4+CD45RO+) cell populations defined by chemokine 
receptor expression (Th17: CCR6+CCR4+CXCR3-CCR10-; Th22: CCR6+CCR4+CXCR3-CCR10+; 
Th1: CCR6-CXCR3+CCR4-; and Th2: CCR6-CXCR3-CCR4+; Treg: CD25hiFoxP3+) were analyzed 
by flow cytometry in peripheral blood of 12 pSS patients positive (IFN+) and 12 patients 
negative (IFN-) for the IFN type I signature and 12 healthy controls (HC).
Results Th17 and Treg percentages were significantly increased in IFN+ patients compared 
with IFN- patients and HC. This was accompanied by a significant decrease in Th1 cell 
percentages in IFN+ patients compared with HC. Interestingly, Th17 cell percentages were 
significantly higher in patients with anti-SSA antibodies, hypergammaglobulinemia and 
elevated expression of monocyte B cell activating factor (BAFF), all three previously found 
in IFN+ patients. 
Conclusions Here we show for the first time increased Th17 cell percentages in IFN+ pSS 
patients together with increased Treg and decreased Th1 cell percentages. The co-acting 
potential of IFN type I and Th17 pathway in the pathogenesis of pSS warrants further 
investigation.
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INTRODUCTION
Primary Sjögren’s syndrome (pSS) is a generalized autoimmune disease characterized by 
lymphocytic infiltrates in salivary and lacrimal glands. Recently, a novel T helper cell subset 
has been identified, named Th17. Naive CD4+ T cells differentiate into Th17 cells under the 
influence of IL-6 and TGF-β [1]. Expansion and stability of the Th17 population is induced by 
IL-21 and IL-23, respectively [2, 3]. Th17 cells and their cytokines IL-17A, IL-17F, IL-21 and 
IL-22, have been implicated in several autoimmune diseases, including pSS [4, 5]. 
In the infiltrates in glands of both pSS patients and mouse models for pSS, IL-17 and 
IL-17 producing cells were observed, and IL-17A is thought to play an important role in 
the development of these infiltrates [6-10]. In peripheral blood of pSS patients the number 
of IL-17 producing CD4+ T cells [8] and IL-17 plasma levels were increased [9]. Moreover, 
overexpression of IL-17A in salivary glands of pSS-non-susceptible C57BL/6J mice resulted in 
induction of pSS-like disease, supporting a role for IL-17 in disease development [11].
Several lines of evidence support a key role for interferon (IFN) type I in the pathogenesis 
of pSS [12]. We recently showed that IFN type I induced gene expression, named the IFN 
type I signature, is present in 55% of pSS patients and correlates with higher disease activity, 
anti-SSA/anti-SSB antibodies, IgG levels and B cell activating factor (BAFF) gene expression 
[13]. Our observation was in line with the described local and systemic increased IFN type I 
expression in pSS [14-18].
Interestingly, co-activity between IFN type I and Th17 pathway has been suggested in 
autoimmune diseases [19, 20]. IFN type I treatment was effective in EAE, a mouse model for 
MS, if the disease was Th1 driven, but caused exacerbation if the disease was Th17 driven 
[20]. In line with this, MS patients that did not respond to IFN type I therapy had higher 
serum levels of IL-17A before therapy onset [20]. These two observations suggest additional 
effects of the IFN type I and Th17 system to co-act in the pathogenesis of autoimmune 
diseases. Further evidence strengthening the co-activity between the Th17 and IFN type 
I pathways was provided by the Ro52/TRIM21-/- mouse model. Ro52/TRIM21 is involved 
in the ubiquitination of interferon regulatory factors (IRFs), a process which limits the IFN 
type I response [21]. Antibodies directed against Ro52 are present in about 75% of pSS 
patients [22]. After ear tagging Ro52/TRIM21-/- mice develop an SLE like phenotype [23]. 
Interestingly, when these mice are crossed on an IL-23p19-/- mouse line, they do not 
develop SLE, indicating that the development of an SLE phenotype through enhanced IFN 
type I production in these mice is dependent on the IL-23/Th17 pathway. 
 In pSS patients higher serum IL-22 levels were observed, correlating with higher 
anti-SSA/SSB antibodies, hypergammaglobulinemia and rheumatoid factor [24]. Interestingly 
we found higher anti-SSA/SSB antibodies, hypergammaglobulinemia and rheumatoid factor 
in IFN type I signature positive patients compared with IFN type I negative patients [13]. 
Moreover, BAFF ― a factor strongly correlating with the presence of the IFN type I signature 
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in our cohort study ― is involved in dendritic cell (DC) maturation and DC driven Th17 cell 
differentiation in vitro [25]. BAFF gene silencing ameliorated joint pathology and inhibited 
the generation of Th17 cells in the joints of a collagen induced arthritis (CIA) mouse model. 
IL-17 was furthermore shown to be involved in BAFF-mediated exacerbation of CIA.
In summary, a role for Th17 cells and IL-17A has been found in pSS [5-11]. In addition, 
the evidence for the involvement of IFN type I in pSS is increasing [12-18]. Several animal 
models suggest an association between IFN type I and Th17 cells [19-21]. So far, no studies 
on co-occurrence of these two key players in pSS patients have been performed. Here we 
show, for the first time, an increase in Th17 cells in pSS patients that are positive for the IFN 
type I signature, reflecting an increased IFN type I activity. Furthermore, we investigated 
the relationship between Th17 cell frequency and various disease manifestations and BAFF 
gene expression. 
PATIENTS AND METHODS
Patients
24 patients with a positive diagnosis for pSS according to 2002 American-European 
criteria [26] were recruited at the outpatient clinic of the Immunology department of 
the Erasmus Medical Center Rotterdam. Patients treated with prednisone >10 mg daily, 
immunosuppressants or biologicals were excluded. The level of disease activity was 
assessed using EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) [27]. 12 age and 
gender matched healthy controls neither suffering from autoimmune diseases nor using 
corticosteroids were included. Characteristics of patients and controls are summarized in 
Table 1. Medical Ethical Review Committee of the Erasmus MC approved the study and 
written informed consent was obtained. 
Blood collection and isolation of monocytes
Blood was collected in clotting tubes for serum preparation (stored at -80°C) and in sodium-
heparin tubes for peripheral blood mononuclear cell (PBMC) preparation as described 
previously [28]. CD14 positive monocytes were isolated as described[28]. 
RQ-PCR
Total RNA was isolated from purified monocytes followed by cDNA preparation and RQ-
PCR analysis using predesigned primer/probe sets (Applied Biosystems) [28]. For calculation 
of relative expression, all samples were normalized against expression of the household 
gene Abl [29]. Fold change values were determined from normalized CT values using 2ΔΔCT 
method (User Bulletin, Applied Biosystems, Foster City, California).
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Table 1. Demographics and clinical characteristics of participants
Variable pSS patients (n=24) Healthy controls (n=12)
IFN type I negative (n=12) IFN type I positive (n=12)
Demographics
   N females (n) 12/12 (100%) 12/12 (100%) 12/12 (100%)
   Age (years) 63.2±10.7 62.3±11.4 54.8±14.2
Disease duration (years) 12.3±7.4 14.0±7.9 -
ESSDAI 1.0 (1.0,1.25) 2.0 (1.0,3.0) -
Laboratory parameters
   Anti-SSA (n) 4/12 (33%) 12/12 (100%) -
   Anti-Ro52 (n) 4/12 (33%) 12/12 (100%) -
   Anti-Ro60 (n) 2/12 (17%) 11/12 (92%) -
   Anti-SSB (n) 1/12 (8%) 10/12 (83%) -
   IgG (g/l) 9.25 (6.10,13.10) 16.55 (10.48,20.05) -
   IgA (g/l) 1.84 (1.31,2.87) 3.20 (1.61,4.45) -
   IgM (g/l) 1.09 (0.66,2.68) 1.20 (0.90,3.90) -
Medical therapy
   Pilocarpine (n) 6/11 (55%) 4/12 (33%) -
   Hydroxychloroquine (n) 6/11 (55%) 8/12 (67%) -
   Corticosteroids (n) 0/11 (0%) 1/12 (8%) -
Values are the mean ± SD, median (25% quartile,75% quartile) or number (%) of patients, depending on whether 
the data are continuous or dichotomous, and whether the data are normally distributed or not.
 
Flow cytometry and antibodies 
Monoclonal antibody stainings, intracellular cytokine detection and flow cytometry were 
performed as described previously [30]. For intracellular cytokine detection by flow 
cytometry, cells were stimulated for 4 hours with 50 ng/ml PMA, 500 ng/ml ionomycin 
(Sigma-Aldrich, St. Louis, MO) and Golgistop (BD Biosciences, San Diego, CA). Detection 
of the transcription factor Foxp3 was performed using the transcription factor staining 
buffer set, according to the manufacturer’s instructions (eBioscience, San Diego, CA). The 
following monoclonal antibodies (MoAb) were purchased from BD Biosciences: CXCR3, 
CCR4, CD45RO, CCR6 and CD4. Furthermore, Foxp3 MoAb was purchased from eBioscience 
(San Diego, CA). CCR6, and CD25 MoAb were obtained from BioLegend (San Diego, CA). 
CCR10 was purchased from R&D systems (Minneapolis, MN). Samples were acquired on a 
FACSCantoII flow cytometer and analyzed using FlowJo v7.6 research software (Tree Star 
Inc. Ashland, OR). Cells were gated on the lymphocyte fraction. 
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Measurement of immunoglobulin levels and autoantibodies
IgG, IgA, IgM were measured via turbidimetry using an Modular P800 (Roche, Almere, The 
Netherlands). 
Anti-SSA and anti-SSB were determined by EliA (Thermo Scientific, Waltham, MA) 
and confirmed with ANA profile immunoblot (EuroImmun, Luebeck, Germany). When 
discrepant, QUANTA Lite ELISA-kit from INOVA (San Diego, CA) was used for confirmation. 
Calculation of IFN scores
IFN scores were calculated as described before [13]. The standardized 
expression levels of IFI44, IFI44L, IFIT3, LY6E and MX1 were summed for each subject to 
provide an IFN type I expression score. The mean and SD level of each IFN inducible gene 
in the HC group were used to standardize expression levels of each gene for each study 
subject. As previously described we set the threshold for a positive IFN type I signature at 
IFN score of 10. pSS patients were stratified according to their IFN type I signature status 
(IFN score<10 vs. IFN score ≥10). 
Statistical analyses
Statistical analyses were performed using SPSS 20.0 package. When data were not 
normally distributed, values were expressed as medians with interquartile ranges (IQRs) 
and comparisons were made using the non-parametric Mann-Whitney U test. For normally 
distributed data, independent T test was used to compare means. In case of more than 
two samples one-way ANOVA was performed or the non-parametric Kruskal-Wallis test. 
Correlations were assessed either using Pearson correlation test for normally distributed 
data or Spearman’s rho when data were not normally distributed. Differences were 
considered statistically significant if p<0.05. 
RESULTS
Stratification of pSS patients into IFN type I signature positive and negative patients
Previously we described the prevalence of the IFN type I signature in pSS based on the 
mRNA expression levels of 5 interferon type I inducible genes (IFIGs) in monocytes: IFI44, 
IFI44L, IFIT3, LY6E and MX1 [13]. Mean
HC
 and SD
HC
 of each gene in the HC-group were 
used to standardize expression levels. IFN scores per subject represent the sum of these 
standardized scores. In this cohort the threshold for a positive IFN type I signature was set 
at an IFN score of 10, as described before [13]. pSS patients were stratified in IFN+ and IFN- 
patients according to their IFN type I scores (IFN score<10 vs. IFN score ≥10). 
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Increased Th17, Treg percentages and decreased Th1 percentages in pSS patients positive 
for the IFN type I signature 
We hypothesized that the frequency of Th17 cells would be increased in IFN+ patients. 
To test this hypothesis, T helper (Th) cell populations were analyzed in peripheral blood 
of 12 IFN+ patients, 12 IFN- patients and 12 HCs by chemokine receptor expression. The 
gating strategy is shown in figure 1. To distinguish Th1, Th2, Th17 and Th22 cells a gating 
strategy was used as previously described [31]. In short, after gating on lymphocytes, we 
first excluded CD25+ cells in order to omit regulatory T cells (Treg), which were analyzed 
in a separate staining. Subsequently, we gated on CD4+CD45RO+ cells to obtain memory 
Th cells. This Th memory pool was divided into a CCR6- and a CCR6+ fraction. In the CCR6- 
fraction, we distinguished Th1 and Th2 cells based on the expression CXCR3 and CCR4, since 
Th1 cells are CXCR3+CCR4- and Th2 are CXCR3-CCR4+ [32]. In the CCR6+ fraction, we first 
selected CXCR3-CCR4+ cells. This fraction contains both Th17 and Th22 cells. They were 
separated based on CCR10 expression, as Th17 cells do not express CCR10 and Th22 cells do 
[32-34]. The Treg cells were studied in a separate staining. After gating on lymphocytes, we 
selected CD4+CD45RO+ cells to obtain memory Th cells. Subsequently, by gating on CD25+ 
we enriched for Tregs. To analyze the Treg population, we included expression of Foxp3, the 
Treg-specific transcription factor.
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Figure 1. Gating strategy for the T helper cell populations 
T helper memory (CD4+CD45RO+) cell populations were defined by chemokine receptor expression by flow 
cytometry in peripheral blood. Th17: CCR6+CCR4+CXCR3-CCR10-; Th22: CCR6+CCR4+CXCR3-CCR10+; Th1: CCR6-
CXCR3+CCR4-; and Th2: CCR6-CXCR3-CCR4+; Treg: CD25hiFoxP3+.
Chapter 6
114
By applying this gating strategy we found that chemokine receptor defined Th17 and Treg cell 
percentages were significantly increased in IFN+ versus IFN- patients (p=0.005 and p=0.020 
respectively) and HC (p=0.029 and p=0.015 respectively). In contrast, Th1 cell percentages 
were decreased in IFN+ patients compared with HC (p=0.004). Percentages of Th22 and Th2 
cells were unchanged between groups (Figure 2A).
Th17 cell percentages positively correlated significantly with Th22 cell percentages 
(r=0.458, p=0.024) (Figure 2B) and with Treg percentages (r=0.523, p=0.037) (Figure 2C). 
Moreover, a significant negative correlation was observed between Th17 cell populations 
and Th1 cell populations (r=-0.424, p=0.039) (Figure 2D). 
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Figure 2. Th17 and Treg cell proportions are increased in IFN+ patients compared with IFN- patients and healthy 
controls and Th1 percentages are decreased in IFN+ patients 
(A) FACS analysis of T helper subset populations, obtained as described under (Figure S1). Correlation between 
Th17 population and: (B) Th22 population (n=22). (C) Treg population (n=22). (D) Th1 population (n=22). The 
correlation coefficients (r) and P values are shown. Horizontal line indicates mean for 8-12 IFN+ patients, 8-12 IFN- 
patients and 8-12 healthy controls (HC). 
* p<0.05; **p<0.01; to compare means one-way ANOVA was performed followed by the independent T test; for 
correlations Pearson correlation test was used.
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Th17 cell percentages correlate with IFN scores and are increased in patients with anti-SSA 
antibodies and higher serum IgA levels
A significant positive correlation was found between the expression of IFIGs, as reflected 
by the IFN scores and Th17 cell percentages (r=0.553, p=0.005) (Figure 3A). When patients 
were stratified according to their autoantibody status (anti-SSA positive vs. anti-SSA 
negative) for comparison of their Th17 percentages, patients with anti-SSA showed higher 
Th17 percentages than patients without anti-SSA (p=0.025) (Figure 3B). This increase was 
observed for both anti-Ro52 (=0.025) (Figure 3C) and anti-Ro60 antibodies (p=0.01) (Figure 
3D). Interestingly, we previously described pSS patients with anti-SSA antibodies to have 
higher IFN scores [13]. No significant differences in Th17 percentages were found with 
respect to anti-SSB autoantibody status (Figure 3E). 
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Figure 3. Th17 cell percentages correlate with IFN scores and are increased in patients with anti-SSA antibodies 
and with higher IgA levels
(A) Correlation between IFN scores and Th17 percentages. (B) Th17 percentages in pSS patients negative (n=8) or 
positive (n=16) for anti-SSA. (C) Th17 percentages in pSS patients negative (n=8) or positive (n=16) for anti-Ro52. 
(D) Th17 percentages in pSS patients negative (n=11) or positive (n=13) for anti-Ro60. (E) Th17 percentages in pSS 
patients negative (n=13) or positive (n=11) for anti-SSB. (F) Correlation between Th17 percentages and serum IgA 
levels. The correlation coefficients (r) and P values are shown. Horizontal line indicates median. For correlations 
Pearson correlation test was used and to compare means the Mann-Whitney U test was used.
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Next to the presence of auto-antibodies, we also observed higher IgG serum levels in pSS 
patients positive for the IFN type I signature [13]. In this cohort no correlation was found 
between IgG or IgM serum levels and Th17 percentages (data not shown), but a significant 
correlation between IgA serum levels and Th17 percentages was observed (r=0.553, 
p=0.011) (Figure 3F). 
Since we previously found higher ESSDAI disease activity scores in patients with higher 
IFN scores [13], we next investigated whether Th17 cell percentages are also associated with 
the ESSDAI disease activity scores. No significant correlation was observed between the 
ESSDAI disease activity scores and Th17 percentages (data not shown). 
BAFF mRNA expression is positively correlated with Th17 percentages and negatively 
correlated with Th1 percentages
As already mentioned, a factor known to be involved in the pathogenesis of pSS and found 
to correlate strongly with the IFN type I signature is BAFF. In this pSS cohort, again a strong 
positive correlation between IFN scores and monocyte BAFF mRNA expression in pSS patients 
was found (r=0.780, p<0.0001) (Figure 4A). Furthermore, a positive significant correlation 
was present between BAFF mRNA expression and Th17 cell percentages (r=0.412, p=0.046) 
(Figure 4B). A negative significant correlation was found between BAFF mRNA and Th1 cell 
percentages (r=-0.478, p=0.018) (Figure 4C).
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Figure 4. BAFF mRNA expression is positively correlated with Th17 percentages and negatively correlated with 
Th1 percentages
Correlation between monocyte BAFF mRNA expression and (A) IFN score, (B) Th17 percentages, (C) Th1 percentages 
in pSS patients (n=24). The correlation coefficients (r) and P values are shown. For correlations Pearson correlation 
test was used.
DISCUSSION 
The present study demonstrated that chemokine receptor defined Th17 cell percentages 
are increased in peripheral blood from pSS patients positive for the IFN type I signature. 
Moreover, Th17 cell percentages were significantly correlated with anti-SSA antibodies, 
hypergammaglobulinemia and monocyte BAFF mRNA expression, all three previously found 
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in IFN type I signature positive patients. These findings strengthen the hypothesis that IFN 
type I and Th17 cells act in concert to sustain and amplify the autoimmune processes in 
Sjögren’s syndrome [13]. 
A possible mechanism explaining the co-occurrence of increased IFN type I activity 
and increased Th17 percentages might be that both IFN type I and DC production of 
Th17 inducing cytokines such as IL-6 and IL-23 are simultaneously regulated through TLR 
signalling. Indeed TLR7 activation in plasmacytoid DCs, the main producers of IFN type I, 
promotes and modifies Th17 cell differentiation and function [35]. IFN type I itself is also 
able to promote Th17 differentiation and IL-17 production through induction of STAT3 in 
T cells and IL-6 induction in DCs [36, 37]. In addition Santini et al. showed that IFN type I 
conditioned monocytes differentiate into DCs driving the development of Th17 cells from 
autologous naive CD4 T cells [38]. 
Next to the direct effect of IFN type I on Th17 cells, IFN type I may also act indirectly 
through the production of BAFF. BAFF gene silencing in a CIA mouse model showed 
inhibited generation of Th17 cells in the arthritic joint [25]. In addition IL-17A can induce the 
formation of neutrophil extracellular traps (NETs) [39], which could potentially provide new 
auto-antigens to activate TLRs on DCs, thereby forming a pro-inflammatory loop. 
IL-17 and Th17 cells are also increased in the salivary glands of pSS patients. Salivary 
gland epithelial cells of pSS patients showed a skewed cytokine production, with increased 
IL-6 and decreased TGF-ß concentrations [40]. Moreover, salivary gland epithelial cells are 
able to produce IFN type I upon TLR3 stimulation with poly (I:C) [41]. Thus, a scenario with 
the pSS salivary gland epithelial cells contributing to an environment which is enriched in 
IFN type I and Th17 cells leading to a chronic inflammatory loop can be envisaged. 
The increase in chemokine receptor defined Th17 cell percentages in IFN+ patients 
compared with IFN- patients and HCs was accompanied by a significant decrease in Th1 
cell percentages in IFN+ patients versus HCs. Furthermore, there was a significant negative 
correlation between Th1 fractions and Th17 fractions (Fig 1). A possible explanation for 
this reciprocal relationship might be found in STAT3 signaling. In mice, STAT3 activation 
in T lymphocytes and other hematopoietic cells was shown to inhibit Th1 differentiation 
through inhibition of IL-12, necessary for Th1 differentiation, and T-bet, the Th1 lineage 
master transcription factor. At the same time, STAT3 signaling stimulates Th17 development 
by increasing IL-23 gene transcription and ROR-γt expression [42, 43] 
Interestingly, we observed an increase in Treg cell percentages in IFN+ patients versus 
IFN- patients and HCs, and a significant correlation between Th17 and Treg cell percentages 
(Fig 1). This is in concordance with previous research showing an increase in Treg cells 
(defined as CD4+CD25high cells) in peripheral blood and salivary gland tissue in Sjögren’s 
syndrome patients [44, 45]. However, others have shown a decrease in Treg cells in pSS 
[46-48]. The discrepancies between these studies cannot readily be explained, but different 
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medication might play a role. Immunosuppressive drugs including biologicals have an 
inducing or a reducing effect on Treg cell numbers (reviewed in [49]). In this study, no 
patients were receiving biologicals and no effect of medication on different Th subsets or 
cytokine expression was detected (data not shown). A limitation of our study is that no 
functional analysis of the Treg population has been performed.
Recently CD3+CD4-CD8- DN T cells were found as major producers of IL-17 in pSS [50]. 
DN T cells displayed a Th17 phenotype, as supported by their ROR-γt expression. Moreover, 
these cells produced IL-17 in the infiltrated salivary glands. Active involvement of DN T cells 
in the pathogenesis of pSS has been suggested. Whether these DN T cells are linked to IFN 
type I pathway as well, remains a matter for future research. 
Although we have shown in this study an increase in chemokine receptor defined Th17 
cells (CD4+CD45RO+CCR6+CXCR3-CCR4+CCR10-cells) in IFN+ patients versus IFN- patients 
and healthy controls, due to limitations in current antibody-fluorochrome availability 
we were not able to analyze cytokine expression in these chemokine defined Th17 cells. 
Future studies where both chemokine receptor expression and cytokine expression can 
simultaneously be assessed, are called for. 
In conclusion, our study shows for the first time a co-occurrence of increased IFN type 
I activity and increased Th17 cell percentages in pSS. This was accompanied by higher Treg 
percentages and reduced percentages of Th1 cells in IFN+ patients. These findings provide 
support for the concept that IFN type I acts in concert with Th17 cells in pSS. This observation 
might have implications for future treatment of pSS and other systemic autoimmune diseases 
where IFN type I plays a role. Up till now there is mainly symptomatic treatment for pSS 
and no evidence-based therapies yet. Our data demonstrate that Th17 cell percentages are 
increased in IFN+ pSS patients, paving the way for combination therapies possibly resulting 
in more significant clinical effects in the future.
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ABSTRACT
Introduction A hallmark of systemic autoimmune diseases like systemic lupus erythematosus 
(SLE) is the increased expression of Interferon (IFN) type I inducible genes, so-called IFN 
type I signature. Recently, T helper 17 subset (Th17 cells), which produces IL-17A, IL-17F, 
IL-21 and IL-22, has been implicated in SLE. As CCR6 enriches for Th17 cells, we used this 
approach to investigate whether CCR6+ memory T helper cells producing IL-17A, IL-17F, 
IL-21 and/or IL-22 are increased in SLE patients and whether this increase is related to the 
presence of IFN type I signature. 
 
Methods 25 SLE patients and 15 healthy controls (HC) were included. SLE patients were 
divided into IFN type I signature positive (IFN+) (n=16) and negative (IFN-) (n=9) patients as 
assessed by mRNA expression of IFN inducible genes (IFIGs) in monocytes. Expression of IL-
17A, IL-17F, IL-21 and IL-22 by CD4+CD45RO+CCR6+ T cells (CCR6+ cells) was measured by 
flow cytometry and compared between IFN+, IFN- patients and HC.
 
Results Increased percentages of IL-17A and IL-17A/IL-17F double producing CCR6+ cells 
were observed in IFN+ patients compared with IFN- patients and HC. IL-17A and IL-17F 
expression within CCR6+ cells correlated significantly with IFIG expression. In addition, we 
found significant correlation between BAFF – a factor strongly correlating with IFN type I − 
and IL-21 producing CCR6+ cells. 
Conclusions We show for the first time higher percentages of IL-17A and IL-17A/IL-
17F double producing CCR6+ memory T helper cells in IFN+ SLE patients, supporting the 
hypothesis that IFN type I co-acts with Th17 cytokines in SLE pathogenesis. 
Th17 cytokines and Interferon type I: partners in crime in SLE?
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a debilitating systemic autoimmune disease 
characterized by the production of auto-reactive antibodies and multi-organ inflammation 
[1]. A hallmark of systemic autoimmune diseases is the increased expression of Interferon 
(IFN) type I in both blood and disease-affected tissues [2]. About half of the SLE patients 
exhibit an IFN type I signature or upregulation of IFN type I induced genes (IFIGs) which have 
been found to correlate with disease activity and severity [3-5]. 
Another key factor in the pathogenesis of SLE apart from IFN type I, is interleukin-17A 
(IL-17A). IL-17A is produced by several immune cell types, including CD4+ T cells (Th17 
cells), CD8+ T cells, CD4-CD8-CD3+ (double negative, DN) T cells, NK cells, γδ-T cells and 
mast cells. Naïve CD4+ T cells differentiate to Th17 cells under the influence of IL-6 and 
TGFβ [6]. The expansion and stability of the Th17 population is regulated by IL-21 and IL-23, 
respectively [7, 8]. C57BL/6-lpr/lpr mice that lack IL-23 receptor signalling are protected 
for SLE development [9]. In SLE patients increased plasma levels of IL-17A correlated with 
disease severity (SLEDAI) [10]. In addition, in peripheral blood of SLE patients an increased 
number of IL-17 producing cells was observed. These cells correlated with disease activity 
and decreased upon treatment [11, 12]. IL-17-producing cells have also been found in 
several affected organs of SLE patients [11, 13].
Co-activity between IFN type I and IL-17/Th17 cells has been suggested in autoimmune 
diseases [14, 15]. In EAE, a mouse model for MS, IFN type I treatment caused exacerbation if 
the disease was Th17 driven but was effective if the disease was Th1 driven [15]. In the same 
study, MS patients that did not respond to IFN type I therapy had higher serum levels of IL-
17A before therapy onset [15]. These two observations suggest additional effects of the IFN 
type I and Th17 system co-acting in the pathogenesis of autoimmune diseases.
Co-activity of IFN type I and Th17 pathways has also been suggested for SLE by the 
Ro52/TRIM21-/- mouse model. Ro52/TRIM21 is involved in the ubiquitination of interferon 
regulatory factors (IRFs), a process which limits the IFN type I response [16]. After ear 
tagging Ro52/TRIM21-/- mice develop an SLE like phenotype [17]. Interestingly, when these 
mice are crossed on an IL-23p19-/- mouse line, they do not develop SLE, indicating that the 
development of a SLE phenotype through enhanced IFN type I production in these mice is 
dependent on the IL-17/Th17 pathway. 
Yet another important factor involved in the pathogenesis of SLE is B cell activating 
factor of the tumor necrosis factor family (BAFF). BAFF transgenic mice develop lupus-
like disease [18] and increased expression of BAFF protein has been found in SLE patients, 
correlating with increased disease activity [19-21]. We previously described a strong 
correlation between BAFF mRNA expression in monocytes and the IFN type I signature in 
primary Sjögren’s syndrome (pSS) patients [22]. Interestingly, IL-21, a cytokine produced 
by Th17 cells, in combination with BAFF has been reported to synergistically induce the 
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differentiation of human memory B cells into antibody-producing plasma cells in absence of 
further co-stimulation [23]. BAFF is known to be involved in germinal center formation [24], 
a process in which IL-17 is also involved [25].     
The above mentioned literature suggests an association between the pathogenic IFN 
type I and Th17 pathway. So far, no studies have been performed on the co-occurrence of 
these pathogenic pathways in SLE patients. In this study, we report for the first time a higher 
percentage of IL-17A and IL-17A/F producing CCR6+ T memory cells in IFN type I positive SLE 
patients. Moreover, BAFF gene expression in monocytes correlates significantly with IL-21 
expression in these CCR6+ cells, supporting the concept of co-activity of IFN type I, Th17 and 
BAFF in the pathogenesis of SLE.  
PATIENTS AND METHODS
Patients
25 patients fulfilling the American College of Rheumatology revised criteria for SLE [26] were 
recruited at the outpatient clinic of the Immunology department and the Rheumatology 
department of the Erasmus Medical Center Rotterdam. The level of disease activity was 
assessed using the SLEDAI [27]. 15 healthy controls (HC) neither suffering from autoimmune 
diseases nor using corticosteroids were included. Characteristics of patients and controls 
are summarized in Table 1. Medical Ethical Review Committee of the Erasmus MC approved 
the study and written informed consent was obtained. 
Table 1. Demographics and clinical characteristics of participants
Variable SLE patients (n=25) Healthy controls (n=15)
IFN type I negative  (n=9) IFN type I positive (n=16)
Demographics
   N females (%) 9/9 (100%) 14/16 (88%) 15/15 (100%)
   Age (years) 41.3±17.5 39.8±15.7 41.0±14.0
Disease duration (years)  12.1±8.0 14.4±11.3 -
SLEDAI 4.0 (1.0,17.0) 4.50 (2.0,10.0) -
Treatment -
    Hydroxychloroquine 7/9 (78%) 11/16 (69%) -
    Corticosteroids 5/9 (56%) 10/16 (63 %) -
    Mycophenolate mofetil 0/9 (0%) 4/16 (25%) -
    Azathioprine 2/9 (22%) 3/16 (19%) -
    Cyclophosphamide 0/9 (0%) 1/16 (6%) -
Values are the mean ± SD, median (25% quartile,75% quartile) or number (%) of patients, depending on whether 
the data are continuous or dichotomous, and whether the data are normally distributed or not
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Blood collection and isolation of monocytes
Blood was collected in clotting tubes for serum preparation (stored at -80°C) and in sodium-
heparin tubes for peripheral blood mononuclear cell (PBMC) preparation as described 
previously [28]. CD14 positive monocytes were isolated as described [28]. 
RQ-PCR
Total RNA was isolated from purified monocytes followed by cDNA preparation and RQ-
PCR analysis using predesigned primer/probe sets (Applied Biosystems) [28]. For calculation 
of relative expression, all samples were normalized against expression of the household 
gene Abl[29]. Fold change values were determined from normalized CT values using 2-ΔΔCT 
method (User Bulletin, Applied Biosystems, Foster City, California).
Flow cytometry
PBMCs were restimulated, stained and measured by flow cytometry as previously described 
[30]. For extracellular staining, CD4, CD45RO and CCR6 monoclonal antibodies were 
obtained from BD Biosciences (San Diego, CA), and CD25 antibodies from Biolegend Inc. (San 
Diego, CA). For intracellular staining, FoxP3, IL-17A, IL-17F and IL-22 monoclonal antibodies 
were obtained from eBioscience (San Diego, CA), and IL-17A monoclonal antibodies from 
Biolegend Inc. Samples were measured on a FACScantoII flow cytometer (BD Biosciences). 
Analysis was performed using FlowJo v7.6 research software (Tree Star Inc. Ashland, OR). 
Factor analysis
Expression levels of 11 IFN type I inducible genes were submitted to a principal component 
analysis to identify correlated groups of genes to reduce data complexity. Kaiser-Meyer-
Olkin measure of sampling adequacy was 0.839 with significant Bartlett’s test of sphericity 
(P< 0.001). Eigenvalues were derived to assess the amount of variance explained by each 
component factor. 
Statistical analyses
Statistical analyses were performed using SPSS 20.0 package. When data were not normally 
distributed, values were expressed as medians with interquartile ranges (IQRs) and 
comparisons were made using the non-parametric Mann-Whitney U test. In case of more 
than two samples the non-parametric Kruskal-Wallis test was performed. Correlations were 
assessed either using Pearson correlation test for normally distributed data or Spearman’s 
rho when data were not normally distributed. Differences were considered statistically 
significant if p<0.05. 
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RESULTS
Prevalence of the IFN type I signature in SLE patients
In monocytes of 25 SLE patients and 15 HCs we assessed the expression levels of 11 IFIGs 
previously assessed in monocytes from patients with primary Sjögren’s syndrome (pSS) 
(IFI27, IFI44L, IFIT3, IFITM1, SERPING1, IFIT1, IFIT2, LY6E, IFI44, XAF1 and MXA) [22]. To 
reduce data complexity, expression levels of the 11 genes were submitted to a principal 
component analysis to identify correlated groups of genes. The results of the principal 
component analysis identified a subset of 4 genes (IFI44L, IFITM1, SERPING1 and LY6E) to 
explain 95% of the total variance of the 11 IFN type I inducible genes within the SLE cohort. 
Figure 1. Prevalence of IFN type I signature in SLE patients 
(A) Heatmap showing gene expression of 4 IFN type I inducible genes in monocytes of SLE patients (n=25) and 
HC (n=15). On the left the HC are depicted and on the right the SLE patients are depicted and subdivided into IFN 
type I signature positive and negative patients. Red colour indicates high gene expression and cases are depicted 
according to ascending IFN scores. (B) Distribution of IFN scores in IFN type I signature positive and negative 
patients and HC. In red IFN type I positive cases are depicted. Blue lines represent medians.
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Given that the expression of these 4 IFN type I inducible genes was not normally distributed, 
log transformations of expression values were performed and IFN scores were calculated 
as described for pSS [22]. Mean
HC
 and SD
HC
 of each gene in the HC-group were used to 
standardize expression levels. IFN scores per subject represent the sum of these standardized 
scores. When we set the threshold for a positive IFN type I signature at IFN score of 8 [22], 
64% of SLE patients displayed an IFN type I signature and one of the 15 HC subjects (7%) 
(Figure 1A and 1B). 
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Figure 2. SLE patients with IFN type I signature show higher percentages of IL-17A and IL-17A/IL-17F producing 
CCR6+ cells
(A)  Representative graphs of proportions of IL-17A and IL-17F expressing cells within CCR6+ memory T cell 
population (defined as CD4+CD45RO+CD25-CCR6+) in PBMCs of IFN negative (IFN-) and IFN positive (IFN+) patients 
and healthy controls (HC). (B) Representative graphs of proportions of IL-17A and IL-22 expressing cells within 
CCR6+ memory T cell population in PBMCs of IFN- and IFN+ patients and HC. (C-E), Proportions of IL-17A [C], IL-17F 
[D] and IL-22 [E] expressing cells within CCR6+ memory T cell population in PBMCs of IFN- (n=9) and IFN+ (n=16) 
patients and HC (n=15). All proportions were measured by intracellular flow cytometry. Horizontal line indicates 
median. *p<0,05; **p<0,01; to compare means Kruskal-Wallis test was used followed by Mann-Whitney U test.
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SLE patients with IFN type I signature show higher percentages of IL-17A and IL-17A/IL-17F 
producing CCR6+ cells
Because CCR6 enriches for Th17 cells [31-33], CCR6+ cells were selected after gating on 
lymphocytes and memory Th cells (CD4+CD45RO+ cells) within PBMCs and after CD25high 
cells were excluded. To investigate whether the IFN type I signature is associated with 
an increase in Th17 cytokines expressed by memory CCR6+ T cells, we measured the 
percentages of IL-17A, IL-17F, IL-22 and IL-21 producing CCR6+ T memory cells in SLE 
patients positive for the IFN type I signature (IFN+) and patients negative for the signature 
(IFN-) and HC. Interestingly, the percentages of CCR6+IL-17A+ cells were significantly 
increased in IFN+ patients as compared with IFN- patients (p=0.03) and a higher trend was 
observed compared with HC (p=0.07) (Figure 2A, D, E). The percentages of CCR6+IL-17F+ 
and in particular the IL-17A/IL-17F double producers were significantly increased in the IFN+ 
group compared with HC (p=0.009) (Figure 2B and D). The percentages of CCR6+IL-22+ cells 
showed a higher trend for IFN+ vs. IFN- patients (p=0.06) and IFN+ patients vs. HC (p=0.09) 
(Figure 2C and E). These data suggest an association between the presence of the IFN type 
I signature and the expression of Th17 cytokines IL-17A and IL-17F in SLE. In addition, we 
investigated whether the Th17 cytokine production is associated with disease activity as 
assessed by SLEDAI scores. No significant correlations were observed between the SLEDAI 
scores and IL-17A and/or IL-17F expression (data not shown). 
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Figure 3. BAFF mRNA expression is correlated with IL-21 expression within CCR6+ memory T cells
(A) Correlation between IFN score and IL-17A expression within CCR6+ memory T cells in SLE patients (n=25). 
(B) Correlation between IFN score and IL-17F expression within CCR6+ memory T cells in SLE patients (n=25). (C) 
Correlation between monocyte BAFF mRNA expression and IFN score in SLE patients and HC (n=40). (D) Correlation 
between monocyte BAFF mRNA expression and IL-21 expression within CCR6+ cells in SLE patients and HC (n=40). 
The correlation coefficients (r) and P values are shown. For correlations Spearman’s rho correlation test was used 
in A, B and D and Pearson correlation test was used in C.
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BAFF mRNA expression is correlated with IL-21 expression within CCR6+ memory T cells
Correlating the expression of IFIGs (as reflected by the total IFN score) with other parameters 
assessed in this study, we observed a significant positive correlation between the expression 
of IL-17A and IL-17F within CCR6+ cells and IFIG expression (Figure 3A and B). Also in this SLE 
cohort, IFIG expression correlated strongly with the BAFF mRNA expression in monocytes 
(r=0.527, p<0.0001) (Figure 3C). No correlation was observed between BAFF and IL-17A 
and/or IL-17F expression. However we did find a significant correlation between BAFF 
mRNA and the percentages of IL-21 producing CCR6+ cells (r=0.406, p=0.010) (Figure 3D). 
Both BAFF and IL-21 are involved in the selection and activation of B cells, which is crucial 
in the pathogenesis of SLE, indicating that downstream factors of the IFN type I and Th17 
pathways might also be associated. 
DISCUSSION
Here we show for the first time a co-occurrence of increased IFN type I activity and increased 
IL-17/Th17 system in SLE patients. We found increased percentages of IL-17A and IL-17F 
producing CCR6+ T memory cells in IFN type I positive SLE patients. This finding further 
strengthens the hypothesis that IFN type I and Th17 cells by co-acting contribute to the 
pathogenesis of SLE. Further research to understand the link between these two pathways 
is warranted.
A possible mechanism explaining the co-occurrence of IFN type I and IL-17/Th17 
immune pathway in SLE could be that both IFN type I and production of IL-6 and IL-23 
by DCs are regulated through IRF-5 [34, 35]. Activation of TLR signalling on DCs will then 
lead to simultaneous enhancement of both pathways. Indeed there is evidence that TLR7 
activation of plasmacytoid DCs, the main producers of IFN type I, promotes and modifies 
Th17 cell differentiation and function [36]. IFN type I itself is also able to promote Th17 
differentiation and IL-17 production through induction of STAT-3 in T cells and IL-6 in DCs 
[37, 38]. In addition, IFN type I conditioned monocytes differentiate into DCs driving the 
development of Th17 cells from autologous naive CD4+ T cells [39]. 
In addition to the direct effect of IFN type I on Th17 cells, IFN type I may also act indirectly 
through the production of BAFF. BAFF is reported to be involved in DC maturation and DC 
driven Th17 cell differentiation in vitro [40]. BAFF gene silencing ameliorated joint pathology 
and inhibited the generation of Th17 cells in the joints of a collagen induced arthritis (CIA) 
mouse model [40]. In turn IL-17A can induce the formation of neutrophil extracellular 
traps (NETs) [41], which could potentially provide new auto-antigens to active TLRs on DCs, 
thereby forming a pro-inflammatory loop.   
We find a correlation between BAFF, an IFN type I inducible factor, and the Th17 produced 
cytokine IL-21. Ettinger et al. showed that IL-21 together with BAFF promotes B cell responses 
by bypassing the need for T cell help or TLR signalling [23]. As these downstream factors are 
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both involved in activation and selection of B cells, these findings again support the concept 
that IFN type I and the Th17 pathway act together in driving the disease process of SLE.
In contrast to others we did not find a correlation between SLEDAI and Th17 cytokines 
[10]. This might be due to the relatively low patient number, which is a limitation of our 
study. 
Although we don’t show a functional link between IFN type I and the Th17 pathway, 
our findings provide the first support for co-occurrence of increased IFN type activity and 
increased IL-17/Th17 system in SLE. The Th17-IFN type I interaction found in this study might 
have implications for future treatment of SLE and other systemic autoimmune diseases 
where IFN type I plays a role. Preliminary results from a phase IIa trial with human IgG1κ 
anti-IFNα antibody in 87 SLE patients, showed so far a 40% reduction in IFN type I induced 
gene expression but no clinical effect compared to placebo (abstract Merrill J et al.*). Our 
data indicate that IFN type I might act in concert with Th17 cytokines, paving the way for 
combination therapies possibly resulting in more significant clinical effects in the future.
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SUMMARY OF DATA IN GENERALIZED AUTOIMMUNE DISEASES
Increased IFN type I activity, reflected by the IFN type I signature in monocytes, was 
observed in about half of the pSS patients, one third of SSc patients and two thirds of SLE 
patients compared with HCs. pSS patients with the IFN type I signature (IFN+) showed higher 
disease activity and IFN+ SSc patients displayed signs of more progressive disease. IFN type 
I signature showed stability over time in pSS patients. MxA protein expression by Enzyme 
immunoassay (EIA) in whole blood lysates and by FACS analysis in monocytes were practical 
and rapid approaches for assessment of IFN type I bioactivity in pSS and SLE. 
Next to increased disease activity, signs of increased BAFF system and IL-17/Th17 
system were found in IFN+ patients. IFN type I signature strongly correlated to BAFF mRNA 
expression in monocytes from pSS, SSc and SLE patients. Moreover, BAFF expression could 
be induced in cultured monocytes by serum of IFN type I signature positive pSS patients. 
Chemokine receptor defined Th17 cells and IL-17 producing CCR6+ T memory cells 
were significantly increased in IFN+ pSS and SLE patients, respectively. Chemokine receptor 
defined Th17 cell percentage was significantly higher in pSS patients with anti-SSA antibodies, 
hypergammagloblulinemia and elevated monocyte BAFF mRNA expression, all previously 
found in IFN type I signature positive patients.
Finally collagen synthesis was increased in IFN+ SSc patients, as determined by N-terminal 
propeptide of type III collagen (PIIINP) levels. 
In summary, IFN+ patients with a systemic autoimmune disease form a separate group 
of patients with a more severe disease and various signs of activation of other immune 
systems, such as the BAFF system, IL-17/Th17 system and fibrosis. 
This chapter will discuss the implications of these findings in relation to the pathogenesis 
and treatment of IFN type I positive generalized autoimmune diseases. Finally, the limitations 
of the studies and future perspectives will be given. 
INCREASED IFN TYPE I ACTIVITY IN GENERALIZED AUTOIMMUNE 
DISEASES
Development of pSS, SLE and SSc has been described upon treatment with IFN type I in 
patients with malignancies and hepatitis C [1-4] supporting the role of IFN type I in the 
pathogenesis of these diseases. About half of the SLE patients exhibit upregulation of IFN 
type I induced genes which has been found to correlate with disease activity and severity as 
well as with the presence of autoantibodies against RNA binding proteins [5-8]. Increased 
IFN type I activity was detected in salivary glands, whole blood, PBMCs and monocytes from 
pSS patients [9-12]. In SSc increased IFN type I activity was reported both in the affected skin 
and in immune cells isolated from the circulation [13-15]. However the prevalence of the 
increased IFN type I activity in pSS and SSc was not established yet. Given that there are 17 
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different IFN type I subtypes, it is difficult to measure serum protein levels using an ELISA. 
Therefore we used the monocyte mRNA expression of a set of IFIGs previously detected in 
a microarray study [10], as our operational definition for the increased IFN type I activation 
– the so-called IFN type I signature. By performing RQ-PCR, we found in 55% of pSS patients 
the IFN type I signature present compared with 4.5% of HCs (Chapter 2). In SSc, 29.3% of 
the patients displayed the IFN type I signature versus none of the HCs (Chapter 4). In line 
with previously reported data, the IFN type I signature was detected in 64% of SLE patients 
(Chapter 7). 
           IFN type I activity has been associated with more active and severe disease in SLE and 
SSc [5-8, 16]. By stratifying pSS patients according to their IFN type I signature status (IFN+ 
and IFN-), significantly higher EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) 
scores were observed in the IFN+ pSS patients (Chapter 2). In SSc patients a correlation 
between increased IFN type I activity and the mean Rodnan Skin Score (mRSS) could not 
be replicated (Chapter 4). A possible explanation for this might be the fact that this study 
comprised patients who had been included in two different centers in which the mRSS was 
performed by different clinicians. We did observe a markedly shorter time between the 
onset of Raynaud’s phenomenon and development of the first non-Raynaud symptom in 
IFN type I positive patients, suggesting a more progressive disease in the IFN+ positive SSc 
patients. 
 A relationship between the presence of IFN type I activity and autoantibodies has been 
described in autoimmune diseases [17-22]. IFN type I induced gene expression was higher 
in pSS patients positive for anti-SSA and/or anti-SSB antibodies (Chapter 2). In SSc the IFN+ 
patients were characterized by the presence of anti-RNP autoantibodies and absence of 
anti-centromere antibodies (Chapter 4). The autoantibodies present can form ICs with 
the autoantigens released upon apoptosis. Interestingly, IFN type I is able to upregulate 
the expression of Fas, Fas-L and Ro52 autoantigen [23, 24]. ICs containing both RNA and 
DNA are found to be potent IFN type I inducers in autoimmune diseases [20, 25-29]. This 
occurs through FcγR-dependent internalization of the ICs by pDCs, followed by TLR7 and 9 
activation. In line with these findings, in IFN+ pSS patients decreased C3 levels and increased 
serum IgG levels were observed (Chapter 2). 
 Why one IFN type I driven autoimmune disease exhibits manifestations mainly in the 
salivary and lacrimal glands, while other IFN type I driven autoimmune diseases primarily 
manifest in the skin and kidneys, remains to be elucidated. Although not limited to this, a 
possible explanation could be genetic or acquired aberrancies in the target tissues.  
Implications for therapy 
The data in this thesis and in the literature indicate a relationship between activated IFN 
type I system and generalized autoimmune diseases, suggesting that downregulation of this 
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system could be a therapeutic approach. Interestingly, anti-IFN-α autoantibodies have been 
detected in 27% of serum samples from SLE patients. These patients had lower IFN type 
I inducible gene expression and were clinically less active [30]. Blockade of the IFN type 
I system with biologic agents can be exerted by interfering with different upstream and 
downstream targets of the IFN type I system.  
One of the therapeutic targets might be IFNα and currently 2 anti-IFNα monoclonal 
antibodies, rontalizumab and sifalimumab, are studied in clinical trials for treatment of 
SLE. Results from phase I trial of sifalimumab revealed that there was a significant dose-
dependent inhibition of the IFN type I signature and corresponding changes in related 
proteins in affected skin (ESI-1 and USP18) after treatment compared with placebo [31]. 
No serious adverse events were reported. Preliminary results from a phase IIa trial with 
sifalimumab in 87 SLE patients presented at the EULAR 2011, showed a 40% reduction in 
IFN type I induced gene expression but no clinical effects compared to placebo (abstract 
Merrill J et al.*). Treatment duration from this study may have not been long enough to 
detect clinical effects.
Rontalizumab was successful in turning off IFIGs (IFI27, MX1, IFI44, IFIT1, OAS1, OAS2, 
and OAS3) in mildly active SLE patients in a phase I trial [32]. Remarkably, the decline in IFIG 
expression following treatment was similar in all patients regardless of their IFIG expression 
at baseline. None of the patients who were designated as being IFN type I high reached the 
levels of IFIG expression seen in the IFN low patients, nor did they reached the basal levels 
detected in the HCs. Also no apparent decline in the levels of IFN type I inducible proteins 
(BLC, I-TAC, MCP-1, BAFF and IP-10) was detectible. An explanation for these results could be 
attributed to the residual activity of other type I interferons, such as IFNβ, IFNω, IFNλ. Also 
other stimuli that are present in the serum of the patients and have the capacity to induce 
expression of the same genes are possible. It is currently not known whether complete 
or partial normalization of IFIGs is required in order to achieve clinical efficacy. Levels of 
autoantibodies (anti dsDNA, anti-SSA, anti-RNP) also did not decline following treatment 
with rontalizumab. For these changes possibly longer treatment periods may be required, 
since these autoantibodies are derived from long-lived plasma cells. An acceptable safety 
profile was demonstrated for rontalizumab in this study.
A limitation of the above discussed monoclonal antibodies is that each antibody targets 
only a subset of the 13 subtypes of IFNα. Induction of anti-IFNα antibodies by active 
immunisation with kinoids (conjugates of cytokines to keyhole limpet haemocyanin), 
involves a polyclonal reaction to all the 13 subtypes of IFNα [33]. A first trial of 28 SLE 
patients treated with IFNα-kinoid showed dose-related reduction in IFIGs in all immunised 
patients who were IFN+ at baseline [34].
Another possible therapeutic target within the IFN type I pathway might be the IFNAR. A 
more profound inhibition of IFN type I effects can be expected when the IFNAR is blocked. 
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Also the pDCs could be directly targeted using human monoclonal antibodies directed 
against BDCA-2 or BDCA-4 [35, 36]. Furthermore, an oligonucleotide that blocks TLR7/9 has 
been tested as experimental therapy for skin inflammation in SLE mice [37]. Finally, the 
use of RNAse to block the stimulation of TLR7 by RNA containing ICs could be a treatment 
possibility and recently showed to be effective in an SLE mouse model [38]. 
Table 1.  Monoclonal antibodies for treatment of pSS, SSc and SLE discussed in this chapter 
Name Target
Rontalizumab  IFNα
Sifalimumab IFNα
Belimumab BAFF
Rituximab CD20
Ustekinumab Il-12/IL-23
Ixekizumab IL-17
Brodalumab IL-17 receptor
Tocilizumab IL-6
A CLINICALLY APPLICABLE BIOMARkER FOR IDENTIFYING SYSTEMIC 
IFN TYPE I ACTIVITY
Since the IFN type I activity is assessed via laborious expression profiles of multiple IFN type I 
inducible genes, we explored in Chapter 3 the possibilities for an easy and practical assay for 
identifying systemic IFN type I bioactivity. This study was the first to simultaneously assess 
protein levels of MxA, CD64, CD169 and BAFF as biomarkers for IFN type I detection. Herein 
MxA was distinguished as the best functional biomarker for systemic IFN type I activity in 
pSS. Intracellular MxA protein was assessed using an EIA method on whole blood and flow 
cytometric analysis on circulating CD14+ monocytes. Flow cytometric detection of MxA in 
monocytes showed a slightly better distinction between IFN+ and IFN- patients than the 
EIA in whole blood. Nevertheless, the MxA-EIA was a more practical assay as it requires 
only 25µl of whole blood, without necessity of laborious PBMC- and subsequent monocyte-
isolation. 
Implications for therapy 
Whole blood MxA levels correlated with ESSDAI scores and patients using HCQ showed 
reduced MxA levels (Chapter 3). HCQ has been shown to impair systemic IFNα production 
[39]. Our data suggests that identifying IFN type I signature by performing MxA-assays might 
prove useful in predicting HCQ treatment responsiveness. Also in the anti-IFN trials, MxA 
might be useful predictor for responsiveness of therapy. 
General discussion 
Ch
ap
te
r 
8
141
IFN TYPE I AND BAFF
BAFF has been implicated in the pathogenesis of generalized autoimmune diseases [40-48]. 
Furthermore, a link between IFN type I and BAFF has been reported [49-51]. In this thesis we 
find a strong correlation between BAFF and IFN type I signature in all 3 autoimmune disease 
(Chapter 2, 4 and 7). BAFF mRNA expression could be induced in cultured monocytes by 
serum from IFN type I signature positive pSS patients (Chapter 2). Moreover a significant 
correlation between BAFF and chemokine defined Th17 cells (Chapter 6) as well as between 
BAFF and IL-21 producing Th17 cells (Chapter 7) was observed. Interestingly, BAFF is 
reported to be involved in DC maturation and DC driven Th17 cell differentiation in vitro 
[52]. BAFF gene silencing ameliorated joint pathology and inhibited the generation of Th17 
cells in the joints of a collagen induced arthritis (CIA) mouse model. IL-17 was furthermore 
shown to be involved in BAFF-mediated exacerbation of CIA. These findings shed light on 
IFN type I as a link between the innate and adaptive immune system through upregulation 
of BAFF and point to IFN type I as well as BAFF as good candidates for therapy. 
Implications for therapy 
As shortly discussed in chapter 1, an antibody to BAFF, belimumab (Table 1), has been shown 
to be beneficial in SLE patients, especially in patients with high disease activity, positive anti-
dsDNA antibodies, low complement or who are on corticosteroids [53]. Without significant 
safety concerns belimumab was well-tolerated [54, 55]. Although the additional benefits 
of belimumab over placebo were modest in patients receiving standard therapy, the main 
benefits are to maintain remission, slow disease progression and reduce steroid use [56]. 
Given these results, belimumab might also be a good therapeutic option for pSS and SSc. 
Interestingly, increased BAFF levels were reported following rituximab therapy in pSS [57] 
and recently also increased IFN type I activity [58]. IFN type I activity negatively predicted 
the therapeutic outcome for rituximab (Table 1) in rheumatoid arthritis [59]. Taken this into 
account, anti-IFN therapy or the addition of belimumab might be more efficacious than 
rituximab solely. 
IFN TYPE I AND FIBROSIS
BAFF mRNA was increased in the IFN type I signature positive SSc patients (Chapter 4). 
BAFF serum levels were found to correlate with the extent of skin fibrosis in SSc [43]. We 
therefore investigated whether an indicator of de novo collagen type III synthesis, namely 
PIIINP, is increased in SSc patients positive for the IFN type I signature. We found increased 
PIIINP levels in SSc compared to HC and by far the highest levels in IFN+ patients (Chapter 
4 and 5). A possible factor linking the IFN type I to fibrosis could be TLR3. IFNα2 has been 
reported to induce TLR3 expression on human dermal fibroblasts, which resulted in increased 
TLR3-induced production of the profibrotic cytokine IL-6 [60]. SSc fibroblasts showed an 
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augmented TLR3 response to IFNα2 compared with HC fibroblasts. In addition, TLR3 
appears to be increased in the skin of SSc individuals [61]. Transcutaneous administration of 
several TLR ligands to mice, especially of TLR3 ligand induced inflammation and progression 
of fibrosis [62]. 
Implications for therapy 
SSc is a difficult to treat severely debilitating disease. Imatinib mesylate is used as a 
treatment for therapy-refractory SSc with high variability in therapeutic outcomes ranging 
from ineffective/toxic responses to extremely encouraging clinical improvement [63]. We 
performed an open label study with Imatinib in 10 therapy resistant SSc patients (Chapter 
5). Similar to previous studies, a small percentage of patients responded [63]. Interestingly 
only the responding patients showed a high IFN type I activation, high BAFF mRNA levels and 
high PIIINP serum levels, indicating that IFN type I signature might be a potential biomarker 
for the selection of SSc patients for Imatinib treatment. The use of such a biomarker could 
avoid high costs and potential side effects in patients who are unlikely to respond to Imatinib. 
IFN type I might also be a suited target for treatment of SSc patients. Blocking the IFN type I 
activity could result in decrease of fibrosis both directly by diminished IFN type I activity, as 
well as indirectly through inhibition of BAFF. 
IFN TYPE I AND TH17 PATHwAY
The role of IFN type I on the T cell activation and differentiation is complex and consists of 
contrasting data. The results of the performed studies depend on whether the influence 
of IFN type I was studied on naive or activated T cells, and whether in vitro or in vivo 
experiments were conducted [64]. Early on, IFN type I has been shown to play a role in 
the differentiation of human Th1 cells through induction of STAT4 [65]. In contrast to these 
data, in this thesis decreased Th1 cell percentages were observed for pSS patients with the 
IFN type I signature (Chapter 6). A role of IFN type I on the development of CD4+ helper 
memory T cells upon cognate Ag exposure has been described [66]. Furthermore, IFN type 
I was observed to stimulate cytotoxic T cells and long lived central memory CD8+ T cells 
[64, 67]. Recently, a co-activity between IFN type and Th17 subset has been suggested. 
TLR7 activation promotes and modifies Th17 cell differentiation and function mainly related 
to increased IL-1β and IL-23p19 production of pDCs [68]. IFN type I itself is also able to 
promote Th17 differentiation and IL-17 production through induction of STAT3 in T cells and 
IL-6 induction in DCs [69, 70]. Finally, IFN type I conditioned monocytes differentiate into 
DCs driving the development of autologous naive CD4 T cells into Th17 cells through IL-23 
production [71]. 
Next to these data on an association between IFN type I and Th17 pathway, 2 mouse 
models have led us to hypothesize that Th17 cells are increased in patients with the IFN 
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type I signature. The first mouse model is the EAE model which showed improvement upon 
IFN type I treatment if the disease was Th1 driven, and exacerbation if the disease was 
Th17 driven [72], suggesting IFN type I as a driving force behind Th17. The second model is 
the Ro52-/- mouse model [73]. Ro52 is involved in the ubiquitination of IRFs, a mechanism 
reported to limit the IFN type I response. The Ro52-/- mice appeared phenotypically normal 
if left unmanipulated. However, these mice developed severe dermatitis with neutrophil 
infiltrates induced by metal ear tags. These affected mice also developed signs of systemic 
lupus with hypergammaglobulinemia, autoantibodies to dsDNA, proteinuria, and kidney 
pathology. Next to the inflamed skin, Th17 cells were detected in the draining lymph nodes 
in these mice. Interestingly, when these mice were crossed on an IL-23p19-/- mouse line, 
they did not develop the systemic autoimmune symptoms upon ear tagging, indicating that 
the development of an SLE phenotype through enhanced IFN type I production in these 
mice is dependent on the IL-23/Th17 pathway. 
To test our hypothesis that Th17 cells are increased in patients with the IFN type I signature, 
we used flowcytometry to phenotypically characterize the PBMCs from pSS and SLE patients 
and study the differences between IFN+ and IFN- patients. We detected increased IL-17/
Th17 proportions in the peripheral blood of both pSS and SLE patients positive for the IFN 
type I signature (Chapter 6 and 7). In pSS we observed a significant increase in chemokine 
receptor defined Th17 cells (CD4+CD45RO+CCR6+CCR4+CXCR3-CCR10- cells), while in SLE 
we found an increased percentages of IL-17A and IL-17F producing CCR6+ T memory cells. 
Furthermore, in SLE we detected a significant correlation between the downstream factors 
of IFN type I and Th17 pathway, namely BAFF and IL-21 production by CCR6+ T memory 
cells, respectively (Chapter 7). In pSS patients, BAFF correlated significantly with chemokine 
receptor defined Th17 cell percentages and negatively with Th1 cell proportions (Chapter 
6). These data provide the first ex vivo support for the co-occurrence of IFN type I and Th17 
pathway in patients with generalized autoimmune diseases, underscoring the role of IFN 
type I in linking the innate and adaptive immunity. 
Interestingly, IL-21 is the main effector cytokine produced by follicular Th (Tfh) cells. 
Tfh are important for germinal center formation and B cell differentiation into plasma cells 
and memory B cells [74, 75]. Increased frequencies of circulating Tfh-like cells are found in 
SLE and pSS patients [76]. Moreover increased frequency of Tfh-like cells in SLE correlates 
with autoantibody titers and tissue damage. Although not studied in this thesis, it can be 
envisaged that next to Th17 cells also Tfh cells play an important role in IFN type I signature 
positive patients.  
Implications for therapy 
Regarding the above mentioned data, various biological drugs directed against Th17 
cytokines might be effective as therapeutic options. Since preliminary results from a phase 
IIa trial with sifalimumab showed so far disappointing results, combination therapies 
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blocking both IFN type I and Th17 pathway might result in more significant therapeutic 
effects, provided that safety concerns can be addressed.  
Monoclonal antibodies directed against Th17 cytokines are being studied in autoimmune 
diseases such as psoriasis and rheumatoid arthritis. Ustekinumab, a fully human IgG κ 
monoclonal antibody that binds to the common p40 subunit shared by IL-12 and IL-23, has 
shown promising results in patients with active psoriatic arthritis in a phase III trial [77]. The 
benefits of ustekinumab in psoriatic arthritis might be related to the dual effects of inhibiting 
IL-23 and IL-12, with downstream effects on Th1 cells, or could be because of inhibition 
of the IL-23–Th17 axis alone. No deaths, opportunistic infections, tuberculosis infection 
or malignancies were reported, although 3 patients had major adverse cardiovascular 
events. Use of a humanized anti-IL-17 monoclonal antibody, ixekizumab, improved the 
clinical symptoms of psoriasis in a phase II trial [78]. No serious adverse events or major 
cardiovascular events were observed. In another phase II study, the use of a human anti-
interleukin-17-receptor monoclonal antibody, brodalumab, significantly improved plaque 
psoriasis without major adverse side effects [79]. Finally, tocilizumab, a humanized anti-
IL-6 receptor monoclonal antibody is now in clinical use in RA. In a 5-year extension study, 
tocilizumab demonstrated sustained long-term efficacy and a good safety profile [80]. These 
agents might be useful in future therapy for pSS, SLE and SSc. As with other biological agents, 
the safety of these anti-Th17 biologic therapies merits close long-term follow up, especially 
to fully assess major adverse events such as cardiovascular risks.
THE HYPOTHETICAL MECHANISM FOR THE PATHOPHYSIOLOGY OF 
IFN TYPE I MEDIATED AUTOIMMUNE DISEASES
Figure 1 shows a hypothetical mechanism for the pathophysiology of IFN type I mediated 
autoimmune diseases, based on the data given in this thesis. Increased apoptosis and 
impaired clearance of apoptotic material have been proposed to play a role in the 
pathogenesis of systemic autoimmune diseases [81, 82]. Whether a viral infection, target 
organ specific abnormalities such as the increased expression of Fas, Fas-L, Perforin and 
granzyme B in pSS salivary glands, damage due to environmental factors like sunlight, 
decrease in estrogens, several medications or a combination of aforementioned factors 
initiate apoptosis, remains to be elucidated. Due to insufficient clearance of apoptotic 
cells, these cells undergo secondary necrosis and disintegrate into apoptotic blebs. Under 
normal conditions, chromatin does not induce an immune response. However during 
apoptosis, many chromatin modifications take place and chromatin containing apoptosis-
associated modifications present in the apoptotic blebs are a target for autoantibodies 
[83]. After DCs take this chromatin up, these cells have been reported to mature, 
stimulate autoreactive T cells and finally induce an antibody production by B cells [84-86]. 
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Figure 1. Simplified hypothetical mechanism for the pathophysiology of IFN type I mediated autoimmune 
diseases
Subsequently, the abundantly produced autoantibodies can form ICs with autoantigens 
present in the apoptotic remains. These ICs induce IFN type I production, IFIG expression 
and production of IFN type I induced proteins such as MxA via FcγRIIa-mediated endocytosis 
and subsequent TLR-7/9 activation. Produced IFN type I stimulates the monocyte to produce 
BAFF, which stimulates the differentiation/maturation and survival of B cells. IFN type I also 
induces Th17 differentiation through production of IL-6 and IL-23 by conventional DCs for 
example. Th17 cells produce subsequently IL-17A, IL-17F, IL-22 and IL-21. IL-17A was recently 
reported to stimulate the neutrophils to release extracellularly chromatin structures termed 
as neutrophil extracellular traps (NETs) [87]. Chromatin structures loaded with antimicrobial 
peptides such as LL37 or HNP (typically present in neutrophil granules) are externalized by 
neutrophils during NETosis [88]. Neutrophils are able to cause tissue damage and promote 
autoimmunity by aberrant formation of NETs [89]. Importantly, netting neutrophils are great 
inducers of IFN type I [90]. In turn, IFN type I has been shown to prime neutrophils to produce 
NETs more easily [91]. Autoantibodies induce NETosis in IFN type I primed neutrophils. Thus 
upon apoptosis, B cells are stimulated to produce autoantibodies that form on the one hand 
ICs with the autoantigens, resulting in pDC activation and IFN type I production. On the 
other hand, the produced autoantibodies induce NETosis in IFN type I primed neutrophils, 
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amplifying the IFN type I response. Hereby a vicious circle is initiated. Our observation that 
IFN type I activation is correlated with decreased neutrophil count in pSS patients (Chapter 
2) is in line with these data. Next to induced NETosis by apoptotic material, impaired NET 
degradation is described in SLE patients [92, 93]. Lastly IFN type I is able to upregulate the 
expression of Fas, Fas-L and Ro52 autoantigen and prime for even more enhanced IFN type 
I production by pDCs. 
 
LIMITATIONS 
Small study samples
Mainly the studies in chapter 6 and 7 as well as the clinical trial for imatinib mesylate in 
chapter 5 involved relative low numbers of patients. These studies nevertheless turned out 
to have enough power to detect differences between IFN+ patients, IFN- patients and HC. 
Furthermore, in all studies patients and healthy controls were matched for age and gender. 
Nevertheless, our studies should be repeated and confirmed in larger study samples, making 
correction for all possible confounders possible. 
Peripheral blood samples 
All our studies were carried out on peripheral blood samples and information is lacking on 
the immune cells in the actual affected organs such as the salivary glands, skin and kidneys. 
We studied the IFN type I inducible gene expression in CD14+CD16- monocytes instead of 
PBMCs, as monocytes were found to be involved in the pathogenesis of pSS [94]. Moreover, 
CD14CD16- monocytes are thought to be precursors for the DCs and macrophages in the 
peripheral tissue, offering possibilities to study the mononuclear phagocyte system in these 
diseases. Comparing the three autoimmune diseases studied in this thesis, pSS target organs 
are the most accessible to perform research on. However, at our immunology outpatient 
clinic relatively few salivary gland biopsies are performed due to low diagnostic sensitivity 
of the biopsies and the possible complications for the patient. 
Influence of medication
The majority of the patients in our studies used medication, with possible effects on the 
immune system. Lower MxA levels were detected in pSS patients using HCQ (Chapter 3). To 
draw clear conclusion on the effect of medication on IFN type I activity, longitudinal follow-
up studies are required in which IFN type I activity is compared between medication naive 
patients before the start of treatment and the same patients after taking medication. 
Technical limitations
Due to limitations in current antibody-fluorochrome availability, we were not able to analyze 
cytokine expression on chemokine receptor defined Th17 cells (CD4+CD45RO+CCR6+CXCR3-
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CCR4+CCR10-cells) in chapter 6. Future studies where both chemokine receptor expression 
and cytokine expression can simultaneously be assessed, are warranted.
PERSPECTIVES
Generalized autoimmune diseases are evidently heterogeneous diseases with a multi-
factorial pathophysiology. Currently, therapy is mainly symptomatic without clear treatment 
guidelines. Variation in chosen therapy exists between doctors and there is also variation 
in therapy outcome between patients. Stratification of patients in subgroups according to 
the pathophysiological mechanisms (e.g. increased IFN type I activity versus low IFN type I 
activity) and appropriate evidence-based personalized therapies (e.g. anti-IFN therapy) will 
lead to improved management of these diseases and therefore increased quality of life for 
the patients. Taking into account the before described pathophysiological mechanism and 
the results from clinical trials with biologicals, it is questionable whether inhibition of one 
pathogenic mechanism such as solely IFN type I, BAFF or Th17 will be sufficient for significant 
clinical responses. Perhaps that combination therapies such as anti-IFN type I together with 
anti-CD20 or anti-Th17 will lead to more significant therapeutic effects. Determining the 
IFN type I signature is the first step in the right direction regarding personalized therapies 
and monitoring responsiveness of therapy. Longitudinal studies have to clarify whether the 
in this thesis used cut-off values for the definition of a positive IFN type I signature (i.e. 
increased IFN type I activity) are sufficient for stratifying patients into therapy subgroups. 
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SUMMARY
When the immune system fails to recognize the body’s own constituent parts as ‘self’ and 
responds against its components, it is called autoimmunity and an autoimmune disease 
can develop. Primary Sjögren’s syndrome (pSS), systemic lupus erythematosus (SLE) and 
systemic sclerosis (SSc) are examples of autoimmune diseases where multiple organs and 
tissues are affected by an autoimmune process. These diseases are called ‘generalized 
autoimmune diseases’, because of the multisystem involvement. Interferon (IFN) type I 
has been implicated in the pathogenesis of generalized autoimmune diseases. IFN type I in 
general is produced in humans upon viral infection and originally defined by its capacity to 
interfere with viruses; this is reflected in its name. In patients with generalized autoimmune 
diseases IFN type I seems to be produced without evidence for a viral infection. 
The aim of this thesis was to determine the prevalence of the increased IFN type I activity in 
pSS and to elucidate the relation between the increased IFN type I activity and: 
 a) disease manifestations 
 b) other immune abnormalities, typical for generalized autoimmune diseases
In humans IFN type I includes more than 17 different subtypes. Therefore assessing IFN 
type I levels in blood of patients is not practical to determine the total IFN type I activity. The 
IFN type I inducible gene expression levels in circulating blood cells (the so-called ‘IFN type I 
signature’) are used as a tool for the assessment of systemic IFN type I activity. This has been 
addressed in Chapter 2. By assessing the IFN type I signature in pSS patients, we observed in 
about half of the pSS patients increased IFN type I activity. This increased IFN type I activity 
seems to be stable over time and correlates with increased EULAR Sjögren’s Syndrome 
Disease Activity Index (ESSDAI) scores and various disease manifestations such as higher 
autoantibody levels, higher serum IgG, lower complement and lymphocyte and neutrophil 
counts. Also a strong correlation with B cell activating factor (BAFF) is described in chapter 2. 
 Since the IFN type I activity is assessed via laborious expression profiles of multiple IFN 
type I inducible genes, we explored in Chapter 3 the possibilities for an easy and more 
practical assay to measure systemic IFN type I bioactivity. The levels of MxA protein (also 
an IFN inducible gene and protein) were distinguished as the best functional biomarker for 
systemic IFN type I activity in pSS. 
The prevalence of the increased IFN type I activity in SSc patients has not been established 
yet. In Chapter 4 we describe in about one third of SSc patients the presence of the IFN 
type I signature. Also the association between IFN type I and disease manifestations, BAFF 
expression and collagen metabolism was established. In addition, the possible role of the 
IFN type I signature as a biomarker for progressive disease is investigated. 
Imatinib mesylate is used as a treatment for therapy-refractory SSc with high variability 
in therapeutic outcomes ranging from ineffective/toxic responses to extremely encouraging 
clinical improvement. This high variability in treatment outcomes stresses the need for 
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a biomarker identifying SSc patients likely to respond to Imatinib treatment. Chapter 5 
describes the IFN type I signature, together with BAFF and N-terminal propeptide of type 
III collagen (PIIINP, which is an indicator of activated collagen metabolism) as possible 
predictors for SSc patients responding to Imatinib treatment.
Recently, a T helper 17 subset (Th17 cells), which produces IL-17A, IL-17F, IL-21 and 
IL-22, has been implicated in generalized autoimmune diseases. A possible co-activity 
between the pathogenic IFN type I and the IL-17/Th17 pathway has been suggested. Data 
about co-occurrence of these two pathways in patients has not been shown yet. In Chapter 
6 chemokine receptor defined Th17 cells have been assessed and found increased in  IFN 
positive pSS patients as compared to IFN negative pSS patients. In Chapter 7 we compare 
the actual percentages of IL-17A and IL-17F producing CCR6+ T memory cells in IFN positive 
and IFN negative SLE patients. We find these cells significantly increased in IFN positive SLE 
patients. 
Finally, the results of the different chapters are integrated in Chapter 8. Generalized 
autoimmune diseases are evidently heterogeneous diseases with a multi-factorial 
pathophysiology with a prominent role for IFN type I in at least a large subgroup of patients. 
Why one IFN type I driven autoimmune disease exhibits manifestations mainly in the 
salivary and lacrimal glands and another primarily manifests signs and symptoms in the skin 
and kidneys, remains to be elucidated. Stratification of patients in subgroups according to 
pathophysiological mechanisms described here (e.g. in increased IFN type I activity versus 
low IFN type I activity) and appropriate evidence-based individualized therapies (e.g. anti-
IFN therapies) will most likely lead to improved management of these diseases and therefore 
increased quality of life for the patients. 
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SAMENVATTING                                                                              
Wanneer het immuunsysteem zich richt tegen lichaamseigen cellen en deze gaat aanvallen, 
spreekt men van auto-immuniteit. Het primaire syndroom van Sjögren (pSS), systemische 
lupus erythematodes (SLE) en systemische sclerose (SSc) zijn voorbeelden van auto-
immuunziekten waarbij meerdere organen en weefsels aangedaan kunnen zijn. Daarom 
worden deze ziekten ook wel ‘gegeneraliseerde auto-immuunziekten’ genoemd. Er zijn 
aanwijzingen voor een rol van Interferon (IFN) type I in de pathogenese van gegeneraliseerde 
auto-immuunziekten. IFN type I wordt over het algemeen in het lichaam van mensen met 
een virale infectie geproduceerd en wordt ‘interferon’ genoemd omdat het interfereert met 
de infecterende virussen. Echter, in patiënten met een gegeneraliseerde auto-immuunziekte 
lijkt IFN geproduceerd te worden zonder dat er aanwijzingen zijn voor een virale infectie. 
Het doel van dit proefschrift was om de prevalentie van verhoogde IFN type I activiteit in 
pSS te bepalen en de relatie te bestuderen tussen verhoogde IFN type I activiteit en:  
  a) ziekte verschijnselen
 b) andere immuun afwijkingen kenmerkend voor gegeneraliseerde auto-immuunziekten. 
In mensen bestaat IFN type I  uit een familie van meer dan 17 verschillende soorten, die een 
iets andere structuur hebben, maar allen IFN type I genoemd worden. Daarom is het meten 
van IFN type I waarden in bloed van patiënten niet de juiste maat voor de daadwerkelijk 
aanwezige IFN type I activiteit. IFN type I geïnduceerde gen expressie of de zogenaamde 
‘IFN type I handtekening’, wordt als een maat voor de IFN type I activiteit gebruikt. Dit 
wordt uiteengezet in Hoofdstuk 2. Door het bepalen van de IFN type I handtekening in 
pSS patiënten, hebben wij in ongeveer de helft van de pSS patiënten verhoogde IFN type I 
activiteit gevonden. Bezien over een langere tijdsduur lijkt deze IFN type I activiteit stabiel 
en is deze gecorreleerd aan verhoogde pSS ziekte activiteit welke bepaald werd door middel 
van de ESSDAI score. Ook verscheidene andere ziekte manifestaties zoals autoantistoffen, 
hoger serum IgG, lager complement en lymfocyt en neutrofiel aantallen correleren met de 
IFN type I activiteit. Verder is er een sterke correlatie met B cel activerende factor (BAFF) 
beschreven in Hoofdstuk 2. 
  Aangezien IFN type I activiteit bepaald wordt middels arbeidsintensieve gen expressie 
profielen van meerdere IFN type I induceerbare genen, hebben wij in Hoofdstuk 3 een snelle 
en gemakkelijke assay voor het bepalen van IFN type I activiteit onderzocht en vergeleken 
met de IFN type I handtekening. Het MxA eiwit bleek een goed alternatief voor de IFN 
geïnduceerde genexpressie profielen en is dus bruikbaar als biomarker voor systemische 
IFN type I activiteit in pSS.
  De prevalentie van verhoogde IFN type I activiteit in monocyten van SSc patiënten is nog 
niet aangetoond. In Hoofdstuk 4 beschrijven wij in ongeveer één derde van SSc patiënten de 
aanwezigheid van de IFN type I handtekening. Ook is er een associatie tussen IFN type I en 
ziekte verschijnselen, BAFF expressie en collageen metabolisme gevonden. Daarbij is tevens 
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de mogelijke rol van IFN type I als een biomarker voor progressieve ziekte onderzocht. 
  Imatinib mesilaat wordt als een behandeling voor therapieresistente SSc patiënten 
gebruikt en heeft een hoge variabiliteit in therapeutische effecten variërend van 
geen respons of toxisch respons tot aanmoedigende klinische verbetering. Deze 
hoge variabiliteit benadrukt de noodzaak voor een biomarker die SSc patiënten kan 
identificeren die positief op Imatinib zullen reageren. Hoofdstuk 5 beschrijft dat 
de IFN type I handtekening, samen met BAFF en N-terminaal propeptide van type 
III collageen (PIIINP, welke een maat voor geactiveerde collageen metabolisme is) 
mogelijk voorspellen welke SSc patiënten op behandeling met Imatinib zullen reageren. 
  Recent is er een nieuwe T helper set namelijk de zogenaamde Th17 cellen gevonden. 
Deze Th17 cellen, die IL-17A, IL-17F, IL-21 en IL-22 produceren, lijken een rol te spelen 
in de pathogenese van gegeneraliseerde auto-immuunziekten. Mogelijk bevorderen 
IFN type I en IL-17/Th17 samen het ziekteproces in deze auto-immuunziekten. Data 
over de gelijktijdige aanwezigheid van deze twee ziekte-bevorderende mechanismen 
in patiënten ontbreken nog. In Hoofdstuk 6 zijn in pSS patiënten de chemokine receptor 
gedefinieerde Th17 cellen bepaald en verhoogd gevonden in IFN positieve patiënten 
in vergelijking met IFN negatieve patiënten. Hoofdstuk 7 vergelijkt de IL-17A en IL-17F 
producerende CCR6+ T cel percentages tussen IFN positieve en IFN negatieve SLE patiënten. 
Deze IL-17 producerende cellen zijn verhoogd gevonden in IFN positieve SLE patiënten. 
  Ten slotte worden de resultaten van de verschillende hoofdstukken geïntegreerd in 
Hoofdstuk 8. Gegeneraliseerde auto-immuunziekten zijn heterogene ziekten met een 
multifactoriële pathofysiologie waar IFN type I deel van uitmaakt. Waarom de ene IFN 
gemedieerde ziekte manifestaties in vooral speeksel- en traanklieren heeft, terwijl in 
andere IFN type I gemedieerde ziekten vooral de huid en nieren aangedaan zijn, moet nog 
onderzocht worden. Mogelijk kan het indelen van patiënten in subgroepen gebaseerd op het 
pathofysiologisch mechanisme (bijvoorbeeld met behulp van de IFN type I handtekening) 
en hierop gebaseerde behandeling (bijvoorbeeld met anti-IFN type I) leiden tot een betere 
behandeling en kwaliteit van leven voor deze groep patiënten. 
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LIST OF ABBREVIATIONS
ACA Anti-centromere antibodies
AIM2  Absent in melanoma 2
ANA  Anti-nuclear antibodies
ANOVA  Analysis of variance
anti-CCP  Antibodies against cyclic citrullinated peptides
APC  Antigen presenting cell
APRIL  A proliferation-inducing ligand
ASMA  Anti-smooth muscle antibodies
BAFF  B cell activating factor of the tumor necrosis factor family
BAFF-R  BAFF receptor
BCMA  B cell maturation antigen receptor
BCR  B cell receptor
BDCA  Blood dendritic cell antigen
BSA  Bovine serum albumin
C3  Complement component 3
C4  Complement component 4
CCR4  Chemokine (C-C motif) receptor 4
CCR6  Chemokine (C-C motif) receptor 6
CCR10  Chemokine (C-C motif) receptor 10
CD3  Cluster of differentiation 3
CD4  Cluster of differentiation 4
CD8  Cluster of differentiation 8
CD19  Cluster of differentiation 19
CD20  Cluster of differentiation 20
CD22  Cluster of differentiation 22
CD28  Cluster of differentiation 28
CD64  Cluster of differentiation 64
CD80  Cluster of differentiation 80
CD86  Cluster of differentiation 86
CD169  Cluster of differentiation 169
CD45RO  Protein tyrosine phosphatase, receptor type, C 
cDNA  Copy DNA
CIA  Collagen induced arthritis
CNS  Central nervous system
CRP  C-reactive protein
CXCL9  Chemokine (C-C motif) ligand 9
CXCL10  Chemokine (C-C motif) ligand 10
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CXCL11  Chemokine (C-C motif) ligand 11
CXCL12  Chemokine (C-C motif) ligand 12
CXCL13  Chemokine (C-C motif) ligand 13
CXCL19  Chemokine (C-C motif) ligand 19
CXCL21  Chemokine (C-C motif) ligand 21
CXCR3  Chemokine (C-X-C motif) receptor 3
CXCR5  Chemokine (C-X-C motif) receptor 5
DAI  DNA-dependent activator of IRF
DC  Dendritic cell
dcSSc  Diffuse cutaneous systemic sclerosis
ΔΔCT  Delta delta Cycle treshold
DHEA  Dehydroepiandrosterone
DHEA-S  Dehydroepiandrosterone sulfate
DLCO  Diffusing capacity for carbon monoxide
DN  Double negative
DNA  Deoxyribonucleic acid
dsDNA  Double stranded DNA
EAE  Experimental autoimmune encephalomyelitis
EBV  Epstein-Barr virus
EIA  Enzyme immuno assay
ELISA  Enzyme Linked Immuno Sorbent Assay
ENA  Extractable Nuclear Antigens
ER  Endoplasmatic reiculum
ESR  Erythrocyte sedimentation rate
ESSDAI  EULAR Sjögren’s Syndrome Disease Activity Index
FACS  Flow cytometric analysis
Fas-L  Fas Ligand
FcγRII  Fc fragment of IgG, low affinity III, receptor
GC  Germinal center
G-CSF  Granulocyte colony-stimulating factor
GM-CSF  Granulocyte-macrophage colony-stimulating factor
Hb  Haemoglobin
HC  Healthy control
HCQ  Hydroxychloroquine
HCV  Hepatitis C virus
HIV  Human immunodeficiency virus
HLA  Human leukocyte antigen
HTLV1  Human T-lymphotropic virus Type I
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ICAM  Intercellular adhesion molecule
ICs  Immunecomplexes
IFI27  Interferon, alpha-inducible protein 27
IFI44  Interferon-induced protein 44
IFI44L  Interferon-induced protein 44-like
IFIGs  Interferon type I induced genes
IFIT1 Interferon-induced protein with tetratricopeptide repeats 1
IFIT2  Interferon-induced protein with tetratricopeptide repeats 2
IFIT3  Interferon-induced protein with tetratricopeptide repeats 3
IFITM1  Interferon induced transmembrane protein 1
IFN  Interferon
IFN-  Interferon negative
IFN+  Interferon positive
IFNAR  Interferon type I receptor 
IFNAR1  Interferon type I receptor 1
IFNAR2  Interferon type I receptor 2
IgA  Immunoglobulin A
IgG  Immunoglobulin G
IgG1  Immunoglobulin G1
IgG2a  Immunoglobulin G2a
IgM  Immunoglobulin M
IKKE Inhibitor of kappa light polypeptide gene enhancer in B-cells kinase epsilon
IL-1β  Interleukin 1β
IL-4  Interleukin 4
IL-5  Interleukin 5
IL-6  Interleukin 6
IL-10  Interleukin 10
IL-12  Interleukin 12
IL-13  Interleukin 13
IL-17  Interleukin 17
IL-17A  Interleukin 17A
IL-17F  Interleukin 17F
IL-17R  Interleukin 17 receptor
IL-21  Interleukin 21
IL-22  Interleukin 22
IL-23  Interleukin 23
IM  Imatinib mesylate
IP-10  Interferon gamma-induced protein 10
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IQRs  Interquartile ranges
IRAK 1  Interleukin receptor associated kinase 1
IRAK 4  Interleukin receptor associated kinase 4
IRF  Interferon regulatory factor
IRF3  Interferon regulatory factor 3
IRF5  Interferon regulatory factor 5
IRF7  Interferon regulatory factor 7
ISRE  Interferon stimulated response elements
Jak1  Janus family kinase 1
lcSSc  Limited cutaneous systemic sclerosis
LGP2  Laboratory of Genetic and Physiology 2
LPS  Lipopolysaccharides
LY6E  Lymphocyte antigen 6 complex, locus E
M3R  Muscarinic 3 receptor
Mabs  Monoclonal antibodies
MAVS  Mitochondrial antiviral-signaling
MCP-1  Monocyte chemotactic protein-1
MDA5  Melanoma differentiation antigen 5
MHC  Major histocompatibility complex 
mRSS  Mean Rodnan Skin Score
MS  Multiple sclerosis
MX1  Myxovirusresistance protein 1
MxA  Myxovirusresistance protein 1
MyD88  Myeloid differentiation factor 88
ND  Not determined
NETs  Neutrophil extracellular traps
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated B cells
NK  Natural Killer
NLR  NOD-like receptors
NS  Nonsignificant
NSAIDs  Non-steroidal anti-inflammatory drugs
PBMCs  Peripheral blood mononuclear cells
pDC  Plasmacytoid dendritic cell
PIIINP  N-terminal propeptide of type III procollagen
PNS  Peripheral nervous system
poly (I:C)  Polyinosinic:polycytidylic acid
PRRs  Pattern recognition receptors
pSS  Primary Sjögren’s syndrome
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RA  Rheumatoid arthritis
RF  Rheumatoid factor
RIG-1  Retinoic acid-inducible gene 1
RLR  RIG-I like receptor
RNA  Ribonucleic acid
RNP  Ribonucleoprotein
RQ-PCR  Real time quantitative polymerase chain reaction
SD  Standard deviation 
SERPING1  Serpin peptidase inhibitor, clade G, member 1
SGEC  Salivary gland epithelial cells
SLE  Systemic Lupus Erythematosus
SLEDAI  Systemic Lupus Erythematosus Disease Activity Index
SS  Sjögren’s syndrome
SSc  Systemic sclerosis
STAT1  Signal transducer and activator of transcription 1
STAT2  Signal transducer and activator of transcription 2
STAT4  Signal transducer and activator of transcription 4
TACI Transmembrane activator and calcium modulator ligand interactor
TBK1  TANK-binding kinase 1
TCR  T cell receptor
TGF-β  Transforming growth factor β
Th  T helper
Th2  T helper 2 
Th17  T helper 17
Th22  T helper 22 
TLC  Total lung capacity
TLR  Toll like receptor
TLR 3  Toll like receptor 3
TLR 4  Toll like receptor 4
TLR 7  Toll like receptor 7
TLR 9  Toll like receptor 9
TMB  Tetramethylbenzidine
TNF  Tumor necrosis factor
TNF-α  Tumor necrosis factor α
TRAF3  Tumor necrosis factor receptor-associated factor 3
TRAF6  Tumor necrosis factor receptor-associated factor 6
Treg  Regulatory T cell
TRIF  TIR containing adaptor molecule
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TRIM21  Tripartite motif-containing protein 21
TWEAK  TNF-like weak inducer of apoptosis
Tyk2  Tyrosine kinase 2
USP18  Ubiquitin specific peptidase 18
VCAM  Vascular cell adhesion protein
XAF1  XIAP associated factor 1
XIAP  X-chromosome-linked inhibitor of apoptosis
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DANKWOORD
Yes, eindelijk aangekomen bij het schrijven van het meest gelezen deel van dit boekje. Ik zal 
hierin proberen om iedereen te bedanken die mij de afgelopen 4 jaar geholpen, geïnspireerd 
en gesteund heeft bij het tot stand brengen van dit proefschrift. 
Prof. Benner en Prof. Hooijkaas, ik wil u beiden bedanken voor de mogelijkheid om mijn 
promotieonderzoek op de afdeling Immunologie te kunnen uitvoeren. Ik heb de afgelopen 
jaren met veel plezier op de afdeling gewerkt.  
Prof. Drexhage, beste Hemmo, ik kan het me als de dag van gisteren herinneren dat 
ik bij jou als geneeskunde student kwam solliciteren voor mijn keuzeonderzoek. Jij vroeg 
me meteen of ik zou willen promoveren waarop ik volmondig ‘nee’ antwoorde met als 
toevoeging ‘dat ik liever 4 jaar klinische ervaring zou willen opdoen dan 4 jaar lang op een 
lab zitten’. Jouw woorden destijds ‘dus jij wilt ergens in Gouda internistje worden’ en ‘ik 
zie het al jij bent geen onderzoekster’ waren het begin van vele enerverende discussies en 
dialogen. Het duurde niet lang totdat ik het enthousiasme voor het onderzoek te pakken 
had en hier ben ik dan 4 jaar later het dankwoord van mijn proefschrift aan het schrijven. Ik 
wil je bedanken voor alle wetenschappelijke prikkelingen, jouw helpende ‘helicopter view’ 
bij het schrijven van mijn manuscripten en je altijd open en uitnodigende houding hoe druk 
je ook was. 
Prof. Van Hagen, beste Martin, ondanks dat wij later in mijn promotie traject met elkaar 
zijn gaan samenwerken, wil ik je bedanken voor al je hulp, wijze raad en klinische inzichten. 
Ik kijk met veel plezier uit naar de opleiding interne geneeskunde.
Dr. Versnel, beste Marjan, als copromotor ben jij zeer nauw betrokken geweest bij dit 
onderzoek. Ik wil je bedanken voor de manier waarop jij dit gedaan hebt. Ondanks dat ik 
als arts geen ervaring op het gebied van onderzoek had en jij geen eerdere ervaring met 
het superviseren van klinische OIO’s, heb jij mij vanaf het begin de vrijheid geboden om 
vorm aan mijn eigen ideeën te geven. Dit met het volle vertrouwen dat het wel goed zou 
komen, zelfs toen dat vertrouwen op momenten bij mij ontbrak. Bovendien was je een 
enorm toegankelijke supervisor; jouw deur stond altijd open om stukken na te kijken, over 
ideeën te brainstormen of een luisterend oor te bieden. En als je niet op het lab aanwezig 
was, stond je wel stand-by per e-mail, telefoon of whatsapp. Bedankt hiervoor! 
I would like to thank the members of the reading committee, prof.dr. Jacques-Eric 
Gottenberg, prof.dr. Timothy Radstake and dr. Bart Jacobs for your review and academic 
input. Dr. Elke Theander, thank you for coming to the Netherlands to participate in my 
dissertation committee. 
Lieve Corine, mijn paranimf en ook één van de grootste bikkels die ik ken. Jij hebt mij de 
fijne kneepjes van het vak geleerd. Daar waar ik me nog verwonderde over de ijsmachine 
op het lab, probeerde jij mij histologie coupes te leren kleuren, RNA te isoleren en andere 
voor mij wereldvreemde technieken op het lab. Ik kon op mijn beurt ook af en toe wat 
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voor jou betekenen zoals bloedende duimen verbinden of hechtingen verwijderen. Ik heb 
in ieder geval op meerdere vlakken veel van je geleerd en ben heel blij dat jij als paranimf 
naast mij zult staan. Lieve Naomi, my sweet choco! Thanks for being a great partner in 
crime during this journey! Een betere reisgenoot naar Athene, Washington en New York 
had ik niet kunnen wensen! And the ‘chocolate-vanilla chronicle’ will be continued soon in 
Kyoto! Lieve Wouter, er waren vast momenten dat je het niet makkelijk had als enige man 
in de groep en op de OIO-kamer, maar wat hebben wij vrouwen met jou een lol gehad! 
Bedankt voor al je hulp met figuren, statistiek, computer problemen, styling adviezen, 
je heerlijke espressootjes, je Haagse humor en bovenal je gezelligheid! Lieve Karin W, 
de afgelopen vier jaar heb jij veel ingrediënten aan mijn PhD traject toegevoegd; van de 
grootste lol op en buiten de werkvloer, tot de beste filosofische gesprekken onder het genot 
van een falafelburger en schnaps in het Westerpaviljoen. En natuurlijk niet te vergeten, 
de door jou zelf samengestelde cd’s afgestemd op de verschillende fasen van dit 4-jarig 
traject en uiteraard Rosie en Jumbo. Vielen Dank für all den Spaß und deine Freundschaft! 
Angelique, lieve Angie, jij zorgde voor het ‘thuis’ gevoel op het lab. De Turkse deuntjes die 
uit jouw telefoon menig keer geklonken hebben in combinatie met jouw open en warme 
persoonlijkheid, waren vaak een bron van energie in de afgelopen 4 jaar. Beste Harm, 
voordat ik jou ontmoet had, geloofde ik niet dat er mensen bestonden die nooit slecht 
gehumeurd waren. Jij hebt me doen inzien dat dit onjuist was! Beste Annemarie, jij hebt 
mij als student de allereerste techniek op het lab geleerd, namelijk Ficollen. Bedankt voor 
je geduld en je hulp. Thomas, jij was het muzikale talent op het lab en voor mij ook een 
vraagbaak voor allerlei gekke weetjes. Ik zal in ieder geval nooit vergeten wie Tapio Wirkkala 
was. Karin B, door jou heb ik in mijn 4de promotiejaar de wondere wereld van de psychiatrie 
tijdens de diensten van de GGZ Bavo ontdekt. Ook vond ik in jou een gelijke betreffende 
de dagelijkse worstelingen van een klinische OIO. Bedankt voor alle gezellige momenten 
onder het genot van een theetje op het lab. Lieve Jo, door jou had ik het stukje Brabant 
terug op een Rotterdams lab. Beste Wim, bedankt voor je samenwerking en je kritische blik 
betreffende de systemische sclerose manuscripten. Alle andere collega’s van de Unit Auto-
Immuunziekten − Roos, Lucy, A3, Pieter, Joey, Serena, Bas, Anjali, Jeroen, Prayer en Connie 
− graag wil ik jullie ook allen bedanken voor jullie samenwerking en gezelligheid. 
Ook buiten de unit hebben de nodige mensen bijgedragen aan mijn onderzoek. Beste 
Menno, ik wil jou bedanken voor je hulp met mijn Mozaïek project en de B cellen. Ondanks 
dat jij gelooft dat ik een trauma aan FACSen heb overgehouden, ik beloof je mijn best te doen 
om het B cel project na mijn promotie af te maken. Jorn en Diana, ook jullie bedankt voor 
jullie hulp met FACSen. Erik, Sandra en Odilia, zonder jullie zouden de Th17 manuscripten 
niet tot stand zijn gekomen. Enorme dank voor de fijne en vlotte samenwerking. Dames 
van het secretariaat, dank voor al jullie hulp en ondersteuning gedurende de afgelopen 4 
jaar. Sandra de Bruin, ik weet dat ik op het laatste moment bij je aankwam voor de figuren, 
desondanks heb je er iets moois van weten te maken waar ik je voor wil bedanken. 
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Ook heb ik in de kliniek hulp gehad bij het verzamelen van patiënt materiaal. Beste 
Paul, Virgil en Jan, bedankt voor jullie samenwerking en de gezelligheid op de poli ondanks 
jullie drukke poli schema’s. Dr. Dolhain bedankt voor uw hulp bij het verzamelen van SLE 
materiaal. Ook de dames van de poli immunologie en de prikkamer, jullie zijn een enorme 
steun geweest. Door jullie opgewektheid en vriendelijkheid vonden patiënten het nooit 
een punt om extra bloed voor wetenschappelijk onderzoek af te staan. Beste Joop, zoals ik 
ook op je afscheidsdiner verteld heb, jij bent een enorme voorbeeld en inspirator voor mij 
geweest. Voor Sjögren patiënten is jouw vertrek echt een verlies geweest!  
Alle studenten, Ashley, Kim, Samara en Eline, bedankt voor jullie hulp en inzet! Alle 
andere mede OIO’s die ik nog niet genoemd heb, Mati, Prisca, Armanda, Lizenka, Ewout, 
Hessel, Kim, Leendert, Magda R, Magda B, Hanna, Alice, Anna, Nicole, Wendy, Christina, 
Britt, dank voor jullie steun, gezelligheid en de leuke AIO weekenden. Veel plezier en 
succes met jullie verdere carrières! Lieve Chris, not only my colleague, but also my friend, 
neighbour, running mate, cat sitter and culinary inspiration, danke für alles!
Ook buiten het Erasmus MC hebben de nodige mensen bijgedragen aan dit onderzoek. 
Ik wil de samenwerkingspartners Tim en Lenny uit Nijmgegen en Utrecht hartelijk danken 
voor de prettige samenwerking and also dr. Matti Waris thank you for your collaboration. 
NWO en in het bijzonder Mirjam Rigterink, bedankt voor de mooie beurs en ook voor de 
ongelooflijke ervaring gedurende het hele proces. Dear Liz, your presentation trainings were 
brilliant! Thank you so much for your help and your inspiration!
Zonder de steun van vrienden en familie was dit boekje niet afgekomen. Lieve 
Myrthe en Stana, bedankt voor jullie onvoorwaardelijke vriendschap en al jullie steun en 
aanmoedigingen de afgelopen 4 jaar. Lieve Shilpi, Güler en Miljana, bedankt voor de SATC 
achtige afspraakjes, precies datgene dat ik na een onderzoeksdag vaak nodig had! Het 
prachtige omslag is geheel aan jouw talent te danken Shilpi, bedankt voor je ontwerp! Lieve 
Habib Jan, ik heb lang niet met iemand zo veel gelachen als met jou, dank voor al je grappen 
en verhalen! Lieve Samir, my cousin en mijn raadgever, bedankt voor al de handsfree 
gespreken en de vakantie in 2011.
Lieve Zina, mijn aller liefste twinny! Ondanks dat jij enkel 10 minuten ouder bent, 
heb jij mij altijd beschermd en over mij gewaakt als ‘the big sister’. Ik zou dan ook 
niemand liever als paranimf naast me willen hebben! De afgelopen jaren heb ik het jou 
als ziekenhuisapotheker in opleiding in het Erasmus MC niet makkelijker gemaakt met 
alle verwarringen in de wandelgangen en over de mail. Ik ben enorm trots dat z.brkic.1@
erasmusmc.nl 19 september aan mijn zijde zal staan. Zina en Thomas, bedankt dat jullie 
onvoorwaardelijk en altijd voor mij klaar stonden!
Draga mama i dragi tata, jullie bijdrage aan dit boekje kan ik moeilijk in woorden vatten. 
Ondanks de situatie die jullie noodzaakte om een nieuw leven in een heel ander land te 
beginnen, hebben jullie ervoor gezorgd dat mij nooit aan iets ontbrak en dat ik altijd datgene 
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kon doen dat ik wilde. Als ik ergens het zelfvertrouwen vandaan kan halen dat ik alles in het 
leven kan bereiken wat ik wil, dan is dat wel uit jullie goede voorbeelden. Jullie hebben altijd 
achter mijn keuzes gestaan, al hebben jullie je vast bij sommige keuzes even achter het oor 
moeten krabben. Bedankt hiervoor en bedankt voor het onvoorwaardelijke vangnet en de 
liefde! Jullie zijn mijn helden en vandaar dat ik dit boekje aan jullie opdraag. 
 And last but not least, dragi Mirza, wat heb jij het laatste 1.5 jaar van mijn promotie tot 
een ware vreugde gemaakt! Hvala ti na strpljenju, podršci i ljubavi. Volim te puno!
Zana
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from secondary school at the Dongemond College in Raamsdonksveer and attended the 
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